Provided herein are polypeptides which include tenth fibronectin type iii domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
|
1. A nucleic acid encoding a polypeptide comprising a tenth fibronectin type iii (10Fn3) domain comprising BC, DE and FG loops, wherein the polypeptide binds specifically to human glypican-3 (GPC3), and wherein
(a) the BC, DE and FG loops comprise SEQ ID NOs: 6, 7 and 8, respectively;
(b) the BC, DE and FG loops comprise SEQ ID NOs: 19, 20 and 21, respectively;
(c) the BC, DE and FG loops comprise SEQ ID NOs: 32, 33 and 34, respectively;
(d) the BC, DE and FG loops comprise SEQ ID NOs: 45, 46 and 47, respectively;
(e) the BC, DE and FG loops comprise SEQ ID NOs: 58, 59 and 60, respectively;
(f) the BC, DE and FG loops comprise SEQ ID NOs: 71, 72 and 73, respectively;
(g) the BC, DE and FG loops comprise SEQ ID NOs: 84, 85 and 86, respectively;
(h) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 101, respectively;
(i) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 129, respectively;
(j) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 156, respectively;
(k) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 183, respectively;
(l) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 210, respectively;
(m) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 237, respectively;
(n) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 264, respectively;
(o) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 291, respectively; or
(p) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 318, respectively.
2. The nucleic acid of
3. The nucleic acid of
4. The nucleic acid of
5. The nucleic acid of
6. The nucleic acid of
8. A pharmaceutical composition comprising the nucleic acid of
9. The nucleic acid of
10. The nucleic acid of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a continuation of U.S. application Ser. No. 15/760,449, filed on Mar. 15, 2018, now U.S. Pat. No. 10,584,160, which is a 35 U.S.C. 371 national stage filing of International Application No. PCT/US2016/053185, filed Sep. 22, 2016, and which claims priority to U.S. Provisional Application 62/222,633 filed Sep. 23, 2015. The contents of the aforementioned applications are hereby incorporated by reference.
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 24, 2020, named 2020_01_23_Sequence_Listing_for filing_-_MXI-546USCN.txt and is 411,808 bytes in size.
Glypican-3 is an oncofetal antigen that belongs to the glypican family of glycosyl-phosphatidylinositol-anchored heparin sulfate proteoglycans. Glypicans regulate the activity of several growth factors including Wnts, Hedgehogs, bone morphogenic proteins and fibroblast growth factors (FGFs) (Filmus et al. FEBS J. 2013, 280:2471-2476). Glypicans are characterized by a covalent linkage to complex polysaccharide chains called heparinsulphate glycosaminoglycans. Glypicans are involved in cell signaling at the cellular-extracellular matrix interface. (Sasisekharan et al., Nature Reviews|Cancer, Volume 2 (2002). To date, six distinct members of the human glypican family have been identified. Cell membrane-bound glypican-3 is composed of two subunits, linked by one or more disulfide bonds.
Glypican-3 is expressed in fetal liver and placenta during development and is down-regulated or silenced in normal adult tissues. Mutations and depletions in the glypican-3 gene are responsible for the Simpson-Golabi-Behmel or Simpson dysmorphia syndrome in humans. Glypican-3 is expressed in various cancers and, in particular, hepatocellular carcinoma (“HCC”), melanoma, Wilm's tumor, and hepatoblastoma. (Jakubovic and Jothy; Ex. Mol. Path. 82:184-189 (2007); Nakatsura and Nishimura, Biodrugs 19(2):71-77 (2005). The cell surface form of Glypican-3 is highly expressed in HCC (>50%) and in other cancers including squamous lung cancer (approximately 25%).
Glypican-3 promotes tumor growth in vitro and in vivo by stimulating canonical Wnt signaling which induces the cytosolic accumulation and nuclear translocation of the transcription factor β-catenin (Filmus, supra). It has been shown that GPC3 can form a complex with several Wnts (Capurro et al., Cancer Res., 2005, 65:6245-6254), and Frizzleds, the signaling receptor for Wnts (Filmus, et al., Genome Biol., 2008, 9:224).
HCC is the third leading cause of cancer-related deaths worldwide. Each year, HCC accounts for about 1 million deaths. (Nakatsura and Nishimura, Biodrugs 19(2):71-77 (2005).) Hepatitis B virus, hepatitis C virus, and chronic heavy alcohol use leading to cirrhosis of the liver remain the most common causes of HCC. Its incidence has increased dramatically in the United States because of the spread of hepatitis C virus infection and is expected to increase for the next 2 decades. HCC is treated primarily by liver transplantation or tumor resection. Patient prognosis is dependent on both the underlying liver function and the stage at which the tumor is diagnosed. (Parikh and Hyman, Am J. Med. 120(3):194-202 (2007).) Effective HCC treatment strategies are needed.
Provided herein are polypeptides containing fibronectin based scaffolds (FBS) that bind to human glypican-3 and conjugates of these polypeptides that are suitable as therapeutic and diagnostic agents.
In one aspect, provided is a polypeptide comprising an FBS which specifically binds to human glypican-3 (GPC3). In some embodiments, the anti-GPC3 FBS is conjugated to therapeutic or diagnostic agent.
In another aspect, provided are methods of treating cancer in a human subject by administering to the subject a therapeutically effective amount of a polypeptide comprising an anti-GPC3 FBS or an anti-GPC3 FBS-drug conjugate. In some embodiments, the cancer overexpresses glypican-3 relative to non-cancerous cells. In some embodiments, the cancer is liver cancer (e.g., hepatocellular carcinoma, hepatoblastoma), melanoma, Wilm's tumor or lung cancer (e.g., squamous lung cancer).
In another aspect, provided are methods of detecting GPC3 in vitro and in vivo, comprising contacting a cell with a polypeptide comprising an anti-GPC3 FBS under conditions to allow binding of the anti-GPC3 FBS to GPC3, and detecting complexes comprising the anti-GPC3 FBS and GPC3. In some embodiments, the anti-GPC3 FBS is linked to a detectable label (e.g., FITC).
Also provided are compositions, including pharmaceutical and diagnostic compositions, comprising the anti-GPC3 FBS polypeptides and/or anti-GPC3 FBS drug conjugates.
Also provided are nucleic acid molecules encoding the anti-GPC3 FBS, as well as expression vectors comprising such nucleic acids and host cells comprising such expression vectors. Also provided are kits comprising the anti-GPC3 FBS polypeptides and anti-GPC3 FBS conjugates and instructions for use.
Other features and advantages of the instant invention will be apparent from the following detailed description and examples which should not be construed as limiting.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by the skilled artisan. Although any methods and compositions similar or equivalent to those described herein can be used in practice or testing of the present invention, the preferred methods and compositions are described herein.
The terms “glypican-3, “glypican proteoglycan 3,” “GPC3,” “OTTHUMP00000062492,” “GTR2-2,” “SGB,” “DGSX,” “SDYS,” “SGBS,” “OCI-5,” and “SGBS1” are used interchangeably, and include variants, isoforms and species homologs of human glypican-3. The complete amino acid sequence of an exemplary human glypican-3 has Genbank/NCBI accession number NM_004484 (SEQ ID NO: 344).
An “amino acid residue” is the remaining portion of an amino acid after a water molecule has been lost (an H+ from the nitrogenous side and an OH− from the carboxylic side) in the formation of a peptide bond.
By “polypeptide” is meant any sequence of two or more amino acids, regardless of length, post-translation modification, or function. Polypeptides can include natural amino acids and non-natural amino acids such as those described in U.S. Pat. No. 6,559,126, incorporated herein by reference. Polypeptides can also be modified in any of a variety of standard chemical ways (e.g., an amino acid can be modified with a protecting group; the carboxy-terminal amino acid can be made into a terminal amide group; the amino-terminal residue can be modified with groups to, e.g., enhance lipophilicity; or the polypeptide can be chemically glycosylated or otherwise modified to increase stability or in vivo half-life). Polypeptide modifications can include the attachment of another structure such as a cyclic compound or other molecule to the polypeptide and can also include polypeptides that contain one or more amino acids in an altered configuration (i.e., R or S; or, L or D).
An “isolated” polypeptide is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In certain embodiments, the polypeptide will be purified (1) to greater than 95% by weight of polypeptide as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing condition using Coomassie blue or, preferably, silver stain.
As used herein, a “10Fn3 domain” or “10Fn3 moiety” or “10Fn3 molecule” refers to wild-type 10Fn3 and biologically active variants thereof, e.g., biologically active variants that specifically bind to a target, such as a target protein. A wild-type human 10Fn3 domain may comprise the amino acid sequence set forth in SEQ ID NO: 1. Biologically active variants of a wild-type human 10Fn3 domain include 10Fn3 domains that comprise at least, at most or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40 or 45 amino acid changes, i.e., substitutions, additions or deletions, relative to a 10Fn3 domain comprising SEQ ID NOs: 1.
An “Adnectin” or “Adx” or “adnectin” or “adx” refers to a human 10Fn3 molecule that has been modified (relative to the wild-type sequence) to bind specifically to a target.
A “GPC3 Adnectin” or “anti-GPC3 Adnectin” is an Adnectin that binds specifically to GPC3, e.g., with a KD of 1 μM or less.
A “region” of a 10Fn3 domain (or moiety or molecule) as used herein refers to either a loop (AB, BC, CD, DE, EF and FG), a β-strand (A, B, C, D, E, F and G), the N-terminus (corresponding to amino acid residues 1-7 of SEQ ID NO: 1), or the C-terminus (corresponding to amino acid residues 93-94 of SEQ ID NO: 1).
A “north pole loop” of a 10Fn3 domain (or moiety) refers to any one of the BC, DE and FG loops of a 10Fn3 domain.
A “south pole loop” of a 10Fn3 domain (or moiety) refers to any one of the AB, CD and EF loops of a 10Fn3 domain.
A “scaffold region” refers to any non-loop region of a human 10Fn3 domain. The scaffold region includes the A, B, C, D, E, F and G β-strands as well as the N-terminal region (amino acids corresponding to residues 1-7 of SEQ ID NO: 1) and the C-terminal region (amino acids corresponding to residues 93-94 of SEQ ID NO: 1).
“Percent (%) amino acid sequence identity” herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a selected sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST℠, BLAST℠-2, ALIGN, ALIGN-2 or Megalign (DNASTAR®) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared.
For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by a sequence alignment program, such as BLAST℠, BLAST℠-2, ALIGN, ALIGN-2 or Megalign (DNASTAR®), in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
As used herein, the term “Adnectin binding site” refers to the site or portion of a protein (e.g., GPC3) that interacts or binds to a particular Adnectin. Adnectin binding sites can be formed from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Adnectin binding sites formed by contiguous amino acids are typically retained on exposure to denaturing solvents, whereas Adnectin binding sites formed by tertiary folding are typically lost on treatment of denaturing solvents.
An Adnectin binding site for an anti-GPC3 Adnectin described herein may be determined by application of standard techniques typically used for epitope mapping of antibodies including, but not limited to protease mapping and mutational analysis.
As used herein, an amino acid residue in a polypeptide is considered to “contribute to binding” a target if (1) any of the non-hydrogen atoms of the residue's side chain or main chain is found to be within five angstroms of any atom of the binding target based on an experimentally determined three-dimensional structure of the complex, and/or (2) mutation of the residue to its equivalent in wild-type 10Fn3 (e.g., SEQ ID NO: 1), to alanine, or to a residue having a similarly sized or smaller side chain than the residue in question, leads to a measured increase of the equilibrium dissociation constant to the target (e.g., an increase in the kon).
The terms “specifically binds,” “specific binding,” “selective binding, and “selectively binds,” as used interchangeably herein in the context of FBS binding to GPC3 refers to an FBS that exhibits affinity for GPC3, but does not significantly bind (e.g., less than about 10% binding) to a different polypeptides as measured by a technique available in the art such as, but not limited to, Scatchard analysis and/or competitive binding assays (e.g., competition ELISA, BIACORE assay). The term is also applicable where e.g., a binding domain of an FBS described herein is specific for GPC3 from one or more species (e.g., human, rodent, primate), but does not does not cross-react with other glypicans (e.g., glypican-1, glypican-2, glypican-5, glypican-6).
The term “preferentially binds” as used herein in the context of Adnectins binding to GPC3 refers to the situation in which an Adnectin described herein binds GPC3 at least about 20% greater than it binds a different polypeptide as measured by a technique available in the art such as, but not limited to, Scatchard analysis and/or competitive binding assays (e.g., competition ELISA, BIACORE assay).
The term “KD,” as used herein, e.g., in the context of Adnectins binding to GPC3, is intended to refer to the dissociation equilibrium constant of a particular Adnectin-protein (e.g., GPC3) interaction or the affinity of an Adnectin for a protein (e.g., GPC3), as measured using a surface plasmon resonance assay or a cell binding assay. A “desired KD,” as used herein, refers to a KD of an Adnectin that is sufficient for the purposes contemplated. For example, a desired KD may refer to the KD of an Adnectin required to elicit a functional effect in an in vitro assay, e.g., a cell-based luciferase assay.
The term “ka”, as used herein in the context of Adnectins binding to a protein, is intended to refer to the association rate constant for the association of an Adnectin into the Adnectin/protein complex.
The term “kd”, as used herein in the context of Adnectins binding to a protein, is intended to refer to the dissociation rate constant for the dissociation of an Adnectin from the Adnectin/protein complex.
The term “IC50”, as used herein in the context of Adnectins, refers to the concentration of an Adnectin that inhibits a response, either in an in vitro or an in vivo assay, to a level that is 50% of the maximal inhibitory response, i.e., halfway between the maximal inhibitory response and the untreated response.
The term “glypican activity” or “glypican-3” activity as used herein refers to one or more of growth-regulatory or morphogenetic activities associated with activation of cell signaling by GPC3, for example, activation of Wnt signaling. For example, GPC3 may modulate tumor cell growth by complex formation with Wnt and/or Frizzeled proteins. GPC3 may also activate signaling pathways and tumor cell growth by interacting with FGF. GPC3 activity can be determined using art-recognized methods, such as those described herein. The phrases “glypican-3 activity” or “antagonize glypican-3 activity” or “antagonize glypican-3” are used interchangeably to refer to the ability of the anti-GPC3 FBS and anti-GPC3 drug conjugates provided herein to neutralize or antagonize an activity of GPC3 in vivo or in vitro. The terms “inhibit” or “neutralize” as used herein with respect to an activity of an anti-GPC3 FBS means the ability to substantially antagonize, prohibit, prevent, restrain, slow, disrupt, eliminate, stop, reduce or reverse e.g., progression or severity of that which is being inhibited including, but not limited to, a biological activity or property, a disease or a condition (e.g., tumor cell growth). The inhibition or neutralization is preferably at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or higher.
As used herein, the term “linked” refers to the association of two or more molecules. The linkage can be covalent or non-covalent. The linkage may be between a polypeptide and a chemical moiety or another polypeptide moiety. The linkage also can be genetic (i.e., recombinantly fused). Such linkages can be achieved using a wide variety of art recognized techniques, such as chemical conjugation and recombinant protein production.
The term “PK” is an acronym for “pharmacokinetic” and encompasses properties of a compound including, by way of example, absorption, distribution, metabolism, and elimination by a subject. A “PK modulation protein” or “PK moiety” as used herein refers to any protein, peptide, or moiety that affects the pharmacokinetic properties of a biologically active molecule when fused to or administered together with the biologically active molecule. Examples of a PK modulation protein or PK moiety include PEG, human serum albumin (HSA) binders (as disclosed in U.S. Publication Nos. 2005/0287153 and 2007/0003549, PCT Publication Nos. WO 2009/083804 and WO 2009/133208), human serum albumin and variants thereof, transferrin and variants thereof, Fc or Fc fragments and variants thereof, and sugars (e.g., sialic acid).
The serum or plasma “half-life” of a polypeptide can generally be defined as the time taken for the serum concentration of the polypeptide to be reduced by 50%, in vivo, for example due to degradation of the polypeptide and/or clearance or sequestration of the polypeptide by natural mechanisms. The half-life can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art, and may, for example, generally involve the steps of administering a suitable dose of a polypeptide to a primate; collecting blood samples or other samples from said primate at regular intervals; determining the level or concentration of the polypeptide in said blood sample; and calculating, from (a plot of) the data thus obtained, the time until the level or concentration of the polypeptide has been reduced by 50% compared to the initial level upon dosing. Methods for determining half-life may be found, for example, in Kenneth et al., Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists (1986); Peters et al., Pharmacokinete Analysis: A Practical Approach (1996); and Gibaldi, M. et al., Pharmacokinetics, Second Rev. Edition, Marcel Dekker (1982).
Serum half-life can be expressed using parameters such as the t1/2-alpha, t1/2-beta and the area under the curve (AUC). An “increase in half-life” refers to an increase in any one of these parameters, any two of these parameters, or in all three these parameters. In certain embodiments, an increase in half-life refers to an increase in the t1/2-beta and/or HL Lambda z, either with or without an increase in the t1/2-alpha and/or the AUC or both.
The term “detectable” refers to the ability to detect a signal over the background signal. The term “detectable signal” is a signal derived from non-invasive imaging techniques such as, but not limited to, positron emission tomography (PET). The detectable signal is detectable and distinguishable from other background signals that may be generated from the subject. In other words, there is a measurable and statistically significant difference (e.g., a statistically significant difference is enough of a difference to distinguish among the detectable signal and the background, such as about 0.1%, 1%, 3%, 5%, 10%, 15%, 20%, 25%, 30%, or 40% or more difference between the detectable signal and the background) between the detectable signal and the background. Standards and/or calibration curves can be used to determine the relative intensity of the detectable signal and/or the background.
A “detectably effective amount” of a composition comprising an imaging agent described herein is defined as an amount sufficient to yield an acceptable image using equipment that is available for clinical use. A detectably effective amount of an imaging agent provided herein may be administered in more than one injection. The detectably effective amount can vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, and the like. Detectably effective amounts of imaging compositions can also vary according to instrument and methodologies used. Optimization of such factors is well within the level of skill in the art. In certain embodiments, a GPC3 imaging agent, e.g., those described herein, provides a differentiation factor (i.e., specific signal to background signal) of 2 or more, e.g., 3, 4, 5 or more.
The terms “individual,” “subject,” and “patient,” used interchangeably herein, refer to an animal, preferably a mammal (including a nonprimate and a primate), e.g., a human.
A “cancer” refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth divide and grow results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream.
“Treatment” or “therapy” of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication, condition or biochemical indicia associated with a disease.
“Administration” or “administering,” as used herein in the context of anti-GPC3 Adnectins, refers to introducing a GPC3 Adnectin or GPC3 Adnectin-based probe or a labeled probe (also referred to as the “imaging agent”) described herein into a subject. Any route of administration is suitable, such as intravenous, oral, topical, subcutaneous, peritoneal, intra-arterial, inhalation, vaginal, rectal, nasal, introduction into the cerebrospinal fluid, or instillation into body compartments can be used.
The terms “co-administration” or the like, as used herein, are meant to encompass administration of the selected pharmaceutical agents to a single patient, and are intended to include regimens in which the agents are administered by the same or different route of administration or at the same or different time.
The term “therapeutically effective amount” refers to at least the minimal dose, but less than a toxic dose, of an agent which is necessary to impart a therapeutic benefit to a subject.
As used herein, an “effective amount” refers to at least an amount effective, at dosages and for periods of time necessary, to achieve the desired result.
As used herein, a “sufficient amount” refers to an amount sufficient to achieve the desired result.
The term “sample” can refer to a tissue sample, cell sample, a fluid sample, and the like. The sample may be taken from a subject. The tissue sample can include hair (including roots), buccal swabs, blood, saliva, semen, muscle, or from any internal organs. The fluid may be, but is not limited to, urine, blood, ascites, pleural fluid, spinal fluid, and the like. The body tissue can include, but is not limited to, skin, muscle, endometrial, uterine, and cervical tissue.
Overview
Provided herein are novel fibronectin based scaffold polypeptides which bind to human glypican-3. Such polypeptides can be coupled to other therapeutic and diagnostic agents and are useful, for example, in targeting therapeutic and diagnostic agents to cells and tissues expressing glypican-3 (e.g., cancer cells over-expressing glypican-3).
I. Anti-GPC3 Fibronectin Based Scaffolds
As used herein, a “fibronectin based scaffold” or “FBS” protein or moiety refers to proteins or moieties that are based on a fibronectin type III (“Fn3”) repeat and can be modified to bind specifically to given targets, e.g., target proteins. Fn3 is a small (about 10 kDa) domain that has the structure of an immunoglobulin (Ig) fold (i.e., an Ig-like β-sandwich structure, consisting of seven β-strands and six loops). Fibronectin has 18 Fn3 repeats, and while the sequence homology between the repeats is low, they all share a high similarity in tertiary structure. Fn3 domains are also present in many proteins other than fibronectin, such as adhesion molecules, cell surface molecules, e.g., cytokine receptors, and carbohydrate binding domains. For reviews see Bork et al., Proc. Natl. Acad. Sci. USA, 89(19):8990-8994 (1992); Bork et al., J. Mol. Biol., 242(4):309-320 (1994); Campbell et al., Structure, 2(5):333-337 (1994); Harpez et al., J. Mol. Biol., 238(4):528-539 (1994)). The term “FBS” protein or moiety is intended to include scaffolds based on Fn3 domains from these other proteins (i.e., non fibronectin molecules).
An Fn3 domain is small, monomeric, soluble, and stable. It lacks disulfide bonds and, therefore, is stable under reducing conditions. Fn3 domains comprise, in order from N-terminus to C-terminus, a beta or beta-like strand, A; a loop, AB; a beta or beta-like strand, B; a loop, BC; a beta or beta-like strand, C; a loop, CD; a beta or beta-like strand, D; a loop, DE; a beta or beta-like strand, E; a loop, EF; a beta or beta-like strand, F; a loop, FG; and a beta or beta-like strand, G. The seven antiparallel β-strands are arranged as two beta sheets that form a stable core, while creating two “faces” composed of the loops that connect the beta or beta-like strands. Loops AB, CD, and EF are located at one face (“the south pole”) and loops BC, DE, and FG are located on the opposing face (“the north pole”).
The loops in Fn3 molecules are structurally similar to complementary determining regions (CDRs) of antibodies, and when altered, may be involved in binding of the Fn3 molecule to a target, e.g., a target protein. Other regions of Fn3 molecules, such as the beta or beta-like strands and N-terminal or C-terminal regions, when altered, may also be involved in binding to a target. Any or all of loops AB, BC, CD, DE, EF and FG may participate in binding to a target. Any of the beta or beta-like strands may be involved in binding to a target. Fn3 domains may also bind to a target through one or more loops and one or more beta or beta-like strands. Binding may also require the N-terminal or C-terminal regions.
An anti-GPC3 FBS may be based on the tenth fibronectin type III domain, i.e., the tenth module of human Fn3 (10Fn3) in which one or more solvent accessible loops have been randomized or mutated. The amino acid sequence of a wild-type human 10Fn3 moiety is as follows:
(SEQ ID NO: 1)
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTV
PGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT
The AB, CD and EF loops are underlined; the BC, FG, and DE loops are emphasized in bold; the β-strands are located between or adjacent to each of the loop regions; and the N-terminal region is shown in italics). The last two amino acid residues of SEQ ID NO: 1 are a portion of a C-terminal region. The core 10Fn3 domain begins with amino acid 9 (“E”) and ends with amino acid 94 (“T”) and corresponds to an 86 amino acid polypeptide. The core wild-type human 1Fn3 domain is set forth in SEQ ID NO: 2. Both variant and wild-type 10Fn3 proteins are characterized by the same structure, namely seven beta-strand domain sequences designated A through G and six loop regions (AB loop, BC loop, CD loop, DE loop, EF loop, and FG loop) which connect the seven beta-strand domain sequences. The beta strands positioned closest to the N- and C-termini may adopt a beta-like conformation in solution. In SEQ ID NO: 1, the AB loop corresponds to residues 14-17, the BC loop corresponds to residues 23-31, the CD loop corresponds to residues 37-47, the DE loop corresponds to residues 51-56, the EF loop corresponds to residues 63-67, and the FG loop corresponds to residues 76-87.
Accordingly, in certain embodiments, the anti-GPC3 FBS moiety (e.g., anti-GPC3 Adnectin) comprises a 10Fn3 domain that is defined generally by the following degenerate sequence:
(SEQ ID NO: 3)
VSDVPRDLEVVAA(X)uLLISW(X)vYRITY(X)wFTV(X)xATISGL(X)y
YTITVYA(X)zISINYRT,
or by a sequence lacking 1, 2, 3, 4, 5, 6 or 7 N-terminal amino acids, respectively.
In SEQ ID NO: 3, the AB loop is represented by (X)u, the BC loop is represented by (X)v, the CD loop is represented by (X)w, the DE loop is represented by (X)x, the EF loop is represented by (X)y and the FG loop is represented by Xz. X represents any amino acid and the subscript following the X represents an integer of the number of amino acids. In particular, u, v, w, x, y and z may each independently be anywhere from 2-20, 2-15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids. The sequences of the beta strands (underlined in SEQ ID NO: 3) may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 3. In some embodiments, the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, e.g., conservative substitutions, across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 3.
It should be understood that not every residue within a loop region needs to be modified or altered in order to achieve a 1Fn3 binding domain having strong affinity for a desired target. Additionally, insertions and deletions in the loop regions may also be made while still producing high affinity anti-GPC3 10Fn3 binding domains. By “altered” is meant one or more amino acid sequence alterations relative to a template sequence (i.e., the corresponding wild-type human fibronectin domain) and includes amino acid additions, deletions, substitutions or a combination thereof.
In some embodiments, the anti-GPC3 FBS moiety comprises a 10Fn3 domain wherein the non-loop regions comprise an amino acid sequence that is at least 80, 85, 90, 95, 98, or 100% identical to the non-loop regions of SEQ ID NO: 1, and wherein at least one loop selected from AB, BC, CD, DE, EF and FG is altered.
In some embodiments, one or more loops selected from AB, BC, CD, DE, EF and FG may be extended or shortened in length relative to the corresponding loop in wild-type human 10Fn3. In any given polypeptide, one or more loops may be extended in length, one or more loops may be reduced in length, or combinations thereof. In some embodiments, the length of a given loop may be extended by 2-25, 2-20, 2-15, 2-10, 2-5, 5-25, 5-20, 5-15, 5-10, 10-25, 10-20, or 10-15 amino acids. In some embodiments, the length of a given loop may be reduced by 1-15, 1-11, 1-10, 1-5, 1-3, 1-2, 2-10, or 2-5 amino acids. In particular, the FG loop of 10Fn3 is 13 residues long, whereas the corresponding loop in antibody heavy chains ranges from 4-28 residues. Therefore, in some embodiments, the length of the FG loop of 10Fn3 may be altered in length as well as in sequence to obtain the greatest possible flexibility and target affinity in polypeptides relying on the FG for target binding.
In certain embodiments, the anti-GPC3 FBS moiety comprises a tenth fibronectin type III (10Fn3) domain, wherein the 10Fn3 domain comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop EF; and a loop FG; and has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain. In some embodiments, the anti-GPC3 Adnectin described herein comprise a 10Fn3 domain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-loop regions of SEQ ID NO: 1 or 2, wherein at least one loop selected from BC, DE, and FG is altered. In certain embodiments, the BC and FG loops are altered, in certain embodiments, the BC and DE loops are altered, in certain embodiments, the DE and FG loops are altered, and in certain embodiments, the BC, DE, and FG loops are altered, i.e., the 10Fn3 domains comprise non-naturally occurring loops. In certain embodiments, the AB, CD and/or the EF loops are altered. In some embodiments, one or more specific scaffold alterations are combined with one or more loop alterations.
In some embodiments, the non-ligand binding sequences of the anti-GPC3 10Fn3 may be altered provided that the 10Fn3 retains ligand binding function and/or structural stability. In some embodiments, the non-loop region of a 1Fn3 domain may be modified by one or more conservative substitutions. As many as 5%, 10%, 20% or even 30% or more of the amino acids in the 10Fn3, domain may be altered by a conservative substitution without substantially altering the affinity of the 1Fn3 for a ligand. In certain embodiments, the non-loop regions, e.g., the 3-strands may comprise anywhere from 0-15, 0-10, 0-8, 0-6, 0-5, 0-4, 0-3, 1-15, 1-10, 1-8, 1-6, 1-5, 1-4, 1-3, 2-15, 2-10, 2-8, 2-6, 2-5, 2-4, 5-15, or 5-10 conservative amino acid substitutions. In exemplary embodiments, the scaffold modification may reduce the binding affinity of the 1Fn3 binder for a ligand by less than 100-fold, 50-fold, 25-fold, 10-fold, 5-fold, or 2-fold. It may be that such changes may alter the immunogenicity of the 1Fn3 in vivo, and where the immunogenicity is decreased, such changes may be desirable. As used herein, “conservative substitutions” are residues that are physically or functionally similar to the corresponding reference residues. That is, a conservative substitution and its reference residue have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like. Exemplary conservative substitutions include those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al., Atlas of Protein Sequence and Structure, 5:345-352 (1978 and Supp.). Examples of conservative substitutions include substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine.
In some embodiments, one or more of Asp 7, Glu 9, and Asp 23 is replaced by another amino acid, such as, for example, a non-negatively charged amino acid residue (e.g., Asn, Lys, etc.). A variety of additional alterations in the 1Fn3 scaffold that are either beneficial or neutral have been disclosed. See, for example, Batori et al., Protein Eng., 15(12):1015-1020 (December 2002); Koide et al., Biochemistry, 40(34):10326-10333 (Aug. 28, 2001).
In other embodiments, the hydrophobic core amino acid residues (bolded residues in SEQ ID NO: 3 above) are fixed, and any substitutions, conservative substitutions, deletions or additions occur at residues other than the hydrophobic core amino acid residues in the 10Fn3 scaffold. Thus, in some embodiments, the hydrophobic core residues of the polypeptides provided herein have not been modified relative to the wild-type human 10Fn3 domain (e.g., SEQ ID NO: 1).
A 10Fn3 molecule may comprise the flexible linker between the 10th and 11th repeat of the Fn3 domain, i.e., EIDKPSQ (SEQ ID NO: 369). The wild type 10Fn3 polypeptide with EIDKPSQ (SEQ ID NO: 369) at its C-terminus is represented by
(SEQ ID NO: 4)
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTV
PGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT
EIDKPSQ
In some embodiments, one or more residues of the integrin-binding motif “arginine-glycine-aspartic acid” (RGD) (amino acids 78-80 of SEQ ID NO: 1) may be substituted so as to disrupt integrin binding. In some embodiments, the FG loop of the polypeptides provided herein does not contain an RGD integrin binding site. In one embodiment, the RGD sequence is replaced by a polar amino acid-neutral amino acid-acidic amino acid sequence (in the N-terminal to C-terminal direction). In certain embodiments, the RGD sequence is replaced with SGE or RGE.
A. Exemplary Anti-GPC3 Adnectins
In some embodiments, the BC loop of the anti-GPC3 FBS (e.g., an Adnectin that binds specifically to human GPC3) comprises an amino acid sequence set forth in SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99, wherein, optionally, the BC loop comprises 1, 2 or 3 amino acid substitutions, deletions or insertions relative to the BC loop of SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99.
In some embodiments, the DE loop of the anti-GPC3 FBS comprises an amino acid sequence set forth in SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100, wherein, optionally, the DE loop comprises 1, 2 or 3 amino acid substitutions, deletions or insertions relative to the DE loop of SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100.
In some embodiments, the FG loop of the anti-GPC3 FBS comprises an amino acid sequence set forth in SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318, wherein, optionally, the FG loop comprises 1, 2 or 3 amino acid substitutions, deletions or insertions relative to the FG loop of SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318.
In some embodiments, the BC loop of the anti-GPC3 Adnectin (i.e., an Adnectin that binds specifically to human GPC3) comprises an amino acid sequence set forth in SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99, wherein, optionally, the BC loop comprises 1, 2 or 3 amino acid substitutions, deletions or insertions relative to the BC loop of SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99; the DE loop of the anti-GPC3 Adnectin comprises an amino acid sequence set forth in SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100, wherein, optionally, the DE loop comprises 1, 2 or 3 amino acid substitutions, deletions or insertions relative to the DE loop of SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100; and the FG loop of the anti-GPC3 FBS comprises an amino acid sequence set forth in SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318, wherein, optionally, the FG loop comprises 1, 2 or 3 amino acid substitutions, deletions or insertions relative to the FG loop of SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318.
In some embodiments, the anti-GPC3 FBS comprises a BC loop comprising an amino acid sequence set forth in SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99; a DE loop comprising amino acid sequence set forth in SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100; and an FG loop comprising an amino acid sequence set forth in SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318.
In some embodiments, the anti-GPC3 FBS comprises the BC, DE, and FG loops as set forth in SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99; 7, 20, 33, 46, 59, 72, 85 or 100; and 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318, respectively, and has amino acid substitutions in the BC, DE, and FG loops which allow the FBS to maintain binding to GPC3.
In some embodiments, the anti-GPC3 FBS comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 6, 7 and 8, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 6, 7 and 8, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin (e.g., an anti-FBS moiety comprising a human 10Fn3) comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 19, 20 and 21, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 19, 20 and 21, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 19, 20 and 21, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)x, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 32, 33 and 34, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 32, 33 and 34, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 32, 33 and 34, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 45, 46 and 47, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 45, 46 and 47, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 45, 46 and 47, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 58, 59 and 60, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 58, 59 and 60, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 58, 59 and 60, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 71, 72 and 73, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 71, 72 and 73, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 71, 72 and 73, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)x, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 84, 85 and 86, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 84, 85 and 86, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 84, 85 and 86, respectively.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, have amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 99, 100 and 101, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 101, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution, and the FG loop has 0, 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, such as conservative amino acid substitutions.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 101, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 129, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 129, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 156, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 156, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 183, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 183, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 210, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 210, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 237, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 237, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 264, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 264, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 291, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 291, respectively.
In some embodiments, the anti-GPC3 Adnectin comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein the BC, DE, and FG loops comprise the amino acid sequences set forth in SEQ ID NOs: 99, 100 and 318, respectively, wherein the BC loop has 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions, such as conservative amino acid substitutions, and the DE loop has 0, 1, 2 or 3 amino acid substitutions, such as a conservative amino acid substitution.
In certain embodiments, an anti-GPC3 Adnectin comprises the sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 99, 100 and 318, respectively.
The scaffold regions of such anti-GPC3 Adnectins may comprise anywhere from 0 to 20, from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the scaffold amino acids residues of SEQ ID NO: 3. Such scaffold modifications may be made, so long as the anti-GPC3 Adnectin is capable of binding GPC3 with a desired KD.
In certain embodiments, the anti-GPC3 Adnectin comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to that of an anti-GPC3 Adnectin disclosed herein and having, e.g., any one of SEQ ID NOs: 5, 18, 31, 44, 57, 70, 83 and 98.
In certain embodiments, the anti-GPC3 Adnectin comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 5, 9-18, 22-31, 35-44, 48-57, 61-70, 74-83, 87-98, 102-128, 130-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343.
In certain embodiments, the anti-GPC3 Adnectins described herein comprise an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 6, 7, and 8, respectively; and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 19, 20 and 21, respectively; and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 32, 33 and 34, respectively; and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 45, 46 and 47, respectively; and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 58, 59 and 60, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 71, 72 and 73, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 84, 85 and 86, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 101, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 129, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 129, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 156, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 183, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 210, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 237, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 264, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 291, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In certain embodiments, the anti-GPC3 Adnectin comprises BC, DE, and FG loops as set forth in SEQ ID NOs: 99, 100 and 318, respectively and an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 or 98.
In some embodiments, the anti-GPC3 Adnectin comprises an amino acid sequence selected from the group consisting of 5, 18, 31, 44, 57, 70, 83, 98, 128, 155, 182, 209, 209, 236, 263, 290 and 317.
In some embodiments, anti-GPC3 Adnectin further comprises a C-terminal moiety selected from the group consisting of PmXn, PmCXn and PmCXn1CXn2, wherein X is any amino acid and m, n, n1 and n2 are independently 0 or an integer of 1, 2, 3, 4, 5 or more.
In some embodiments, the anti-GPC3 Adnectin comprises an amino acid sequence selected from the group consisting of 5, 9-18, 22-31, 35-44, 48-57, 61-70, 74-83, 87-98, 102-128, 130-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343.
In certain embodiments, anti-GPC3 Adnectin comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 98, 102-128, 129-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343, optionally with one or more histidines (e.g., 6×His) at the C-terminus.
In certain embodiments, the anti-GPC3 Adnectin comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 102-127. In certain embodiments, the anti-GPC3 Adnectin comprises SEQ ID NOs: 114-118. In other embodiments, the anti-GPC3 Adnectin comprises SEQ ID NOs: 123-127.
Provided herein are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 10Fn3 domain comprising the BC, DE and FG loops of ADX_6077_A01, i.e., SEQ ID NOs: 99, 100 and 101. Provided herein are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 10Fn3 domain comprising a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 10Fn3 domain comprising a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, wherein one of the two amino acid residues DG in the FG loop is substituted with another amino acid. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 10Fn3 domain comprising a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, wherein amino acid residue D of DG in the FG loop (i.e., D78; the numbering is relative to that in SEQ ID NO: 102) is substituted with another amino acid, e.g., E, S, A, and G. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 10Fn3 domain comprising a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, wherein amino acid residue G of DG in the FG loop (i.e., D79) is substituted with another amino acid residue, e.g., S, A, L or V. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 10Fn3 domain comprising a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, 129, 156, 183, 210, 237, 264, 291 or 318. Any of the polypeptides described in this paragraph may comprise a cysteine residue linked directly or indirectly to the C-terminal end of the polypeptide and/or may comprise one of the following amino acid residues or sequences linked directly or indirectly to the C-terminal end of the polypeptide: P, PC, PCHHHHHH (SEQ ID NO: 395), PCPPPPPC (SEQ ID NO: 416) or PCPPPPPCHHHHHH (SEQ ID NO: 424).
Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 1Fn3 domain comprising the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 1Fn3 domain comprising the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and the 1Fn3 domain comprises a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, or which differs therefrom in one amino acid of DG. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 1Fn3 domain comprising SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and the 1Fn3 domain comprises a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, 129, 156, 183, 210, 237, 264, 291 or 318. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 1Fn3 domain comprising the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and further comprises a cysteine residue linked directly or indirectly to the C-terminal end of the polypeptide. Also provided are polypeptides that bind specifically to human GPC3 with a KD of 10−7 or less, wherein the polypeptides comprise a 1Fn3 domain comprising the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and further comprises one of the following amino acid residues or sequences linked directly or indirectly to the C-terminal end of the polypeptide: P, PC, PCHHHHHH (SEQ ID NO: 395), PCPPPPPC (SEQ ID NO: 416) or PCPPPPPCHHHHHH (SEQ ID NO: 424).
Provided herein are polypeptides comprising the amino acid sequence of ADX_6077_A01 or ADX_6912_G02 (with or without an N-terminal methionine) and with or without a 6×His tail.
Also provided herein are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise the BC, DE and FG loops of ADX_6077_A01, i.e., SEQ ID NOs: 99, 100 and 101. Provided herein are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101. Also provided are ° Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, wherein one of the two amino acid residues DG in the FG loop is substituted with another amino acid. Also provided are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, wherein amino acid residue D of DG in the FG loop (i.e., D78; the numbering is relative to that in SEQ ID NO: 102) is substituted with another amino acid, e.g., E, S, A, and G. Also provided are ° Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, wherein amino acid residue G of DG in the FG loop (i.e., D79) is substituted with another amino acid residue, e.g., S, A, L or V. Also provided are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, 129, 156, 183, 210, 237, 264, 291 or 318. Any of the 10Fn3 proteins described in this paragraph may comprise a cysteine residue linked directly or indirectly to its C-terminus and/or may comprise one of the following amino acid residues or sequences linked directly or indirectly to the C-terminus: P, PC, PCHHHHHH (SEQ ID NO: 395), PCPPPPPC (SEQ ID NO: 416) or PCPPPPPCHHHHHH (SEQ ID NO: 424).
Also provided are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 107′ or less, and comprise the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions. Also provided are 1Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, or which differs therefrom in one amino acid of DG. Also provided are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and comprise a BC loop comprising SEQ ID NO: 99, a DE loop comprising SEQ ID NO: 100 and an FG loop comprising SEQ ID NO: 101, 129, 156, 183, 210, 237, 264, 291 or 318. Also provided are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 10−7 or less, and comprise a 10Fn3 domain comprising the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and further comprises a cysteine residue linked directly or indirectly to its C-terminus. Also provided are 10Fn3 proteins that bind specifically to human GPC3 with a KD of 107′ or less, and comprise a 10Fn3 domain comprising the ADX_6077_A01 core sequence, i.e., SEQ ID NO: 98, or an amino acid sequence that is at least 90%, 95%, 97%, 98%, or 99% identical thereto or that differs therefrom in 1-10, 1-5, 1-3, 1-2 or 1 amino acid substitution (e.g., conservative amino acid substitutions), deletions or additions, and further comprises one of the following amino acid residues or sequences linked directly or indirectly to its C-terminus: P, PC, PCHHHHHH (SEQ ID NO: 395), PCPPPPPC (SEQ ID NO: 416) or PCPPPPPCHHHHHH (SEQ ID NO: 424).
Provided herein are 10Fn3 proteins comprising the amino acid sequence of ADX_6077_A01 or ADX_6912_G02 (with or without an N-terminal methionine) and with or without a 6×His tail.
Also provided are drug conjugates comprising one of the polypeptides or 10Fn3 proteins described in the above paragraphs, conjugated to a drug moiety, such as a tubulysin analog.
Further provided are 10Fn3 proteins or polypeptides comprising 10Fn3 domains comprising at their C-terminus a sequence comprising one or more cysteines, wherein at least one cysteine is conjugated to a tubulysin analog described herein. For example, 10Fn3 proteins or polypeptides comprising 10Fn3 domains may be linked to a peptide comprising the amino acid sequence PmCn, wherein m and n are independent an integer of 1 or more and wherein one or more cysteines is conjugated to a tubulysin analog described herein.
In certain embodiments, BC, DE and/or FG loop amino acid sequences of any one of the anti-GPC3 Adnectins (e.g., SEQ ID NOs: 5, 9-18, 22-31, 35-44, 48-57, 61-70, 74-83, 87-98, 102-128, 130-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343) described herein are grafted into non-10Fn3 domain protein scaffolds. For instance, one or more loop amino acid sequences is exchanged for or inserted into one or more CDR loops of an antibody heavy or light chain or fragment thereof. In other embodiments, the protein domain into which one or more amino acid loop sequences are exchanged or inserted includes, but is not limited to, consensus Fn3 domains (Centocor, US), ankyrin repeat proteins (Molecular Partners AG, Zurich Switzerland), domain antibodies (Domantis, Ltd, Cambridge, Mass.), single domain camelid nanobodies (Ablynx, Belgium), lipocalins (e.g., anticalins; Pieris Proteolab AG, Freising, Germany), Avimers (Amgen, CA), affibodies (Affibody AG, Sweden), ubiquitin (e.g., affilins; Scil Proteins GmbH, Halle, Germany), protein epitope mimetics (Polyphor Ltd, Allschwil, Switzerland), helical bundle scaffolds (e.g. alphabodies, Complix, Belgium), Fyn SH3 domains (Covagen AG, Switzerland), or atrimers (Anaphor, Inc., CA).
B. Cross-Competing Anti-GPC3 Adnectins
Also provided are Adnectins that compete (e.g., cross-compete) for binding to human GPC3 with the particular anti-GPC3 Adnectins described herein. Such competing Adnectins can be identified based on their ability to competitively inhibit binding to GPC3 of Adnectins described herein in standard GPC3 binding assays. For example, standard ELISA assays can be used in which a recombinant GPC3 protein is immobilized on the plate, one of the Adnectins is fluorescently labeled and the ability of non-labeled Adnectins to compete off the binding of the labeled Adnectin is evaluated.
In certain embodiments, a competitive ELISA format can be performed to determine whether two anti-GPC3 Adnectins bind overlapping Adnectin binding sites on GPC3. In one format, Adnectin #1 is coated on a plate, which is then blocked and washed. To this plate is added either GPC3 alone, or GPC3 pre-incubated with a saturating concentration of Adnectin #2. After a suitable incubation period, the plate is washed and probed with a polyclonal anti-GPC3 antibody, such as a biotinylated anti-GPC3 polyclonal antibody, followed by detection with streptavidin-HRP conjugate and standard tetramethylbenzidine development procedures. If the OD signal is the same with or without preincubation with Adnectin #2, then the two Adnectins bind independently of one another, and their Adnectin binding sites do not overlap. If, however, the OD signal for wells that received GPC3/Adnectin #2 mixtures is lower than for those that received GPC3 alone, then binding of Adnectin #2 is confirmed to block binding of Adnectin #1 to GPC3.
Alternatively, a similar experiment is conducted by surface plasmon resonance (SPR, e.g., BIAcore). Adnectin #1 is immobilized on an SPR chip surface, followed by injections of either GPC3 alone or GPC3 pre-incubated with a saturating concentration of Adnectin #2. If the binding signal for GPC3/Adnectin #2 mixtures is the same or higher than that of GPC3 alone, then the two Adnectins bind independently of one another, and their Adnectin binding sites do not overlap. If, however, the binding signal for GPC3/Adnectin #2 mixtures is lower than the binding signal for GPC3 alone, then binding of Adnectin #2 is confirmed to block binding of Adnectin #1 to GPC3. A feature of these experiments is the use of saturating concentrations of Adnectin #2. If GPC3 is not saturated with Adnectin #2, then the conclusions above do not hold. Similar experiments can be used to determine if any two GPC3 binding proteins bind to overlapping Adnectin binding sites.
Both assays exemplified above may also be performed in the reverse order where Adnectin #2 is immobilized and GPC3-Adnectin #1 are added to the plate. Alternatively, Adnectin #1 and/or #2 can be replaced with a monoclonal antibody and/or soluble receptor-Fc fusion protein.
In another embodiment, competition can be determined using a HTRF sandwich assay.
Candidate competing anti-GPC3 Adnectins can inhibit the binding of an anti-GPC3 Adnectin described herein to GPC3 by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% and/or their binding is inhibited by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%. The % competition can be determined using the methods described above.
In some embodiments, molecules that compete with the anti-GPC3 Adnectins described herein need not be an Adnectin, but can be any type of molecule that binds to GPC3, such as, but not limited to, an antibody, a small molecule, a peptide, and the like.
In certain embodiments, an Adnectin binds to the same Adnectin binding site on GPC3 as a particular anti-GPC3 Adnectin described herein. Standard mapping techniques, such as protease mapping, mutational analysis, HDX-MS, x-ray crystallography and 2-dimensional nuclear magnetic resonance, can be used to determine whether an Adnectin binds to the same Adnectin binding site as a reference Adnectin (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996)).
In some embodiments, anti-GPC3 Adnectins provided herein bind to a discontinuous Adnectin binding site on human GPC3. In some embodiments, an anti-GPC3 FBS binds a region of, e.g., 10-20 amino acid residues, within human GPC3 (SEQ ID NO:344) which comprises SEQ ID NO: 345. In some embodiments, an anti-GPC3 Adnectin binds a region of, e.g., 10-20 amino acid residues, within human GPC3 (SEQ ID NO: 344) which comprises SEQ ID NO: 346. In other embodiments, an anti-GPC3 FBS binds two regions of, e.g., 10-20 amino acid residues, each within human GPC3 (SEQ ID NO: 344), one comprising SEQ ID NO: 345 and the other region comprising SEQ ID NO: 346, respectively.
C. N-Terminal and C-Terminal Modified Anti-GPC3 Adnectins
In some embodiments, the amino acid sequences of the N-terminal and/or C-terminal regions of an Adnectin are modified by deletion, substitution or insertion relative to the amino acid sequences of the corresponding regions of 10Fn3 domains comprising, e.g., SEQ ID NO: 1.
In certain embodiments, the amino acid sequence of the first 1, 2, 3, 4, 5, 6, 7, 8 or 9 residues of Adnectins, e.g., having sequences starting with “VSD”, as in, e.g., SEQ ID NO: 1, may be modified or deleted in the polypeptides provided herein. In exemplary embodiments, the amino acids corresponding to amino acids 1-7, 8 or 9 of Adnectins having sequences starting with “VSD”, as in, e.g., SEQ ID NO: 1 are replaced with an alternative N-terminal region having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length.
Exemplary alternative N-terminal regions that can be added to GPC3 Adnectin core sequences or those starting with “VSD” include (represented by the single letter amino acid code) M, MG, G, MGVSDVPRD (SEQ ID NO: 351) and GVSDVPRD (SEQ ID NO: 352). Other suitable alternative N-terminal regions include, for example, XnSDVPRDL (SEQ ID NO: 353), XnDVPRDL (SEQ ID NO: 354), XnVPRDL (SEQ ID NO: 355), XnPRDL (SEQ ID NO: 356), XnRDL (SEQ ID NO: 357), XnDL (SEQ ID NO: 358), or XnL, wherein n=0, 1 or 2 amino acids, wherein when n=1, X is Met or Gly, and when n=2, X is Met-Gly. When a Met-Gly sequence is added to the N-terminus of a 10Fn3 domain, the M will usually be cleaved off, leaving a G at the N-terminus. In other embodiments, the alternative N-terminal region comprises the amino acid sequence MASTSG (SEQ ID NO: 359). In certain embodiments, the N-terminal extension consists of an amino acid sequence selected from the group consisting of: M, MG, and G.
In some embodiments, an alternative C-terminal region having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length can be added to the C-terminal region of GPC3 Adnectins ending in “RT”, as, e.g., in SEQ ID NO: 1. Examples of alternative C-terminal region sequences include, for example, polypeptides comprising, consisting essentially of, or consisting of, EIEK (SEQ ID NO: 360), EGSGC (SEQ ID NO: 361), EIEKPCQ (SEQ ID NO: 362), EIEKPSQ (SEQ ID NO: 363), EIEKP (SEQ ID NO: 364), EIEKPS (SEQ ID NO: 365), EIEKPC (SEQ ID NO: 366), EIDK (SEQ ID NO: 367), EIDKPCQ (SEQ ID NO: 368) or EIDKPSQ (SEQ ID NO: 369). In certain embodiments, the C-terminal region consists of EIDKPCQ (SEQ ID NO: 368). In certain embodiments, 10Fn3 domain is linked to a C-terminal extension sequence that comprises E and D residues, and may be between 8 and 50, 10 and 30, 10 and 20, 5 and 10, and 2 and 4 amino acids in length. In some embodiments, tail sequences include ED-based linkers in which the sequence comprises tandem repeats of ED. In exemplary embodiments, the tail sequence comprises 2-10, 2-7, 2-5, 3-10, 3-7, 3-5, 3, 4 or 5 ED repeats. In certain embodiments, the ED-based tail sequences may also include additional amino acid residues, such as, for example: EI, EID, ES, EC, EGS, and EGC. Such sequences are based, in part, on known Adnectin tail sequences, such as EIDKPSQ (SEQ ID NO: 369), in which residues D and K have been removed. In some embodiments, the ED-based tail comprises an E, I or E1 residues before the ED repeats.
In certain embodiments, the N- or C-terminal extension sequences are linked to the 10Fn3 domain with known linker sequences (e.g., SEQ ID NOs:426-451 in Table 13). In some embodiments, sequences may be placed at the C-terminus of the 10Fn3 domain to facilitate attachment of a pharmacokinetic moiety. For example, a cysteine containing linker such as GSGC may be added to the C-terminus to facilitate site directed PEGylation on the cysteine residue.
In certain embodiments, an alternative C-terminal moiety, which can be linked to the C-terminal amino acids RT (i.e., amino acid 94, e.g., as in SEQ ID NO: 1) of GPC3 Adnectins comprises the amino acids PmXn, wherein P is proline, X is any amino acid, m is an integer that is at least 1 and n is 0 or an integer that is at least 1. In some embodiments, m may be 1, 2, 3 or more. For example, m may be 1-3 or m may be 1-2. “n” may be 0, 1, 2, 3 or more, e.g., n may be 1-3 or 1-2.
The PmXn moiety may be linked directly to the C-terminal amino acid of a 10Fn3 moiety, e.g., to its 94th amino acid (based on amino acid numbering of SEQ ID NO: 1). The PmXn moiety may be linked via a peptide bond to the 94th amino acid of a 10Fn3 moiety. A single proline residue at the end of SEQ ID NO: 1 is referred to as “95Pro” or “Pro95” or “P95” or “95P”.
In certain embodiments, n is not 0, and may be, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. For example, n may be from 0-10, 0-5, 0-3, 1-10, 1-5, 1-3 or 1-2. However, more than 10 amino acids may be linked to the proline. For example, in a tandem FBS moiety or a FBS moiety fused to another polypeptide, the C-terminal amino acid of the FBS moiety may be linked to one or more prolines, and the last proline is linked to the second FBS moiety or to the heterologous moiety. Therefore, in certain embodiments, n may be an integer ranging from 0-100, 0-200, 0-300, 0-400, 0-500 or more.
In certain embodiments, PmXn linked to the C-terminus of a GPC3 Adnectin comprises a cysteine. For example, the first amino acid after the proline may be a cysteine, and the cysteine may be the last amino acid in the molecule or the cysteine may be followed by one or more amino acids. The presence of a cysteine permits the conjugation of heterologous moieties to the FBS moiety, e.g., chemical moieties, e.g., PEG. Exemplary PmXn moieties comprising a cysteine include: PmCXn, wherein C is a cysteine, each X is independently any amino acid, m is an integer that is at least 1 and n is 0 or an integer that is at least 1. In some embodiments, m may be 1, 2, 3 or more. For example, m may be 1-3 or m may be 1-2. “n” may be 0, 1, 2, 3 or more, e.g., n may be 1-3 or 1-2. Other exemplary PmXn moieties include two cysteines, for example, PmCXn1CXn2, wherein each X is independently any amino acid, n1 and n2 are independently 0 or an integer that is at least 1. For example, n1 may be 1, 2, 3, 4 or 5 and n2 may be 1, 2, 3, 4 or 5. Exemplary PmXn moieties include those listed in Table 1.
TABLE 1
Exemplary PmXn moieties
Moieties with 1 proline
Moieties with 2 or more prolines
Moieties with 2 cysteines
P
PP
PCC
PI
PPI
PCGC (SEQ ID NO: 412)
PC
PPC
PCPC (SEQ ID NO: 413)
PID
PPID (SEQ ID NO: 396)
PCGSGC (SEQ ID NO: 414)
PIE
PPIE (SEQ ID NO: 397)
PCPPPC (SEQ ID NO: 415)
PIDK (SEQ ID NO: 382)
PPIDK (SEQ ID NO: 398)
PCPPPPPC (SEQ ID NO: 416)
PIEK (SEQ ID NO: 383)
PPIEK (SEQ ID NO: 399)
PCGSGSGC (SEQ ID NO: 417)
PIDKP (SEQ ID NO: 384)
PPIDKP (SEQ ID NO: 400)
PCHHHHHC (SEQ ID NO: 418)
PIEKP (SEQ ID NO: 385)
PPIEKP (SEQ ID NO: 401)
PCCHHHHHH (SEQ ID NO: 419)
PIDKPS (SEQ ID NO: 386)
PPIDKPS (SEQ ID NO: 402)
PCGCHHHHHH (SEQ ID NO: 420)
PIEKPS (SEQ ID NO: 387)
PPIEKPS (SEQ ID NO: 403)
PCPCHHHHHH (SEQ ID NO: 421)
PIDKPC (SEQ ID NO: 388)
PPIDKPC (SEQ ID NO: 404)
PCGSGCHHHHHH (SEQ ID NO: 422)
PIEKPC (SEQ ID NO: 389)
PPIEKPC (SEQ ID NO: 405)
PCPPPCHHHHHH (SEQ ID NO: 423)
PIDKPSQ (SEQ ID NO: 390)
PPIDKPSQ (SEQ ID NO: 406)
PCPPPPPCHHHHHH (SEQ ID NO: 424)
PIEKPSQ (SEQ ID NO: 391)
PPIEKPSQ (SEQ ID NO: 407)
PCGSGSGCHHHHHH (SEQ ID NO: 425)
PIDKPCQ (SEQ ID NO: 392)
PPIDKPCQ (SEQ ID NO: 408)
PIEKPCQ (SEQ ID NO: 393)
PPIEKPCQ (SEQ ID NO: 409)
PHHHHHH (SEQ ID NO: 394)
PPHHHHHH (SEQ ID NO: 410)
PCHHHHHH (SEQ ID NO: 395)
PPCHHHHHH (SEQ ID NO: 411)
In certain embodiments, for example, the PmXn moiety is selected from the group consisting of PC, PPC and PCC. In another embodiment, the PmXn moiety is PmCXn1CXn2. In certain embodiments, PmCXn1CXn2 is selected from the group consisting of PCPPPC (SEQ ID NO: 415) and PCPPPPPC (SEQ ID NO: 416).
Any of the C-terminal modifications described herein may be applied to GPC3 Adnectins.
Any of the PmXn moieties, e.g., those shown in Table 1 may be followed by a histidine tail, e.g., 6×His tag, or other tag. This does not exclude that a histidine tail may be included in PmXn.
In certain embodiments, the fibronectin based scaffold proteins comprise a 10Fn3 domain having both an alternative N-terminal region sequence and an alternative C-terminal region sequence, and optionally a 6×his tail.
II. Multivalent Polypeptides
In certain embodiments, a protein comprises GPC3 FBS and at least one other FBS. A multivalent FBS may comprise 2, 3 or more FBS, that are covalently associated. In exemplary embodiments, the FBS moiety is a bispecific or dimeric protein comprising two 10Fn3 domains.
The FBS moieties, e.g., 10Fn3 domains, in a multivalent protein may be connected by a polypeptide linker. Exemplary polypeptide linkers include polypeptides having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, or 1-2 amino acids. Suitable linkers for joining the 10Fn3 domains are those which allow the separate domains to fold independently of each other forming a three dimensional structure that permits high affinity binding to a target molecule. Specific examples of suitable linkers include glycine-serine based linkers, glycine-proline based linkers, proline-alanine based linkers as well as any other linkers described herein. In some embodiments, the linker is a glycine-proline based linker. These linkers comprise glycine and proline residues and may be between 3 and 30, 10 and 30, and 3 and 20 amino acids in length. Examples of such linkers include GPG, GPGPGPG (SEQ ID NO: 436) and GPGPGPGPGPG (SEQ ID NO: 437). In some embodiments, the linker is a proline-alanine based linker. These linkers comprise proline and alanine residues and may be between 3 and 30, 10 and 30, 3 and 20 and 6 and 18 amino acids in length. Examples of such linkers include PAPAPA (SEQ ID NO: 438), PAPAPAPAPAPA (SEQ ID NO: 439) and PAPAPAPAPAPAPAPAPA (SEQ ID NO: 440). In some embodiments, the linker is a glycine-serine based linker. These linkers comprise glycine and serine residues and may be between 8 and 50, 10 and 30, and 10 and 20 amino acids in length. Examples of such linkers may contain, for example, (GS)5-10 (SEQ ID NO: 464), (G4S)2-5 (SEQ ID NO: 465), and (G4S)2G (SEQ ID NO: 466). Examples of such linkers include SEQ ID NOs: 427-439. In exemplary embodiments, the linker does not contain any Asp-Lys (DK) pairs.
III. Pharmacokinetic Moieties
For therapeutic purposes, the anti-GPC3 Adnectins described herein may be linked directly or indirectly to a pharmacokinetic (PK) moiety. Improved pharmacokinetics may be assessed according to the perceived therapeutic need. Often it is desirable to increase bioavailability and/or increase the time between doses, possibly by increasing the time that a protein remains available in the serum after dosing. In some instances, it is desirable to improve the continuity of the serum concentration of the protein over time (e.g., decrease the difference in serum concentration of the protein shortly after administration and shortly before the next administration). The anti-GPC3 Adnectin may be attached to a moiety that reduces the clearance rate of the polypeptide in a mammal (e.g., mouse, rat, or human) by greater than two-fold, greater than three-fold, greater than four-fold or greater than five-fold relative to the unmodified anti-GPC3 Adnectin. Other measures of improved pharmacokinetics may include serum half-life, which is often divided into an alpha phase and a beta phase. Either or both phases may be improved significantly by addition of an appropriate moiety. For example, the PK moiety may increase the serum half-life of the polypeptide by more than 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 400, 600, 800, 1000% or more relative to the Fn3 domain alone.
Moieties that slow clearance of a protein from the blood, herein referred to as “PK moieties”, include polyoxyalkylene moieties (e.g., polyethylene glycol), sugars (e.g., sialic acid), and well-tolerated protein moieties (e.g., Fc and fragments and variants thereof, transferrin, or serum albumin). The anti-GPC3 Adnectin may also be fused to albumin or a fragment (portion) or variant of albumin as described in U.S. Publication No. 2007/0048282, or may be fused to one or more serum albumin binding Adnectin, as described herein.
Other PK moieties that can be used in the invention include those described in Kontermann et al., (Current Opinion in Biotechnology 2011; 22:868-76), herein incorporated by reference. Such PK moieties include, but are not limited to, human serum albumin fusions, human serum albumin conjugates, human serum albumin binders (e.g., Adnectin PKE, AlbudAb, ABD), XTEN fusions, PAS fusions (i.e., recombinant PEG mimetics based on the three amino acids proline, alanine, and serine), carbohydrate conjugates (e.g., hydroxyethyl starch (HES)), glycosylation, polysialic acid conjugates, and fatty acid conjugates.
In some embodiments the invention provides an anti-GPC3 Adnectin fused to a PK moiety that is a polymeric sugar. In some embodiments, the PK moiety is a polyethylene glycol moiety or an Fc region. In some embodiments the PK moiety is a serum albumin binding protein such as those described in U.S. Publication Nos. 2007/0178082 and 2007/0269422. In some embodiments the PK moiety is human serum albumin. In some embodiments, the PK moiety is transferrin.
In some embodiments, the PK moiety is linked to the anti-GPC3 Adnectin via a polypeptide linker. Exemplary polypeptide linkers include polypeptides having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, or 1-2 amino acids. Suitable linkers for joining the Fn3 domains are those which allow the separate domains to fold independently of each other forming a three dimensional structure that permits high affinity binding to a target molecule. In exemplary embodiments, the linker does not contain any Asp-Lys (DK) pairs. A list of suitable linkers is provided in Table 14 (e.g., SEQ ID NOs: 426-451).
In some embodiments, an anti-GPC3 Adnectin is linked, for example, to an anti-HSA Adnectin via a polypeptide linker having a protease site that is cleavable by a protease in the blood or target tissue. Such embodiments can be used to release an anti-GPC3 Adnectin for better delivery or therapeutic properties or more efficient production.
Additional linkers or spacers, may be introduced at the N-terminus or C-terminus of a Fn3 domain between the Fn3 domain and the polypeptide linker.
Polyethylene Glycol
In some embodiments, the anti-GPC3 Adnectin comprises polyethylene glycol (PEG). PEG is a well-known, water soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pages 138-161). The term “PEG” is used broadly to encompass any polyethylene glycol molecule, without regard to size or to modification at an end of the PEG, and can be represented by the formula: X—O(CH2CH2O)n-1CH2CH2OH, where n is 20 to 2300 and X is H or a terminal modification, e.g., a C1-4 alkyl. PEG can contain further chemical groups which are necessary for binding reactions, which result from the chemical synthesis of the molecule; or which act as a spacer for optimal distance of parts of the molecule. In addition, such a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs. Branched PEGs are described in, for example, European Published Application No. 473084A and U.S. Pat. No. 5,932,462.
Immunoglobulin Fc Domain (and Fragments)
In certain embodiments, the anti-GPC3 Adnectin is fused to an immunoglobulin Fc domain, or a fragment or variant thereof. As used herein, a “functional Fc region” is an Fc domain or fragment thereof which retains the ability to bind FcRn. In some embodiments, a functional Fc region binds to FcRn, bud does not possess effector function. The ability of the Fc region or fragment thereof to bind to FcRn can be determined by standard binding assays known in the art. In other embodiments, the Fc region or fragment thereof binds to FcRn and possesses at least one “effector function” of a native Fc region. Exemplary “effector functions” include C1q binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an anti-GPC3 Adnectin) and can be assessed using various assays known in the art for evaluating such antibody effector functions.
A “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification. Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g., from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% sequence identity with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and most preferably at least about 90% sequence identity therewith, more preferably at least about 95% sequence identity therewith.
In an exemplary embodiment, the Fc domain is derived from an IgG1 subclass, however, other subclasses (e.g., IgG2, IgG3, and IgG4) may also be used. Shown below is the sequence of a human IgG1 immunoglobulin Fc domain:
(SEQ ID NO: 463)
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK
The core hinge sequence is underlined, and the CH2 and CH3 regions are in regular text. It should be understood that the C-terminal lysine is optional. Allotypes and mutants of this sequence may also be used. As is known in the art, mutants can be designed to modulate a variety of properties of the Fc, e.g., ADCC, CDC or half-life.
In certain embodiments, the Fc region used in the anti-GPC3 Adnectin fusion comprises a 7 region. In certain embodiments, the Fc region used in the anti-GPC3 Adnectin fusion comprises CH2 and CH3 regions. In certain embodiments, the Fc region used in the anti-GPC3 Adnectin fusion comprises a CH2, CH3, and hinge region.
In certain embodiments, the “hinge” region comprises the core hinge residues spanning positions 1-16 of SEQ ID NO: 463 (DKTHTCPPCPAPELLG; SEQ ID NO: 464) of the IgG1 Fc region. In certain embodiments, the anti-GPC3 Adnectin-Fc fusion adopts a multimeric structure (e.g., dimer) owing, in part, to the cysteine residues at positions 6 and 9 of SEQ ID NO: within the hinge region.
IV. Vectors and Polynucleotides
Also provided herein are nucleic acids encoding the anti-GPC3 Adnectins described herein. As appreciated by those skilled in the art, because of third base degeneracy, almost every amino acid can be represented by more than one triplet codon in a coding nucleotide sequence. In addition, minor base pair changes may result in a conservative substitution in the amino acid sequence encoded but are not expected to substantially alter the biological activity of the gene product. Therefore, a nucleic acid sequence encoding a protein described herein may be modified slightly in sequence and yet still encode its respective gene product. Certain exemplary nucleic acids encoding the anti-GPC3 Adnectins and their fusions described herein include nucleic acids having the sequences set forth in SEQ ID NOs: 452-462.
Nucleic acids encoding any of the various proteins comprising an anti-GPC3 Adnectin disclosed herein may be synthesized chemically, enzymatically or recombinantly. Codon usage may be selected so as to improve expression in a cell. Such codon usage will depend on the cell type selected. Specialized codon usage patterns have been developed for E. coli and other bacteria, as well as mammalian cells, plant cells, yeast cells and insect cells. See for example: Mayfield et al., Proc. Natl. Acad. Sci. USA, 100(2):438-442 (Jan. 21, 2003); Sinclair et al., Protein Expr. Purif, 26(1):96-105 (October 2002); Connell, N. D., Curr. Opin. Biotechnol., 12(5):446-449 (October 2001); Makrides et al., Microbiol. Rev., 60(3):512-538 (September 1996); and Sharp et al., Yeast, 7(7):657-678 (October 1991).
General techniques for nucleic acid manipulation are described for example in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Vols. 1-3, Cold Spring Harbor Laboratory Press (1989), or Ausubel, F. et al., Current Protocols in Molecular Biology, Green Publishing and Wiley-Interscience, New York (1987) and periodic updates, herein incorporated by reference. The DNA encoding the polypeptide is operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, viral, or insect genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences that control the termination of transcription and translation. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants are additionally incorporated.
The proteins described herein may be produced recombinantly not only directly, but also as a polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process a native signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader, a factor leader (including Saccharomyces and Kluyveromyces alpha-factor leaders), or acid phosphatase leader, the C. albicans glucoamylase leader, or the signal described in PCT Publication No. WO 90/13646. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available. The DNA for such precursor regions may be ligated in reading frame to DNA encoding the protein.
Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).
Expression and cloning vectors may contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
A suitable selection gene for use in yeast is the trp 1 gene present in the yeast plasmid YRp7 (Stinchcomb et al., Nature, 282:39 (1979)). The trp1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC® No. 44076 or PEP4-1. Jones, Genetics, 85:12 (1977). The presence of the trp1 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC® 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the nucleic acid encoding the protein. Promoters suitable for use with prokaryotic hosts include the phoA promoter, beta-lactamase and lactose promoter systems, alkaline phosphatase, a tryptophan (trp) promoter system, and hybrid promoters such as the tac promoter. However, other known bacterial promoters are suitable. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the protein.
Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT (SEQ ID NO: 465) region where N may be any nucleotide. At the 3′ end of most eukaryotic genes is an AATAAA (SEQ ID NO: 466) sequence that may be the signal for addition of the poly A tail to the 3′ end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.
Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP Patent Publication No. 73,657 and PCT Publication Nos. WO 2011/124718 and WO 2012/059486. Yeast enhancers also are advantageously used with yeast promoters.
Transcription from vectors in mammalian host cells can be controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the ACTIN® promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems.
The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Pat. No. 4,419,446. A modification of this system is described in U.S. Pat. No. 4,601,978. See also Reyes et al., Nature, 297:598-601 (1982) on expression of human β-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the rous sarcoma virus long terminal repeat can be used as the promoter.
Transcription of a DNA encoding a protein by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature, 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5′ or 3′ to the polypeptide-encoding sequence, but is preferably located at a site 5′ from the promoter.
Expression vectors used in eukaryotic host cells (e.g., yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5′ and, occasionally 3′, untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the polypeptide. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO 94/11026 and the expression vector disclosed therein.
The recombinant DNA can also include any type of protein tag sequence that may be useful for purifying the proteins. Examples of protein tags include but are not limited to a histidine tag, a FLAG® tag, a myc tag, an HA tag, or a GST tag. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts can be found in Cloning Vectors: A Laboratory Manual, Elsevier, New York (1985), the relevant disclosure of which is hereby incorporated by reference.
The expression construct may be introduced into the host cell using a method appropriate to the host cell, as will be apparent to one of skill in the art. A variety of methods for introducing nucleic acids into host cells are known in the art, including, but not limited to, electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is an infectious agent).
Suitable host cells include prokaryotes, yeast, mammalian cells, or bacterial cells. Suitable bacteria include gram negative or gram positive organisms, for example, E. coli or Bacillus spp. Yeast, preferably from the Saccharomyces species, such as S. cerevisiae, may also be used for production of polypeptides. Various mammalian or insect cell culture systems can also be employed to express recombinant proteins. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow et al. (Bio/Technology, 6:47 (1988)). Examples of suitable mammalian host cell lines include endothelial cells, COS-7 monkey kidney cells, CV-1, L cells, C127, 3T3, Chinese hamster ovary (CHO), human embryonic kidney cells, HeLa, 293, 293T, and BHK cell lines. Purified proteins are prepared by culturing suitable host/vector systems to express the recombinant proteins. The FBS protein is then purified from culture media or cell extracts.
V. Protein Production
Host cells are transformed with the herein-described expression or cloning vectors for protein production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
The host cells used to produce the proteins may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma)), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), (Sigma)) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enzymol., 58:44 (1979), Barnes et al., Anal. Biochem., 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; PCT Publication Nos. WO 90/03430; WO 87/00195; or U.S. Pat. No. RE30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as Gentamycin drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
Proteins disclosed herein can also be produced using cell-free translation systems. For such purposes the nucleic acids encoding the protein must be modified to allow in vitro transcription to produce mRNA and to allow cell-free translation of the mRNA in the particular cell-free system being utilized (eukaryotic such as a mammalian or yeast cell-free translation system or prokaryotic such as a bacterial cell-free translation system).
Proteins can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, Second Edition, The Pierce Chemical Co., Rockford, Ill. (1984)). Modifications to the protein can also be produced by chemical synthesis.
The proteins disclosed herein can be purified by isolation/purification methods for proteins generally known in the field of protein chemistry. Non-limiting examples include extraction, recrystallization, salting out (e.g., with ammonium sulfate or sodium sulfate), centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, normal phase chromatography, reversed-phase chromatography, gel filtration, gel permeation chromatography, affinity chromatography, electrophoresis, countercurrent distribution or any combinations of these. After purification, proteins may be exchanged into different buffers and/or concentrated by any of a variety of methods known to the art, including, but not limited to, filtration and dialysis.
The purified protein is preferably at least 85% pure, more preferably at least 95% pure, and most preferably at least 98% or 99% pure. Regardless of the exact numerical value of the purity, the protein is sufficiently pure for use as a pharmaceutical product.
One method for expressing Adnectins in E. coli is as follows. A nucleic acid encoding an Adnectin is cloned into the PET9d vector upstream of a HIS6tag and are transformed into E. coli BL21 DE3 plysS cells and inoculated in 5 ml LB medium containing 50 μg/mL kanamycin in a 24-well format and grown at 37° C. overnight. Fresh 5 ml LB medium (50 μg/mL kanamycin) cultures are prepared for inducible expression by aspiration of 200 μl from the overnight culture and dispensing it into the appropriate well. The cultures are grown at 37° C. until A600 0.6-0.9. After induction with 1 mM isopropyl-β-thiogalactoside (IPTG), the culture is expressed for 6 hours at 30° C. and harvested by centrifugation for 10 minutes at 2750 g at 4° C.
Cell pellets (in 24-well format) are lysed by resuspension in 450 μl of Lysis buffer (50 mM NaH2PO4, 0.5 M NaCl, 1× Complete™ Protease Inhibitor Cocktail-EDTA free (Roche), 1 mM PMSF, 10 mM CHAPS, 40 mM imidazole, 1 mg/ml lysozyme, 30 μg/ml DNAse, 2 μg/ml aprotonin, pH 8.0) and shaken at room temperature for 1-3 hours. Lysates are cleared and re-racked into a 96-well format by transfer into a 96-well Whatman GF/D Unifilter fitted with a 96-well, 1.2 ml catch plate and filtered by positive pressure. The cleared lysates are transferred to a 96-well Nickel or Cobalt-Chelating Plate that had been equilibrated with equilibration buffer (50 mM NaH2PO4, 0.5 M NaCl, 40 mM imidazole, pH 8.0) and are incubated for 5 min. Unbound material is removed by positive pressure. The resin is washed twice with 0.3 ml/well with Wash buffer #1 (50 mM NaH2PO4, 0.5 M NaCl, 5 mM CHAPS, 40 mM imidazole, pH 8.0). Each wash is removed by positive pressure. Prior to elution, each well is washed with 50 μl Elution buffer (PBS+20 mM EDTA), incubated for 5 min, and this wash is discarded by positive pressure. Protein is eluted by applying an additional 100 μl of Elution buffer to each well. After a 30 minute incubation at room temperature, the plate(s) are centrifuged for 5 minutes at 200 g and eluted protein collected in 96-well catch plates containing 5 μl of 0.5 M MgCl2 added to the bottom of elution catch plate prior to elution. Eluted protein is quantified using a total protein assay with wild-type 10Fn3 domain as the protein standard.
A method for midscale expression and purification of insoluble Adnectins is as follows. An nucleic acid endcoding an Adnectin(s) followed by the HIS6tag, is cloned into a pET9d (EMD Bioscience, San Diego, Calif.) vector and are expressed in E. coli HMS174 cells. Twenty ml of an inoculum culture (generated from a single plated colony) is used to inoculate 1 liter of LB medium containing 50 μg/ml carbenicillin and 34 μg/ml chloramphenicol. The culture is grown at 37° C. until A600 0.6-1.0. After induction with 1 mM isopropyl-β-thiogalactoside (IPTG) the culture is grown for 4 hours at 30° C. and is harvested by centrifugation for 30 minutes at >10,000 g at 4° C. Cell pellets are frozen at −80° C. The cell pellet is resuspended in 25 ml of lysis buffer (20 mM aH2PO4, 0.5 M NaCl, 1× Complete Protease Inhibitor Cocktail-EDTA free (Roche), ImM PMSF, pH 7.4) using an ULTRA-TURRAX® homogenizer (IKA works) on ice. Cell lysis is achieved by high pressure homogenization (>18,000 psi) using a Model M-1 10S MICROFLUIDIZER® (Microfluidics). The insoluble fraction is separated by centrifugation for 30 minutes at 23,300 g at 4° C. The insoluble pellet recovered from centrifugation of the lysate is washed with 20 mM sodiumphosphate/500 mM NaCl, pH7.4. The pellet is resolubilized in 6.0M guanidine hydrochloride in 20 mM sodium phosphate/500M NaCl pH 7.4 with sonication followed by incubation at 37 degrees for 1-2 hours. The resolubilized pellet is filtered to 0.45 m and loaded onto a Histrap column equilibrated with the 20 mM sodium phosphate/500 M NaCl/6.0 M guanidine pH 7.4 buffer. After loading, the column is washed for an additional 25 CV with the same buffer. Bound protein is eluted with 50 mM Imidazole in 20 mM sodium phosphate/500 mM NaCl/6.0 M guan-HCl pH7.4. The purified protein is refolded by dialysis against 50 mM sodium acetate/150 mM NaCl pH 4.5.
A method for midscale expression and purification of soluble Adnectins is as follows. A nucleic acid encoding an Adnectin(s), followed by the HIS6tag, is cloned into a pET9d (EMD Bioscience, San Diego, Calif.) vector and expressed in E. coli HMS 174 cells. Twenty ml of an inoculum culture (generated from a single plated colony) is used to inoculate 1 liter of LB medium containing 50 μg/ml carbenicillin and 34 μg/ml chloramphenicol. The culture is grown at 37° C. until A600 0.6-1.0. After induction with 1 mM isopropyl-β-thiogalactoside (IPTG), the culture is grown for 4 hours at 30° C. and harvested by centrifugation for 30 minutes at >10,000 g at 4° C. Cell pellets are frozen at −80° C. The cell pellet is resuspended in 25 ml of lysis buffer (20 mM NaH2PO4, 0.5 M NaCl, 1× Complete Protease Inhibitor Cocktail-EDTA free (Roche), ImM PMSF, pH 7.4) using an ULTRA-TURRAX® homogenizer (IKA works) on ice. Cell lysis is achieved by high pressure homogenization (>18,000 psi) using a Model M-1 10S MICROFLUIDIZER® (Microfluidics). The soluble fraction is separated by centrifugation for 30 minutes at 23,300 g at 4° C. The supernatant is clarified via 0.45 m filter. The clarified lysate is loaded onto a Histrap column (GE) pre-equilibrated with the 20 mM sodium phosphate/500M NaCl pH 7.4. The column is then washed with 25 column volumes of the same buffer, followed by 20 column volumes of 20 mM sodium phosphate/500 M NaCl/25 mM Imidazole, pH 7.4 and then 35 column volumes of 20 mM sodium phosphate/500 M NaCl/40 mM Imidazole, pH 7.4. Protein is eluted with 15 column volumes of 20 mM sodium phosphate/500 M NaCl/500 mM Imidazole, pH 7.4, fractions are pooled based on absorbance at A2 so and dialyzed against 1×PBS, 50 mM Tris, 150 mM NaCl; pH 8.5 or 50 mM NaOAc; 150 mM NaCl; pH4.5. Any precipitate is removed by filtering at 0.22 m.
VI. Biophysical and Biochemical Characterization
Binding of the anti-GPC3 Adnectins described herein may be assessed in terms of equilibrium constants (e.g., dissociation, KD) and in terms of kinetic constants (e.g., on-rate constant, kon and off-rate constant, koff). An Adnectin will generally bind to a target molecule with a KD of less than 1 μM, 500 nM, 100 nM, 10 nM, 1 nM, 500 pM, 200 pM, or 100 pM, although higher KD values may be tolerated where the koff is sufficiently low or the kon, is sufficiently high.
In Vitro Assays for Binding Affinity
Exemplary assays for determining the binding affinity of an anti-GPC3 Adnectin includes, but is not limited to, solution phase methods such as the kinetic exclusion assay (KinExA) (Blake et al., JBC 1996; 271:27677-85; Drake et al., Anal Biochem 2004; 328:35-43), surface plasmon resonance (SPR) with the Biacore system (Uppsala, Sweden) (Welford et al., Opt. Quant. Elect 1991; 23:1; Morton and Myszka, Methods in Enzymology 1998; 295:268) and homogeneous time resolved fluorescence (HTRF) assays (Newton et al., J Biomol Screen 2008; 13:674-82; Patel et al., Assay Drug Dev Technol 2008; 6:55-68).
In certain embodiments, biomolecular interactions can be monitored in real time with the Biacore system, which uses SPR to detect changes in the resonance angle of light at the surface of a thin gold film on a glass support due to changes in the refractive index of the surface up to 300 nm away. Biacore analysis generates association rate constants, dissociation rate constants, equilibrium dissociation constants, and affinity constants. Binding affinity is obtained by assessing the association and dissociation rate constants using a Biacore surface plasmon resonance system (Biacore, Inc.). A biosensor chip is activated for covalent coupling of the target. The target is then diluted and injected over the chip to obtain a signal in response units of immobilized material. Since the signal in resonance units (RU) is proportional to the mass of immobilized material, this represents a range of immobilized target densities on the matrix. Association and dissociation data are fit simultaneously in a global analysis to solve the net rate expression for a 1:1 bimolecular interaction, yielding best fit values for kon, koff and Rmax (maximal response at saturation). Equilibrium dissociation constants for binding, KD's are calculated from SPR measurements as koff/kon.
In some embodiments, the anti-GPC3 Adnectins described herein exhibit a KD in the SPR affinity assay described in Example 2 of 1 μM or less, 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 150 nM or less, 100 nM or less, 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less, 10 nM or less, 5 nM or less, or 1 nM or less.
In some embodiments, the anti-GPC3 Adnectin does not substantially bind to related proteins, for example, the anti-GPC3 Adnectin does not substantially bind to Glypican-1, Glypican-2, Glypican-4 or Glypican-6.
It should be understood that the assays described herein above are exemplary, and that any method known in the art for determining the binding affinity between proteins (e.g., fluorescence based-transfer (FRET), enzyme-linked immunosorbent assay, and competitive binding assays (e.g., radioimmunoassays) can be used to assess the binding affinities of the anti-GPC3 Adnectins described herein.
Cell Assays for Binding
In some embodiments, the anti-GPC3 Adnectin and conjugates thereof is internalized into a cell expressing Glypican-3. Standard assays to evaluate polypeptide internalization are known in the art, including, for example, a HumZap internalization assay. To assess binding to tumor cells, e.g. Hep-3b or Hep-G2 (ATCC Deposit No. HB-8064 and HB-8065, respectively), cells can be obtained from publicly available sources, such as the American Type Culture Collection, and used in standard assays, such as flow cytometric analysis.
VII. Drug Conjugates
Also provided are polypeptides comprising a FBS domain, e.g., an Adnectin, conjugated to a therapeutic agent or drug moiety. In an Adnectin-drug conjugate (AdxDC), the FBS moiety (e.g., anti-GPC3 Adnectin) is conjugated to a drug moiety, with the Adnectin functioning as a targeting agent for directing the AdxDC to a target cell expressing GPC3, such as a cancer cell. Once there, the drug is released, either inside the target cell or in its vicinity, to act as a therapeutic agent. For a review on the mechanism of action and use of drug conjugates as used with antibodies, e.g., in cancer therapy, see Schrama et al., Nature Rev. Drug Disc., 5:147 (2006).
Suitable drug moieties for use in drug conjugates include cytoxins or radiotoxins. A cytotoxin or cytotoxic agent includes any agent that is detrimental to (e.g., kills) cells, including, antimetabolites, alkylating agents, DNA minor groove binders, DNA intercalators, DNA crosslinkers, histone deacetylase inhibitors, nuclear export inhibitors, proteasome inhibitors, topoisomerase I or II inhibitors, heat shock protein inhibitors, tyrosine kinase inhibitors, antibiotics, and anti-mitotic agents.
Examples of suitable agents include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents also include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine). Other preferred examples of therapeutic cytotoxins that can be conjugated to an anti-GPC3 Adnectin of the invention include duocarmycins, calicheamicins, maytansines and auristatins, and derivatives thereof.
The Adnectin drug conjugates can be used to modify a given biological response, and the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, an enzymatically active toxin, or active fragment thereof, such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor or interferon-.gamma.; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2 (“IL-2”), interleukin-6 (“IL-6”), granulocyte macrophage colony stimulating factor (“GM-CSF”), granulocyte colony stimulating factor (“G-CSF”), or other growth factors.
An anti-GPC3 Adnectin can be conjugated to a therapeutic agent using linker technology available in the art. Examples of linker types that have been used to conjugate a cytotoxin to an Adnectin include, but are not limited to, hydrazones, thioethers, esters, disulfides and peptide-containing linkers. A linker can be chosen that is, for example, susceptible to cleavage by low pH within the lysosomal compartment or susceptible to cleavage by proteases, such as proteases preferentially expressed in tumor tissue such as cathepsins (e.g., cathepsins B, C, D). Examples of cytotoxins are described, for example, in U.S. Pat. Nos. 6,989,452, 7,087,600, and 7,129,261, and in PCT Application Nos. PCT/US02/17210, PCT/US2005/017804, PCT/US06/37793, PCT/US06/060050, PCT/US2006/060711, WO/2006/110476, and in U.S. Patent Application No. 60/891,028, all of which are incorporated herein by reference in their entirety.
In certain embodiments, the anti-GPC3 Adnectin and therapeutic agent preferably are conjugated via a cleavable linker such as a peptidyl, disulfide, or hydrazone linker. More preferably, the linker is a peptidyl linker which may comprise Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Pro-Val-Gly-Val-Val (SEQ ID NO: 467), Ala-Asn-Val, Val-Leu-Lys, Ala-Ala-Asn, Cit-Cit, Val-Lys, Lys, Cit, Ser, or Glu. The FBS-DCs can be prepared according to methods similar to those described in U.S. Pat. Nos. 7,087,600; 6,989,452; and 7,129,261; PCT Publication Nos. WO 02/096910; WO 07/038658; WO 07/051081; WO 07/059404; WO 08/083312; and WO 08/103693; U.S. Patent Publication Nos. 2006/0024317; 2006/0004081; and 2006/0247295; the disclosures of which are incorporated herein by reference.
A linker can itself be linked, e.g., covalently linked, e.g., using maleimide chemistry, to a cysteine of a PmXn moiety on the anti-GPC3 Adnectin, wherein at least one X is a cysteine. For example, a linker can be covalently linked to an anti-GPC3 Adnectin-PmXn, wherein at least one X is a cysteine. For example, a linker can be linked to an anti-GPC3 Adnectin-PmCn, wherein P is a proline, C is a cysteine, and m and n are integers that are at least 1, e.g., 1-3. Ligation to a cysteine can be performed as known in the art using maleimide chemistry (e.g., Imperiali, B. et al., Protein Engineering: Nucleic Acids and Molecular Biology, Vol. 22, pp. 65-96, Gross, H. J., ed. (2009)). For attaching a linker to a cysteine on an anti-GPC3FBS, the linker may, e.g., comprise a maleimido moiety, which moiety then reacts with the cysteine to form a covalent bond. In certain embodiments, the amino acids surrounding the cysteine are optimized to facilitate the chemical reaction. For example, a cysteine may be surrounded by negatively charged amino acid for a faster reaction relative to a cysteine that is surrounded by a stretch of positively charged amino acids (EP 1074563). Linkage of a drug moiety to a cysteine on an anti-GPC3 Adnectin is a site specific linkage.
For cancer treatment, the drug preferably is a cytotoxic drug that causes death of the targeted cancer cell. Cytotoxic drugs that can be used in anti-GPC3 FBS-DCs include, e.g., the following types of compounds and their analogs and derivatives:
-
- (a) enediynes such as calicheamicin (see, e.g., Lee et al., J. Am. Chem. Soc. 1987, 109, 3464 and 3466) and uncialamycin (see, e.g., Davies et al., WO 2007/038868 A2 (2007); Chowdari et al., U.S. Pat. No. 8,709,431 B2 (2012); and Nicolaou et al., WO 2015/023879 A1 (2015));
- (b) tubulysins (see, e.g., Domling et al., U.S. Pat. No. 7,778,814 B2 (2010); Cheng et al., U.S. Pat. No. 8,394,922 B2 (2013); and Cong et al., U.S. Pat. No. 8,980,824 B2 (2015));
- (c) DNA alkylators such as analogs of CC-1065 and duocarmycin (see, e.g., Boger, U.S. Pat. No. 6,5458,530 B1 (2003); Sufi et al., U.S. Pat. No. 8,461,117 B2 (2013); and Zhang et al., U.S. Pat. No. 8,852,599 B2 (2014));
- (d) epothilones (see, e.g., Vite et al., US 2007/0275904 A1 (2007) and U.S. RE42930 E (2011));
- (e) auristatins (see, e.g., Senter et al., U.S. Pat. No. 6,844,869 B2 (2005) and Doronina et al., U.S. Pat. No. 7,498,298 B2 (2009));
- (f) pyrrolobezodiazepine (PBD) dimers (see, e.g., Howard et al., US 2013/0059800 A1(2013); US 2013/0028919 A1 (2013); and WO 2013/041606 A1 (2013)); and
- (g) maytansinoids such as DM1 and DM4 (see, e.g., Chari et al., U.S. Pat. No. 5,208,020 (1993) and Amphlett et al., U.S. Pat. No. 7,374,762 B2 (2008)).
The foregoing drug moiety references, in addition to disclosing the drug moieties proper, also disclose linkers that can be used in making drug-linker compounds suitable for conjugating them. Particularly pertinent disclosures relating to the preparation of drug-linker compounds are found in Chowdari et al., U.S. Pat. No. 8,709,431 B2 (2012); Cheng et al., U.S. Pat. No. 8,394,922 B2 (2013); Cong et al., U.S. Pat. No. 8,980,824 B2 (2015); Sufi et al., U.S. Pat. No. 8,461,117 B2 (2013); and Zhang et al., U.S. Pat. No. 8,852,599.
Preferably, the drug moiety is a DNA alkylator, tubulysin, auristatin, pyrrolobenzodiazepine, enediyne, or maytansinoid compound, such as:
##STR00001## ##STR00002##
The functional group at which conjugation is effected is the amine (—NH2) group in the case of the first five drugs above and the methyl amine (—NHMe) group in the case of the last two drugs.
To conjugate a drug to an adnectin, a linker group is needed. The drug is combined with the linker to form a drug-linker compound, which is then conjugated to the adnectin. A drug-linker compound can be represented by formula (I)
##STR00003##
wherein
D is a drug;
T is a self-immolating group;
t is 0 or 1;
AAa and each AAb are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
p is 1, 2, 3, or 4;
q is 2, 3, 4, 5, 6, 7, 8, 9, or 10;
r is 1, 2, 3, 4, or 5; and
s is 0 or 1.
In formula II, -AAa-[AAb]p- represents a polypeptide whose length is determined by the value of p (dipeptide if p is 1, tetrapeptide if p is 3, etc.). AAa is at the carboxy terminus of the polypeptide and its carboxyl group forms a peptide (amide) bond with an amine nitrogen of drug D (or self-immolating group T, if present). Conversely, the last AAb is at the amino terminus of the polypeptide and its α-amino group forms a peptide bond with
##STR00004##
depending on whether s is 1 or 0, respectively. Preferred polypeptides -AAa-[AAb]p- are Val-Cit, Val-Lys, Lys-Val-Ala, Asp-Val-Ala, Val-Ala, Lys-Val-Cit, Ala-Val-Cit, Val-Gly, Val-Gln, and Asp-Val-Cit, written in the conventional N-to-C direction, as in H2N-Val-Cit-CO2H). More preferably, the polypeptide is Val-Cit, Val-Lys, or Val-Ala. Preferably, a polypeptide -AAa-[AAb]p- is cleavable by an enzyme found inside the target (cancer) cell, for example a cathepsin and especially cathepsin B.
If the subscript s is 1, drug-linker (I) contains a poly(ethylene glycol) (PEG) group, which can advantageously improve the solubility of drug-linker (I), facilitating conjugation to the adnectin—a step that is performed in aqueous media. Also, a PEG group can serve as a spacer between the adnectin and the peptide -AAa-[AAb]p-, so that the bulk of the adnectin does not sterically interfere with action of a peptide-cleaving enzyme.
As indicated by the subscript t equals 0 or 1, a self-immolating group T is optionally present. A self-immolating group is one such that cleavage from AAa or AAb, as the case may be, initiates a reaction sequence resulting in the self-immolating group disbonding itself from drug D and freeing the latter to exert its therapeutic function. When present, the self-immolating group T preferably is a p-aminobenzyl oxycarbonyl (PABC) group, whose structure is shown below, with an asterisk (*) denoting the end of the PABC bonded to an amine nitrogen of drug D and a wavy line () denoting the end bonded to the polypeptide -AAa-[AAb]p-.
##STR00005##
Another self-immolating group that can be used is a substituted thiazole, as disclosed in Feng, U.S. Pat. No. 7,375,078 B2 (2008).
The maleimide group in formula (I) serves as a reactive functional group for attachment to the adnectin via a Michael addition reaction by a sulfhydryl group on the adnectin, as shown below:
##STR00006##
Alternatively, an ε-amino group in the side chain of a lysine residue of the adnectin can be reacted with 2-iminothiolane to introduce a free thiol (—SH) group. The thiol group can react with the maleimide group in drug-linker (I) to effect conjugation:
##STR00007##
Conjugation by this latter method is sometimes referred to as “random conjugation,” as the number and position of the lysine residues modified by the iminothiolane is difficult to predict.
In certain embodiments, the therapeutic agent in an FBS drug conjugate, e.g., AdxDC, is tubulysin or tubulysin analog. Tubulysins belong to a group of naturally occurring antimitotic polypeptides and depsipeptides that includes the phomopsins, the dolastatins, and the cryptophycins (Hamel et al., Curr. Med. Chem.-Anti-Cancer Agents, 2002, 2:19-53). The tubulysins prevent the assembly of the tubulins into microtubules, causing the affected cells to accumulate in the G2/M phase and undergo apoptosis (Khalil et al., ChemBioChem 2006, 7:678-683).
In addition to the naturally occurring tubulysins, synthetic tubulysin analogs with potent cytotoxic activity which are suitable for use in the FBS scaffold drug conjugate, e.g., AdxDC, provided herein have been described, for example, in U.S. Pat. Nos. 8,394,922 and 8,980,824 (incorporated by reference herein).
In some embodiments, therapeutic agent in the AdxDC is a synthetic tubulysin analog and has a structure represented by formula (II):
##STR00008##
To conjugate a drug moiety, e.g., having formula II, to an FBS scaffold, e.g., an anti-GPC3 FBS scaffold, a linker moiety is used which has a structure represented by formula (III):
##STR00009##
This linker moiety comprises a valine-citrulline (Val-Cit, recited in the conventional N-to-C direction) dipeptide, which is designed to be cleaved by the intracellular enzyme cathepsin B after the AdxDC has reached a target cancer cell and has been internalized by it, thus releasing the therapeutic agent to exert its cytotoxic effect (Dubowchik et al., Biorg. Med. Chem Lett., 1998, 8:3341-3346; Dubowchik et al., Biorg. Med. Chem Lett., 1998, 8:3347-3352; Dubowchik et al., Bioconjugate Chem., 2002, 13:855-869).
Drug (II) and linker (III) are coupled to produce a drug-linker compound having a structure represented by formula (IV), which is then conjugated to the adnectin. The preparation of drug-linker (IV) is described in Cheng et al., U.S. Pat. No. 8,394,922 B2 (2013) (see, e.g.,
In the preparation of an AdxDC conjugate, a therapeutic agent-linker compound having a structure represented by formula (IV) is prepared, which is then conjugated to the FBS scaffold.
##STR00010##
In some embodiments, the FBS-drug conjugate has a structure represented by formula (V).
##STR00011##
wherein m is 1, 2, 3, 4 or more. In certain embodiments, m is 1. In other embodiments, m is 2.
In one embodiment, a thiol group in the side chain of a C-terminal cysteine residue of the anti-GPC3 Adnectin (Adx) is reacted with the maleimide group in compound (V) to effect conjugation:
##STR00012##
In another embodiment, the thiol groups of two cysteines located at the C-terminus of the anti-GPC3 Adnectin (Adx) is reacted with the maleimide group in compound (IV) to effect conjugation of two drug molecules per Adnectin (e.g., DAR2,
In some embodiments, the anti-GPC3Adx in the conjugate has an amino acid sequence as described above in Section IA which has been modified to contain a C-terminal tail comprising a cysteine. In some embodiments, the anti-GPC3Adx comprises a core amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 9-10, 18, 22-23, 31, 35-3644, 48-49, 57, 61-62, 70, 74-75, 83, 87-88, 98, 102-105, 128, 130-132, 155, 157-159, 180, 184-186, 20-, 211-213, 236, 238-240, 263, 265-267, 290, 292-294, 317 and 319-321, which is modified to contain a C-terminal moiety comprising a cysteine.
In some embodiments, the anti-GPC3Adx has been modified to contain a C-terminal moiety consisting PmCXn or PmCXn1CXn2, as defined herein. In certain embodiments, the C-terminal moiety consists of PC, PCC or any one of the C-terminal sequences described herein, e.g., amino acid sequences set forth in SEQ ID NOs: 409-423. In certain embodiments, the C-terminal moiety consists of PC or PCPPPPPC (SEQ ID NO: 416).
In certain embodiments, the modified anti-GPC3 Adx comprises a C-terminal moiety consisting of PmCXn, and is selected from the group consisting of SEQ ID NOs: 11-14, 24-27, 37-40, 50-53, 63-66, 76-79, 89-93, 106-118, 133-145, 160-172, 187-199, 214-226, 241-253, 268-280, 295-307, and 322-334.
In certain embodiments, the modified anti-GPC3 Adx comprises a C-terminal moiety consisting of PmCXn1CXn2, and is selected from the group consisting of SEQ ID NOs: 15-17, 28-30, 41-43, 54-57, 67-70, 80-83, 94-97, 119-127, 146-154, 173-181, 200-208, 227-235, 254-262, 281-289, 308-316, and 335-343.
In particular embodiments, the anti-GPC3 Adx for use in the drug conjugate is any one of SEQ ID NOs: 114-118; 123-127; 141-145; 150-154; 168-172; 177-181; 195-199; 204-208; 222-226; 231-235; 249-253; 258-262; 276-280; 285-289; 303-307; 312-316; 330-334; and 339-343.
Anti-GPC3 Adnectins described herein also can be conjugated to a radioactive isotope to generate cytotoxic radiopharmaceuticals. Examples of radioactive isotopes that can be conjugated to antibodies for use diagnostically or therapeutically include, but are not limited to, iodine131, indium111, yttrium90 and lutetium177. Methods for preparing radioconjugates are established in the art.
VIII. Pharmaceutical Compositions
Also provided are pharmaceutically acceptable compositions comprising the anti-GPC3 Adnectins and conjugates described herein, wherein the composition is essentially endotoxin and/or pyrogen free.
Methods well known in the art for making formulations are found, for example, in “Remington: The Science and Practice of Pharmacy” (20th ed., ed. A. R. Gennaro A R., 2000, Lippincott Williams & Wilkins, Philadelphia, Pa.). Formulations for parenteral administration may, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Nanoparticulate formulations (e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes) may be used to control the biodistribution of the compounds. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. The concentration of the compound in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration.
Therapeutic formulations comprising proteins are prepared for storage by mixing the described proteins having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Osol, A., ed., Remington's Pharmaceutical Sciences, 16th Edition (1980)), in the form of aqueous solutions, lyophilized or other dried formulations. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyidimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as Tween, PLURONIC® or polyethylene glycol (PEG).
The polypeptide may be optionally administered as a pharmaceutically acceptable salt, such as non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid phosphoric acid, or the like. Metal complexes include zinc, iron, and the like. In one example, the polypeptide is formulated in the presence of sodium acetate to increase thermal stability.
The formulations herein may also contain more than one active compounds as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
The proteins may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Osol, A., ed., Remington's Pharmaceutical Sciences, 16th Edition (1980).
The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the proteins described herein, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C., resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S—S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
For therapeutic applications, the proteins are administered to a subject, in a pharmaceutically acceptable dosage form. They can be administered intravenously as a bolus or by continuous in over a period of time, by intramuscular, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. The protein may also be administered by intratumoral, peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and can be determined by those of skill in the art as the clinical situation warrants. Examples of suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose. The methods of the present invention can be practiced in vitro, in vivo, or ex vivo.
Administration of proteins, and one or more additional therapeutic agents, whether co-administered or administered sequentially, may occur as described above for therapeutic applications. Suitable pharmaceutically acceptable carriers, diluents, and excipients for co-administration will be understood by the skilled artisan to depend on the identity of the particular therapeutic agent being co-administered.
When present in an aqueous dosage form, rather than being lyophilized, the protein typically will be formulated at a concentration of about 0.1 mg/ml to 100 mg/ml, although wide variation outside of these ranges is permitted. For the treatment of disease, the appropriate dosage of proteins will depend on the type of disease to be treated, the severity and course of the disease, whether the proteins are administered for preventive or therapeutic purposes, the course of previous therapy, the patient's clinical history and response to the fusion, and the discretion of the attending physician. The protein is suitably administered to the patient at one time or over a series of treatments.
A therapeutically effective dose refers to a dose that produces the therapeutic effects for which it is administered. The exact dose will depend on the disorder to be treated, and may be ascertained by one skilled in the art using known techniques. Preferred dosages can range from about 10 mg/square meter to about 2000 mg/square meter, more preferably from about 50 mg/square meter to about 1000 mg/square meter. In some embodiments, the anti-GPC3Adnectin or anti-GPC3 AdxDC is administered at about 0.01 pg/kg to about 50 mg/kg per day, 0.01 mg/kg to about 30 mg/kg per day, or 0.1 mg/kg to about 20 mg/kg per day.
The anti-GPC3Adnectin or anti-GPC3 AdxDC may be given daily (e.g., once, twice, three times, or four times daily) or less frequently (e.g., once every other day, once or twice weekly, once every two weeks, once every three weeks or monthly). In addition, as is known in the art, adjustments for age as well as the body weight, general health, sex, diet, time of administration, drug interaction, and the severity of the disease may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.
IX. Therapeutic Methods
The anti-GPC3 Adnectins and drug conjugates thereof described herein are suitable for use in the treatment of a cancers having tumor cells expressing GPC3, e.g., high levels of GPC3, e.g., relative to healthy tissues. In some embodiments, the cancer is selected from the group consisting of liver cancer (e.g., hepatocellular carcinoma (HCC) or hepatoblastoma), melanoma, sarcoma, lung cancer (e.g., squamous lung cancer) and Wilm's tumor. Additionally, the GPC3 Adnectins described herein are suitable for use in treating refractory or recurrent malignancies.
As used herein, the term “subject” is intended to include human and non-human animals. Preferred subjects include human patients having disorders mediated by GPC3 activity or undesirable cells expressing high levels of GPC3. When anti-GPC3 Adnectins or drug conjugates thereof are administered together with another agent, the two can be administered in either order or simultaneously.
For example, the anti-GPC3 Adnectins, multispecific or bispecific molecules and the drug conjugates thereof can be used to elicit in vivo or in vitro one or more of the following biological activities: to inhibit the growth of and/or kill a cell expressing GPC3; to mediate phagocytosis or ADCC of a cell expressing GPC3 in the presence of human effector cells, or to potentially modulate GPC3 activity, e.g., by blocking a GPC3 ligand from binding to GPC3.
In certain embodiments, the anti-GPC3 Adnectins or anti-GPC3 AdxDC described herein are combined with an immunogenic agent, for example, a preparation of cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), antigen-presenting cells such as dendritic cells bearing tumor-associated antigens, and cells transfected with genes encoding immune stimulating cytokines (He et ah, 2004). Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF. GPC3 blockade may also be effectively combined with standard cancer treatments, including chemotherapeutic regimes, radiation, surgery, hormone deprivation and angiogenesis inhibitors, as well as another immunotherapeutic agent (e.g., an anti-PD-1, anti-CTLA-4, and anti-LAG-3 Adnectins or antibodies).
Provided herein are methods of combination therapy in which an anti-GPC3 Adnectin and/or or anti-GPC3 AdxDC is administered (simultaneously or successively) with one or more additional agents, e.g., small molecule drugs, antibodies or antigen binding portions thereof, that are effective in stimulating immune responses to thereby enhance, stimulate or upregulate immune responses in a subject.
Generally, an anti-GPC3 Adnectin or anti-GPC3 AdxDC, e.g., described herein, can be combined with an immuno-oncology agent, e.g., (i) an agonist of a stimulatory (e.g., co-stimulatory) molecule (e.g., receptor or ligand) and/or (ii) an antagonist of an inhibitory signal or molecule (e.g., receptor or ligand) on immune cells, such as T cells, both of which result in amplifying immune responses, such as antigen-specific T cell responses. In certain aspects, an immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) molecule (e.g., receptor or ligand) or (ii) an antagonist of an inhibitory (including a co-inhibitory) molecule (e.g., receptor or ligand) on cells involved in innate immunity, e.g., NK cells, and wherein the immuno-oncology agent enhances innate immunity. Such immuno-oncology agents are often referred to as immune checkpoint regulators, e.g., immune checkpoint inhibitor or immune checkpoint stimulator.
In certain embodiments, a anti-GPC3 Adnectin or anti-GPC3 AdxDC is administered with an agent that targets a stimulatory or inhibitory molecule that is a member of the immunoglobulin super family (IgSF). For example, anti-GPC3 Adnectins and or anti-GPC3 AdxDCs, e.g., described herein, may be administered to a subject with an agent that targets a member of the IgSF family to increase an immune response. For example, a anti-GPC3 Adnectin or anti-GPC3 AdxDC may be administered with an agent that targets (or binds specifically to) a member of the B7 family of membrane-bound ligands that includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6 or a co-stimulatory or co-inhibitory receptor binding specifically to a B7 family member.
An anti-GPC3 Adnectin or anti-GPC3 AdxDC may also be administered with an agent that targets a member of the TNF and TNFR family of molecules (ligands or receptors), such as CD40 and CD40L, OX-40, GITR, GITRL, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137, TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDA1, EDA2, TNFR1, Lymphotoxin α/TNFβ, TNFR2, TNFα, LTβR, Lymphotoxin a 102, FAS, FASL, RELT, DR6, TROY, and NGFR (see, e.g., Tansey (2009) Drug Discovery Today 00:1).
T cell responses can be stimulated by administering one or more of the following agents:
-
- (1) An antagonist (inhibitor or blocking agent) of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors), such as CTLA-4, PD-1, PD-L1, PD-L2, and LAG-3, as described above, and any of the following proteins: TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD 113, GPR56, VISTA, B7-H3, B7-H4, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4; and/or
- (2) An agonist of a protein that stimulates T cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
Exemplary agents that modulate one of the above proteins and may be combined with anti-GPC3 Adnectins and/or or anti-GPC3 AdxDCs, e.g., those described herein, for treating cancer, include: Yervoy™ (ipilimumab) or Tremelimumab (to CTLA-4), galiximab (to B7.1), BMS-936558 (to PD-1), MK-3475 (to PD-1), AMP224 (to B7DC), BMS-936559 (to B7-H1), MPDL3280A (to B7-H1), MEDI-570 (to ICOS), AMG557 (to B7H2), MGA271 (to B7H3), IMP321 (to LAG-3), BMS-663513 (to CD137), PF-05082566 (to CD137), CDX-1127 (to CD27), anti-OX40 (Providence Health Services), huMAbOX40L (to OX40L), Atacicept (to TACI), CP-870893 (to CD40), Lucatumumab (to CD40), Dacetuzumab (to CD40), Muromonab-CD3 (to CD3), Ipilumumab (to CTLA-4) and/or MK4166.
Anti-GPC3 Adnectins or anti-GPC3 AdxDC may also be administered with pidilizumab (CT-011), although its specificity for PD-1 binding has been questioned.
Other molecules that can be combined with anti-GPC3 Adnectins or anti-GPC3 AdxDCs for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, anti-GITR agonist antibodies can be combined with antagonists of KIR (e.g., lirilumab).
T cell activation is also regulated by soluble cytokines, and anti GPC3 Adnectins or or anti-GPC3 AdxDCs may be administered to a subject, e.g., having cancer, with antagonists of cytokines that inhibit T cell activation or agonists of cytokines that stimulate T cell activation.
In certain embodiments, anti-GPC3 Adnectins or anti-GPC3 AdxDCs can be used in combination with (i) antagonists (or inhibitors or blocking agents) of proteins of the IgSF family or B7 family or the TNF family that inhibit T cell activation or antagonists of cytokines that inhibit T cell activation (e.g., IL-6, IL-10, TGF-β, VEGF; “immunosuppressive cytokines”) and/or (ii) agonists of stimulatory receptors of the IgSF family, B7 family or the TNF family or of cytokines that stimulate T cell activation, for stimulating an immune response, e.g., for treating proliferative diseases, such as cancer.
Yet other agents for combination therapies include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO 11/107553, WO 11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13/69264; WO14/036357).
Anti-GPC3 Adnectins or anti-GPC3 AdxDCs may also be administered with agents that inhibit TGF-β signaling.
Additional agents that may be combined with an anti-GPC3 Adnectin and or anti-GPC3 AdxDCs include agents that enhance tumor antigen presentation, e.g., dendritic cell vaccines, GM-CSF secreting cellular vaccines, CpG oligonucleotides, and imiquimod, or therapies that enhance the immunogenicity of tumor cells (e.g., anthracyclines).
Yet other therapies that may be combined with an anti-GPC3 Adnectin or anti-GPC3 AdxDC include therapies that deplete or block Treg cells, e.g., an agent that specifically binds to CD25.
Another therapy that may be combined with an anti-GPC3 Adnectin or anti-GPC3 AdxDC is a therapy that inhibits a metabolic enzyme such as indoleamine dioxigenase (IDO), dioxigenase, arginase, or nitric oxide synthetase.
Another class of agents that may be used with a anti-GPC3 Adnectin or anti-GPC3 AdxDC includes agents that inhibit the formation of adenosine or inhibit the adenosine A2A receptor.
Other therapies that may be combined with a anti-GPC3 Adnectin or anti-GPC3 AdxDC for treating cancer include therapies that reverse/prevent T cell anergy or exhaustion and therapies that trigger an innate immune activation and/or inflammation at a tumor site.
An anti-GPC3 Adnectin or anti-GPC3 AdxDC may be combined with more than one immuno-oncology agent, and may be, e.g., combined with a combinatorial approach that targets multiple elements of the immune pathway, such as one or more of the following: a therapy that enhances tumor antigen presentation (e.g., dendritic cell vaccine, GM-CSF secreting cellular vaccines, CpG oligonucleotides, imiquimod); a therapy that inhibits negative immune regulation e.g., by inhibiting CTLA-4 and/or PD1/PD-L1/PD-L2 pathway and/or depleting or blocking Tregs or other immune suppressing cells; a therapy that stimulates positive immune regulation, e.g., with agonists that stimulate the CD-137, OX-40, and/or GITR pathway and/or stimulate T cell effector function; a therapy that increases systemically the frequency of anti-tumor T cells; a therapy that depletes or inhibits Tregs, such as Tregs in the tumor, e.g., using an antagonist of CD25 (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion; a therapy that impacts the function of suppressor myeloid cells in the tumor; a therapy that enhances immunogenicity of tumor cells (e.g., anthracyclines); adoptive T cell or NK cell transfer including genetically modified cells, e.g., cells modified by chimeric antigen receptors (CAR-T therapy); a therapy that inhibits a metabolic enzyme such as indoleamine dioxigenase (IDO), dioxigenase, arginase, or nitric oxide synthetase; a therapy that reverses/prevents T cell anergy or exhaustion; a therapy that triggers an innate immune activation and/or inflammation at a tumor site; administration of immune stimulatory cytokines; or blocking of immuno repressive cytokines.
Anti-GPC3 Adnectins and or anti-GPC3 AdxDCs described herein can be used together with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
Provided herein is the use of any anti-GPC3 Adnectin described herein for the preparation of a medicament for treating subjects afflicted with cancer. The disclosure provides medical uses of any anti-GPC3 Adnectin described herein corresponding to all the embodiments of the methods of treatment employing an anti-GPC3 Adnectin described herein.
X. Detectable Labels
The anti-GPC3 Adnectins described herein also are useful in a variety of diagnostic and imaging applications. In certain embodiments, an anti-GPC3 Adnectin is labeled with a moiety that is detectable in vivo and such labeled Adnectins may be used as in vivo imaging agents, e.g., for whole body imaging. For example, in one embodiment, a method for detecting a GPC3 positive tumor in a subject comprises administering to the subject an anti-GPC3 Adnectin linked to a detectable label, and following an appropriate time, detecting the label in the subject.
An anti-GPC3 Adnectin imaging agent may be used to diagnose a disorder or disease associated with increased levels of GPC3, for example, a cancer in which a tumor selectively overexpresses GPC3. In a similar manner, an anti-GPC3 Adnectin can be used to monitor GPC3 levels in a subject, e.g., a subject that is being treated to reduce GPC3 levels and/or GPC3 positive cells (e.g., tumor cells). The anti-GPC3 Adnectins may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a detectable moiety.
Detectable labels can be any of the various types used currently in the field of in vitro diagnostics, including particulate labels including metal sols such as colloidal gold, isotopes such as I125 or Tc99 presented for instance with a peptidic chelating agent of the N2S2, N3S or N4 type, chromophores including fluorescent markers, biotin, luminescent markers, phosphorescent markers and the like, as well as enzyme labels that convert a given substrate to a detectable marker, and polynucleotide tags that are revealed following amplification such as by polymerase chain reaction. A biotinylated anti-GPC3 FBS would then be detectable by avidin or streptavidin binding. Suitable enzyme labels include horseradish peroxidase, alkaline phosphatase and the like. For instance, the label can be the enzyme alkaline phosphatase, detected by measuring the presence or formation of chemiluminescence following conversion of 1,2 dioxetane substrates such as adamantyl methoxy phosphoryloxy phenyl dioxetane (AMPPD), disodium 3-(4-(methoxyspiro{1,2-dioxetane-3,2′-(5′-chloro)tricyclo{3.3.1.1 3,7}decan}-4-yl) phenyl phosphate (CSPD), as well as CDP and CDP-STAR® or other luminescent substrates well-known to those in the art, for example the chelates of suitable lanthanides such as Terbium(III) and Europium(III).
Detectable moieties that may be used include radioactive agents, such as: radioactive heavy metals such as iron chelates, radioactive chelates of gadolinium or manganese, positron emitters of oxygen, nitrogen, iron, carbon, or gallium, 18F 60Cu, 61Cu, 62Cu, 64Cu, 124I, 86Y, 89Zr, 66Ga, 67Ga, 68Ga, 44Sc, 47Sc, 11C, 111In, 114mIn, 114In, 125I, 124I, 131I, 123I, 131I, 123I, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 89Zr, 186Re, 188Re, 86Y, 90Y, 177Lu, 99Tc, 212Bi, 213Bi, 212Pb, 225Ac, or 153Sm.
The detection means is determined by the chosen label. Appearance of the label or its reaction products can be achieved using the naked eye, in the case where the label is particulate and accumulates at appropriate levels, or using instruments such as a spectrophotometer, a luminometer, a fluorometer, and the like, all in accordance with standard practice.
A detectable moiety may be linked to a cysteine according to methods known in the art. When the detectable moiety is a radioactive agent, e.g., those described further herein, the detectable moiety is linked to an FBS through a chelating agent that is reactive with cysteines, such as a maleimide containing chelating agent, such as maleimide-NODAGA or maleimide-DBCO. Maleimide-NODAGA or maleimide-DBCO can be reacted with a cysteine on the C-terminus of an FBS (e.g., through the PmXn moiety, wherein at least one X is a cysteine), to yield FBS-NODAGA or FBS-DBCO, respectively. Any one of the following chelating agents may be used provided that it comprises, or can be modified to comprise, a reactive moiety that reacts with cysteines: DFO, DOTA and its derivatives (CB-DO2A, 3p-C-DEPA, TCMC, Oxo-DO3A), TE2A, CB-TE2A, CB-TE1A1P, CB-TE2P, MM-TE2A, DM-TE2A, diamsar and derivatives, NODASA, NODAGA, NOTA, NETA, TACN-TM, DTPA, 1B4M-DTPA, CHX-A″-DTPA, TRAP (PRP9), NOPO, AAZTA and derivatives (DATA), H2dedpa, H4octapa, H2azapa, H5decapa, H6phospa, HBED, SHBED, BPCA, CP256, PCTA, HEHA, PEPA, EDTA, TETA, and TRITA based chelating agents, and close analogs and derivatives thereof.
In certain embodiments, an FBS is labeled with a PET tracer and used as an in vivo imaging agent. For example, an FBS may be labeled with the PET tracer 64Cu. 64Cu may be linked to an FBS with a C-terminal cysteine with a chelating agent, such as maleimide-NODAGA.
Other art-recognized methods for labelling polypeptides with radionuclides such as 64Cu and 18F for synthesizing the anti-GPC3 Adnectin-based imaging agents described herein may also be used. See, e.g., US2014/0271467; Gill et al., Nature Protocols 2011; 6:1718-25; Berndt et al. Nuclear Medicine and Biology 2007; 34:5-15, Inkster et al., Bioorganic & Medicinal Chemistry Letters 2013; 23:3920-6, the contents of which are herein incorporated by reference in their entirety.
In certain embodiments, a GPC3 imaging agent comprises a PEG molecule (e.g., 5KDa PEG, 6KDa PEG, 7KDa PEG, 8KDa PEG, 9KDa PEG, or 10KDa PEG) to increase the blood PK of the imaging agent by small increments to enhance the imaging contrast or increase avidity of the anti-GPC3 Adnectin based imaging agent.
XI. Detection of GPC3
In Vivo Detection Methods
In certain embodiments, the labeled anti-GPC3 Adnectins can be used to image GPC3-positive cells or tissues, e.g., GPC3 expressing tumors. For example, the labeled anti-GPC3 Adnectin is administered to a subject in an amount sufficient to uptake the labeled Adnectin into the tissue of interest (e.g., the GPC3-expressing tumor). The subject is then imaged using an imaging system such as PET for an amount of time appropriate for the particular radionuclide being used. The labeled anti-GPC3 Adnectin-bound GPC3-expressing cells or tissues, e.g., GPC3-expressing tumors, are then detected by the imaging system.
PET imaging with a GPC3 imaging agent may be used to qualitatively or quantitatively detect GPC3. A GPC3 imaging agent may be used as a biomarker, and the presence or absence of a GPC3 positive signal in a subject may be indicative that, e.g., the subject would be responsive to a given therapy, e.g., a cancer therapy, or that the subject is responding or not to a therapy.
In certain embodiments, the progression or regression of disease (e.g., tumor) can be imaged as a function of time or treatment. For instance, the size of the tumor can be monitored in a subject undergoing cancer therapy (e.g., chemotherapy, radiotherapy) and the extent of regression of the tumor can be monitored in real-time based on detection of the labeled anti-GPC3 Adnectin.
The amount effective to result in uptake of the imaging agent (e.g., 18F-Adnectin imaging agent, 64Cu-Adnectin imaging agent) into the cells or tissue of interest (e.g., tumors) may depend upon a variety of factors, including for example, the age, body weight, general health, sex, and diet of the host; the time of administration; the route of administration; the rate of excretion of the specific probe employed; the duration of the treatment; the existence of other drugs used in combination or coincidental with the specific composition employed; and other factors.
In certain embodiments, imaging of tissues expressing GPC3 is effected before, during, and after administration of the labeled anti-GPC3 Adnectin.
In certain embodiments, the anti-GPC3 Adnectins described herein are useful for PET imaging of lungs, heart, kidneys, liver, and skin, and other organs, or tumors associated with these organs which express GPC3.
In certain embodiments, the anti-GPC3 imaging agents provide a contrast of at least 50%, 75%, 2, 3, 4, 5 or more. The Examples show that all anti-GPC3 Adnectins that were used provided a PET contrast of 2 or more, and that the affinity of the Adnectins was not important.
When used for imaging (e.g., PET) with short half-life radionuclides (e.g., 18F), the radiolabeled anti-GPC3 Adnectins are preferably administered intravenously. Other routes of administration are also suitable and depend on the half-life of the radionuclides used.
In certain embodiments, the anti-GPC3 imaging agents described herein are used to detect GPC3 positive cells in a subject by administering to the subject an anti-GPC3 imaging agent disclosed herein, and detecting the imaging agent, the detected imaging agent defining the location of the GPC3 positive cells in the subject. In certain embodiments, the imaging agent is detected by positron emission tomography.
In certain embodiments, the anti-GPC3 imaging agents described herein are used to detect GPC3 expressing tumors in a subject by administering to the subject an anti-GPC3 imaging agent disclosed herein, and detecting the imaging agent, the detected imaging agent defining the location of the tumor in the subject. In certain embodiments, the imaging agent is detected by positron emission tomography.
In certain embodiments, an image of an anti-GPC3 imaging agent described herein is obtained by administering the imaging agent to a subject and imaging in vivo the distribution of the imaging agent by positron emission tomography.
Accordingly, provided herein are methods of obtaining a quantitative image of tissues or cells expressing GPC3, the method comprising contacting the cells or tissue with an anti-GPC3 imaging agent described herein and detecting or quantifying the tissue expressing GPC3 using positron emission tomography.
Also provided herein are methods of detecting a GPC3-expressing tumor comprising administering an imaging-effective amount of an anti-GPC3 imaging agent described herein to a subject having a GPC3-expressing tumor, and detecting the radioactive emissions of said imaging agent in the tumor using positron emission tomography, wherein the radioactive emissions are detected in the tumor.
Also provided herein are methods of diagnosing the presence of a GPC3-expressing tumor in a subject, the method comprising
-
- administering to a subject in need thereof an anti-GPC3 imaging agent described herein; and
- obtaining an radio-image of at least a portion of the subject to detect the presence or absence of the imaging agent;
- wherein the presence and location of the imaging agent above background is indicative of the presence and location of the disease.
Also provided herein are methods of monitoring the progress of an anti-tumor therapy against GPC3-expressing tumors in a subject, the method comprising
-
- administering to a subject in need thereof an anti-GPC3 imaging agent described herein at a first time point and obtaining an image of at least a portion of the subject to determine the size of the tumor;
- administering an anti-tumor therapy to the subject;
- administering to the subject the imaging agent at one or more subsequent time points and obtaining an image of at least a portion of the subject at each time point;
- wherein the dimension and location of the tumor at each time point is indicative of the progress of the disease.
In Vitro Detection Methods
In addition to detecting GPC3 in vivo, anti-PDL1 Adnectins, such as those described herein, may be used for detecting a target molecule in a sample. A method may comprise contacting the sample with an anti-GPC3 Adnectins described herein, wherein said contacting is carried out under conditions that allow anti-GPC3 Adnectin-target complex formation; and detecting said complex, thereby detecting said target in said sample. Detection may be carried out using any art-recognized technique, such as, e.g., radiography, immunological assay, fluorescence detection, mass spectroscopy, or surface plasmon resonance. The sample may be from a human or other mammal. For diagnostic purposes, appropriate agents are detectable labels that include radioisotopes, for whole body imaging, and radioisotopes, enzymes, fluorescent labels and other suitable antibody tags for sample testing.
The detectable labels can be any of the various types used currently in the field of in vitro diagnostics, including particulate labels including metal sols such as colloidal gold, isotopes such as I125 or Tc99 presented for instance with a peptidic chelating agent of the N2S2, N3S or N4 type, chromophores including fluorescent markers, biotin, luminescent markers, phosphorescent markers and the like, as well as enzyme labels that convert a given substrate to a detectable marker, and polynucleotide tags that are revealed following amplification such as by polymerase chain reaction. A biotinylated FBS would then be detectable by avidin or streptavidin binding. Suitable enzyme labels include horseradish peroxidase, alkaline phosphatase and the like. For instance, the label can be the enzyme alkaline phosphatase, detected by measuring the presence or formation of chemiluminescence following conversion of 1,2 dioxetane substrates such as adamantyl methoxy phosphoryloxy phenyl dioxetane (AMPPD), disodium 3-(4-(methoxyspiro{1,2-dioxetane-3,2′-(5′-chloro)tricyclo{3.3.1.1 3,7}decan}-4-yl) phenyl phosphate (CSPD), as well as CDP and CDP-Star® or other luminescent substrates well-known to those in the art, for example the chelates of suitable lanthanides such as Terbium(III) and Europium(III). Other labels include those set forth above in the imaging section. The detection means is determined by the chosen label. Appearance of the label or its reaction products can be achieved using the naked eye, in the case where the label is particulate and accumulates at appropriate levels, or using instruments such as a spectrophotometer, a luminometer, a fluorimeter, and the like, all in accordance with standard practice.
XII. Kits and Articles of Manufacture
The anti-GPC3 Adnectins and drug conjugates thereof described herein can be provided in a kit, a packaged combination of reagents in predetermined amounts with instructions for use in the therapeutic or diagnostic methods described herein.
For example, in certain embodiments, an article of manufacture containing materials useful for the treatment or prevention of the disorders or conditions described herein, or for use in the methods of detection described herein, are provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container may hold a composition described herein for in vivo imaging, and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is an anti-GPC3 Adnectin or anti-GPC3 AdxDC described herein. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- 1. A polypeptide comprising a fibronectin based scaffold (FBS) comprising BC, DE and FG loops, wherein one or more of the loops are altered relative to the corresponding loop of the wild-type FBS domain, and wherein the polypeptide binds specifically to human glypican-3 (GPC3) with a KD or 1 μM or less.
- 2. The polypeptide of embodiment 1, wherein the FBS is a fibronectin type III (Fn3) domain.
- 3. The polypeptide of embodiment 2, wherein the Fn3 domain is a human tenth fibronectin type III (10Fn3) domain.
- 4. The polypeptide of any one of the preceding embodiments, wherein the BC loop comprises an amino acid sequence selected from the group consisting of
- (a) SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99; and
- (b) a BC loop with 1, 2 or 3 amino acid substitutions, insertions or deletions relative to the BC loop of SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99
- 5. The polypeptide of any one of the preceding embodiments, wherein the DE loop comprises an amino acid sequence selected from the group consisting of
- (a) SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100; and
- (b) a DE loop with 1, 2 or 3 amino acid substitutions, insertions or deletions relative to the DE loop of SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 or 100.
- 6. The polypeptide of any one of the preceding embodiments, wherein the FG loop comprises an amino acid sequence selected from the group consisting of
- (a) SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318, and
- (b) an FG loop with 1, 2 or 3 amino acid substitutions, insertions or deletions relative to the FG loop of SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 or 318.
- 7. The polypeptide of any one of the preceding embodiments, wherein the BC loop comprises and amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 19, 32, 45, 58, 71, 84 or 99; the DE loop comprises an amino acid sequences selected from the group consisting of SEQ ID NOs: 7, 20, 33, 46, 59, 72, 85 and 100; and the FG loop comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 21, 34, 47, 60, 73, 86, 101, 129, 156, 183, 210, 237, 264, 291 and 318, respectively, and wherein, optionally, the BC, DE and/or FG loop comprises 1, 2 or 3 amino acid substitutions.
- 8. The polypeptide of any one of the preceding embodiments, wherein
- (a) the BC, DE and FG loops comprise SEQ ID NOs: 6, 7 and 8, respectively;
- (b) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 6, 7 and 8;
- (c) the BC, DE and FG loops comprise SEQ ID NOs: 19, 20 and 21, respectively;
- (d) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 19, 20 and 22;
- (e) the BC, DE and FG loops comprise SEQ ID NOs: 32, 33 and 34, respectively;
- (f) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 32, 33 and 34;
- (g) the BC, DE and FG loops comprise SEQ ID NOs: 45, 46 and 47, respectively;
- (h) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 45, 46 and 47;
- (i) the BC, DE and FG loops comprise SEQ ID NOs: 58, 59 and 60, respectively;
- (j) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 58, 59 and 60;
- (k) the BC, DE and FG loops comprise SEQ ID NOs: 71, 72 and 73, respectively;
- (l) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 71, 72 and 73;
- (m) the BC, DE and FG loops comprise SEQ ID NOs: 84, 85 and 86, respectively;
- (n) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 84, 85 and 86;
- (o) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 101, respectively;
- (p) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 99, 100 and 101.
- 9. The polypeptide of any one of the preceding embodiments, wherein the FBS comprises the amino acid sequence set forth in SEQ ID NO: 3, wherein BC, DE and FG loops as represented by (X)v, (X)x, and (X)z, respectively, and
- (a) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 6, 7 and 8, respectively;
- (b) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively;
- (c) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 19, 20 and 21, respectively;
- (d) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 19, 20 and 21, respectively;
- (e) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 32, 33 and 34, respectively;
- (f) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs:32, 33 and 34;
- (g) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 45, 46 and 47, respectively;
- (h) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 45, 46 and 47;
- (i) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 58, 59 and 60, respectively;
- (j) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 58, 59 and 60;
- (k) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 71, 72 and 73, respectively;
- (l) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 71, 72 and 73;
- (m) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 84, 85 and 86, respectively;
- (n) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 84, 85 and 86;
- (o) comprise amino acid sequences at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the BC, DE or FG loop sequences set forth in SEQ ID NOs: 99, 100 and 101, respectively;
- (p) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 101;
- (q) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 129;
- (r) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 156;
- (s) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 183;
- (t) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 210;
- (u) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 237;
- (v) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 264;
- (w) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 264; or
- (x) comprise BC, DE, and FG loops having the amino acid sequences of SEQ ID NOs: 99, 100 and 318.
- 10. The polypeptide of any one of the preceding embodiments, wherein the FBS comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NOs: 3, 5, 18, 31, 44, 57, 70, 83 and 98.
- 11. The polypeptide of any one of the preceding embodiments, wherein the FBS comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 5, 18, 31, 44, 57, 70, 83 and 98.
- 12. The polypeptide of any one of the preceding embodiments, wherein the FBS comprises an amino acid sequence at least 90%, 95%, 98%, 99% or 100% to the amino acid sequence of any one of SEQ ID NOs 5, 9-18, 22-31, 35-44, 48-57, 61-70, 74-83, 87-98, 102-128, 130-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 or 319-343.
- 13. The polypeptide of claim any one of the preceding embodiments, wherein the FBS comprises an amino acid that is at least 95% identical to the amino acid sequence of SEQ ID NOs: 98, 102-128, 129-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343.
- 14. The polypeptide any one of the preceding embodiments, wherein the FBS comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 18, 31, 44, 57, 70, 83, 98, 128, 155, 182, 209, 209, 236, 263, 290 and 317.
- 15. The polypeptide any one of the preceding embodiments, wherein the FBS comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 9-18, 22-31, 35-44, 48-57, 61-70, 74-83, 87-98, 102-128, 130-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343.
- 16. The polypeptide of anyone of the preceding embodiments, wherein the FBS comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 98, 102-128, 129-155, 157-182, 184-209, 211-236, 238-263, 265-290, 292-317 and 319-343.
- 17. The polypeptide of any one of the preceding embodiments, wherein the FBS competes with an FBS comprising the amino acid sequence of SEQ ID NO: 98 for binding with glypican-3.
- 18. The polypeptide of any one of the preceding embodiments, wherein the FBS binds to a region of 10-20 amino acid residues within glypican-3 which comprise HQVSFF (SEQ ID NO:209).
- 19. The polypeptide of any one of the preceding embodiments, wherein the FBS binds to a region of 10-20 amino acid residues within glypican-3 which comprise EQLLQSASM (SEQ ID NO:210).
- 20. The polypeptide of any one of the preceding embodiments, wherein the FBS binds to a discontinuous Adnectin site within glypican-3 comprising HQVSFF (SEQ ID NO:209) and EQLLQSASM (SEQ ID NO:210).
- 21. The polypeptide of any one of the preceding embodiments, further comprising a heterologous protein.
- 22. The polypeptide of any one of the preceding embodiments, further comprising one or more pharmacokinetic (PK) moieties selected from the group consisting of polyethylene glycol, sialic acid, Fc, Fc fragment, transferrin, serum albumin, a serum albumin binding protein, and a serum immunoglobulin binding protein.
- 23. The polypeptide of any one of the preceding embodiments, wherein the C-terminus of the FBS is linked to a moiety consisting of the amino acid sequence PmXn, wherein P is proline, X is any amino acid, m is an integer that is at least 1 and n is 0 or an integer that is at least 1.
- 24. The polypeptide of embodiment 23, wherein m is 1 or 2, and n is an integer from 1-10.
- 25. The polypeptide of embodiment 23 or 24, wherein moiety comprises cysteine.
- 26. The polypeptide of embodiment 25, wherein the moiety consists of the amino acid sequence PmCXn, wherein C is a cysteine, each X is independently any amino acid.
- 27. The polypeptide of embodiment 25, wherein the moiety consists of the amino acid sequence PmCXn1CXn2, wherein each X is independently any amino acid, n1 and n2 are independently 0 or an integer that is at least 1.
- 28. The polypeptide of embodiment 28, wherein n1 and n2 are independently an integer from 1-5.
- 29. The polypeptide of embodiment 23, wherein the moiety is selected from the group consisting of PI, PC, PID, PIE, PIDK (SEQ ID NO: 382), PIEK (SEQ ID NO: 383), PIDKP (SEQ ID NO: 384), PIEKP (SEQ ID NO: 385), PIDKPS (SEQ ID NO: 386), PIEKPS (SEQ ID NO: 387), PIDKPC (SEQ ID NO: 388), PIEKPC (SEQ ID NO: 389), PIDKPSQ (SEQ ID NO: 390), PIEKPSQ (SEQ ID NO: 391), PIDKPCQ (SEQ ID NO: 392), PIEKPCQ (SEQ ID NO: 393), PHHHHHH (SEQ ID NO: 394) and PCHHHHHH (SEQ ID NO: 395).
- 30. The polypeptide of embodiment 26, wherein the moiety is PC or PPC.
- 31. The polypeptide of embodiment 27, wherein the moiety is selected from the group consisting of PCGC (SEQ ID NO: 412), PCPC (SEQ ID NO: 413), PCGSGC (SEQ ID NO: 414), PCPPPC (SEQ ID NO: 415), PCPPPPPC(SEQ ID NO: 416), PCGSGSGC (SEQ ID NO: 417), PCHHHHHC (SEQ ID NO: 418), PCCHHHHHH (SEQ ID NO: 419), PCGCHHHHHH (SEQ ID NO: 420), PCPCHHHHHH (SEQ ID NO: 421), PCGSGCHHHHHH (SEQ ID NO: 422), PCPPPCHHHHHH (SEQ ID NO: 423), PCPPPPPHHHHHH (SEQ ID NO: 424) and PCGSGSGCHHHHHH (SEQ ID NO: 425).
- 32. The polypeptide of embodiment 31, wherein the moiety is PCPPPPPC (SEQ ID NO: 416).
- 33. The polypeptide of any one of embodiments 25-32, wherein the cysteine in the C-terminal moiety is conjugated to a heterologous moiety.
- 34. The polypeptide of embodiment 33, wherein the heterologous moiety is a detectable moiety.
- 35. The polypeptide of embodiment 33, wherein the heterologous moiety is a drug moiety, and the FBS and drug moiety form a FBS-drug conjugate.
- 36. An FBS-drug conjugate comprising the FBS moiety of any one of embodiments 1-31, wherein the drug moiety is conjugated to the FBS moiety by a linker.
- 37. The FBS-drug conjugate of embodiment 36, wherein the linker is a hydrazones, thioether, ester, disulfide or peptide-containing linker.
- 38. The FBS-drug conjugate of embodiment 37, wherein the linker is a peptidyl linker.
- 39. The FBS-drug conjugate of embodiment 38, wherein the peptidyl linker is Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Pro-Val-Gly-Val-Val (SEQ ID NO: 467), Ala-Asn-Val, Val-Leu-Lys, Ala-Ala-Asn, Cit-Cit, Val-Lys, Lys, Cit, Ser, or Glu.
- 40. The FBS-drug conjugate of any one of embodiments 36-39, wherein the drug moiety is a cytotoxic drug.
- 41. The FBS-drug conjugate of embodiment 40, wherein the cytotoxic drug selected from the group consisting of:
- (a) enediynes such as calicheamicin and uncialamycin;
- (b) tubulysins;
- (c) DNA alkylators such as analogs of CC-1065 and duocarmycin;
- (d) epothilones;
- (e) auristatins;
- (f) pyrrolobezodiazepine (PBD) dimers;
- (g) maytansinoids such as DM1 and DM4 and analogs and derivatives thereof.
- 42. The FBS-drug conjugate of embodiment 41, wherein the drug moiety is:
##STR00013## ##STR00014##
- 43. The FBS-drug conjugate of any one of embodiments 36-41, wherein the drug moiety is a synthetic tubulysin analog having the structure of formula (II):
##STR00015##
- 44. The FBS-drug conjugate of any one of embodiments 36-43, wherein the FBS and drug moiety are conjugated with a linker moiety having the structure of formula (III):
##STR00016##
- 45. The FBS-drug conjugate of embodiment 44, wherein the drug-moiety-linker has the structure of formula (IV):
##STR00017##
-
- wherein the maleimide group is reacted with a sulfhydryl group of a cysteine of the FBS, thereby forming a thioether bond between the drug-moiety-linker and the FBS.
- 46. The FBS-drug conjugate of any one of embodiments 36-45, wherein the FBS moiety comprises a C-terminal moiety comprising a cysteine.
- 47. The FBS-drug conjugate of embodiment 46, wherein the C-terminal moiety consists of the amino acid sequence PmCXn, wherein C is a cysteine, each X is independently any amino acid, m is an integer that is at least 1 and n is 0 or an integer that is at least 1.
- 48. The FBS-drug conjugate of embodiment 47, wherein m is 1 or 2, and n is an integer from 1-10.
- 49. The FBS-drug conjugate of embodiment 46, wherein the moiety consists of the amino acid sequence PmCXn1CXn2, wherein each X is independently any amino acid, n1 and n2 are independently 0 or an integer that is at least 1.
- 50. The FBS-drug conjugate of embodiment 49, wherein n1 and n2 are independently an integer from 1-5.
- 51. The FBS-drug conjugate of embodiment 47, wherein the C-terminal moiety is PC or PPC.
- 52. The FBS-drug conjugate of embodiment 49, wherein the moiety is selected from the group consisting of PCGC (SEQ ID NO: 412), PCPC (SEQ ID NO: 413), PCGSGC (SEQ ID NO: 414), PCPPPC (SEQ ID NO: 415), PCPPPPPC(SEQ ID NO: 416), PCGSGSGC (SEQ ID NO: 417), PCHHHHHC (SEQ ID NO: 418), PCCHHHHHH (SEQ ID NO: 419), PCGCHHHHHH (SEQ ID NO: 420), PCPCHHHHHH (SEQ ID NO: 421), PCGSGCHHHHHH (SEQ ID NO: 422), PCPPPCHHHHHH (SEQ ID NO: 423), PCPPPPPHHHHHH (SEQ ID NO: 424) and PCGSGSGCHHHHHH (SEQ ID NO: 425).
- 53. The FBS-drug conjugate of embodiment 52, wherein the moiety is PCPPPPPC (SEQ ID NO: 16).
- 54. An FBS-drug conjugate, having a structure represented by formula (I)
##STR00018##
-
- wherein m is 1, 2, 3 or 4 and Adx is an Adnectin that binds specifically to human GPC3 with a KD or 1 μM or less, and wherein the sulfur atom that is linked to “Adx” is a sulfur atom of a sulfhydryl group of a cysteine of the Adnectin.
- 55. The FBS-drug conjugate of embodiment 54, wherein Adx is a human 10Fn3 domain wherein,
- (a) the BC, DE and FG loops comprise SEQ ID NOs: 6, 7 and 8, respectively;
- (b) the BC, DE and FG loops comprise SEQ ID NOs: 19, 20 and 21, respectively;
- (c) the BC, DE and FG loops comprise SEQ ID NOs: 32, 33 and 34, respectively;
- (d) the BC, DE and FG loops comprise SEQ ID NOs: 45, 46 and 47, respectively;
- (e) the BC, DE and FG loops comprise SEQ ID NOs: 58, 59 and 60, respectively;
- (f) the BC, DE and FG loops comprise SEQ ID NOs: 71, 72 and 73, respectively;
- (g) the BC, DE and FG loops comprise SEQ ID NOs: 84, 85 and 86, respectively;
- (h) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 101, respectively;
- (i) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 129, respectively;
- (j) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 156, respectively;
- (k) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 183, respectively;
- (l) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 210, respectively;
- (m) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 237, respectively;
- (n) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 264, respectively;
- (o) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 264, respectively; or
- (p) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 318, respectively,
and, the 10Fn3 domain comprises a C-terminal moiety consisting of the amino acid sequence PmCXn, or PmCXn1CXn2, wherein each X is independently any amino acid, n1 and n2 are independently 0 or an integer that is at least 1.
- 56. The FBS-drug conjugate of embodiment 55, wherein the C-terminal moiety is PC or PPC, PCGC (SEQ ID NO: 412), PCPC (SEQ ID NO: 413), PCGSGC (SEQ ID NO: 414), PCPPPC (SEQ ID NO: 415), PCPPPPPC(SEQ ID NO: 416), PCGSGSGC (SEQ ID NO: 417), PCHHHHHC (SEQ ID NO: 418), PCCHHHHHH (SEQ ID NO: 419), PCGCHHHHHH (SEQ ID NO: 420), PCPCHHHHHH (SEQ ID NO: 421), PCGSGCHHHHHH (SEQ ID NO: 422), PCPPPCHHHHHH (SEQ ID NO: 423), PCPPPPPHHHHHH (SEQ ID NO: 424) or PCGSGSGCHHHHHH (SEQ ID NO: 425).
- 57. The FBS-drug conjugate of embodiment 52, wherein the moiety is PC or PCPPPPPC (SEQ ID NO: 16).
- 58. The FBS-drug conjugate of embodiment 54, wherein Adx comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-17, 24-30, 38-43, 51-56, 64-69, 77-82, 90-97, 110-127, 137-154, 164-181, 191-208, 218-235, 245-262, 272-289, 299-316 and 326-343.
- 59. The FBS-drug conjugate of embodiment 54, wherein Adx comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 110-127, 137-154, 164-181, 191-208, 218-235, 245-262, 272-289, 299-316 and 326-343.
- 60. The FBS-conjugate of embodiment 54, wherein Adx comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 110-127.
- 61. A pharmaceutical composition comprising a polypeptide of any one of embodiments 1-35, and a pharmaceutically acceptable carrier.
- 62. A pharmaceutical composition comprising an FBS-drug conjugate of any one of embodiments 36-60.
- 63. The composition of embodiment 61 or 62, wherein the composition is essentially endotoxin-free.
- 64. An isolated nucleic acid molecule encoding the polypeptide of any one of embodiments 1-35.
- 65. An expression vector comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-35.
- 66. A cell comprising a nucleic acid encoding the polypeptide of any one of embodiments 1-35.
- 67. A method of producing the polypeptide of any one of embodiments 1-35, comprising culturing the cell of claim 66 under conditions suitable for expressing the polypeptide, and purifying the polypeptide.
- 68. A method of attenuating or inhibiting a glypican-3 disease or disorder in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 61 or 62.
- 69. The method of embodiment 68, wherein the glypican-3 disease or disorder is cancer.
- 70. The method of embodiment 69, wherein the cancer is hepatocellular carcinoma, melanoma, Wilm's tumor, hepatoblastoma ovarian cancer or squamous lung cancer.
- 71. A kit comprising the polypeptide, FBS-drug conjugate or pharmaceutical composition of any one of embodiments 1-62, and instructions for use.
- 72. A method of detecting or measuring glypican-3 in a sample comprising contacting the sample with the polypeptide of any one of embodiments 1-35, and detecting or measuring binding of the FBS to glypican-3.
- 73. An FBS-drug conjugate, having a structure represented by formula (I)
##STR00019##
-
- wherein m is 1 and Adx is an Adnectin comprising the amino acid sequence of any one of SEQ ID NO: 110-117 and 272-289; and wherein the sulfur atom that is linked to “Adx” is a sulfur atom of a sulfhydryl group of the C-terminal cysteine of the Adnectin.
- 74. An FBS-drug conjugate, having a structure represented by formula (I)
##STR00020##
-
- wherein m is 2 and Adx is an Adnectin comprising the amino acid sequence of SEQ ID NO: 119-126 and 281-288; and wherein the sulfur atom that is linked to “Adx” is a sulfur atom of a sulfhydryl group of each of the two C-terminal cysteines of the Adnectin.
- 75. An FBS-drug conjugate, having a structure represented by formula (VI)
##STR00021##
wherein the sulfur atom linked to the cysteine is the sulfur atom of the sulfhydryl group of the cysteine.
- 76. An FBS-drug conjugate, having a structure represented by formula (VII):
##STR00022##
wherein the sulfur atom linked to the cysteines is the sulfur atom of the sulfhydryl group of the cysteines.
The contents of all figures and all references, Genbank sequences, websites, patents and published patent applications cited throughout this application are expressly incorporated herein by reference to the same extent as if there were written in this document in full or in part. The content of PCT/US2015/021466 is specifically incorporated by reference herein.
The invention is now described by reference to the following examples, which are illustrative only, and are not intended to limit the present invention. While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one of skill in the art that various changes and modifications can be made thereto without departing from the spirit and scope thereof.
Glypican-3 (GPC3) binding Adnectins were isolated from an Adnectin library screened with a Glypican-3 protein, or were affinity matured by PROfusion from clones identified in the library. For a detailed description of the RNA-protein technology and fibronectin-based scaffold protein library screening methods see Szostak et al., U.S. Pat. Nos. 6,258,558; 6,261,804; 6,214,553; 6,281,344; 6,207,446; 6,518,018; PCT Publication Nos. WO 00/34784; WO 01/64942; WO 02/032925; and Roberts et al., Proc Natl. Acad. Sci., 94:12297-12302 (1997), herein incorporated by reference.
The amino acid and nucleotide sequences of 7 adnectins with good binding and biophysical properties are provided below:
ADX_4578_F03
(SEQ ID NO: 10)
MGVSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPVQEF
TVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYRTEGSGS*
(SEQ ID NO: 452)
ATGGGAGTTTCTGATGTGCCGCGCGACTTGGAAGTGGTTGCCGCCACCCC
CACCAGCCTGCTGATCTCTTGGCATCCGCCGCATCCGAACATCGTTTCTT
ACCATATCTACTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTC
ACTGTGGAAGGTTCTAAATCTACTGCTAAAATCAGCGGCCTTAAACCTGG
CGTTGATTATACCATCACTGTGTACGCTGTTGCTCCGGAAATCGAAAAAT
ACTACCAGATTTGGATTAATTACCGCACAGAAGGCAGCGGTTCCTAA
ADX_4578_H08
(SEQ ID NO: 23)
MGVSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPVQEF
TVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISINYRTEIDK
PSQ*
(SEQ ID NO: 452)
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCCACCCC
CACCAGCCTGCTGATCAGCTGGTCTGGTTACGACTACGGTGACTCTTATT
ACCGCATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTC
ACTGTGCCTGACGGTTCTAACACAGCTACCATCAGCGGCCTTAAACCTGG
CGTTGATTATACCATCACTGTGTATGCTGTCGAAGCTTACGGTAAAGGTT
ACACTCGTTACACTCCAATTTCCATTAATTACCGCACAGAAATTGACAAA
CCATCCCAGTAA
ADX_4578_B06
(SEQ ID NO: 36)
MGVSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEFTVE
GHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINYRTEGSGS*
(SEQ ID NO: 454)
ATGGGAGTTTCTGATGTGCCGCGCGACTTGGAAGTGGTTGCCGCCACCCC
CACCAGCCTGCTGATCTCTTGGTTCCCGGACCGTTACGTTTACTACATCA
CTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTCACTGTGGAA
GGTCATAAACAGACTGCTTACATCAGCGGCCTTAAACCTGGCGTTGATTA
TACCATCACTGTGTACGCTATCTACTACTACCCGGACGACTTCCAGGGTT
ACCCGCAGCCGATTTCTATTAATTACCGCACAGAAGGCAGCGGTTCCTAA
ADX_4606_F06
(SEQ ID NO: 49)
MGVSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQEFT
VPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTEIDKPSQ*
(SEQ ID NO: 455)
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCCACCCC
CACCAGCCTGCTGATCAGCTGGAACTCTGGTCATTCTGGTCAGTATTACC
GCATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTCACT
GTGCCTCGTTACGGTTACACAGCTACCATCAGCGGCCTTAAACCTGGCGT
TGATTATACCATCACTGTGTATGCTGTCGCTCATTCTGAAGCTTCTGCTC
CAATTTCCATTAATTACCGCACAGAAATTGACAAACCATCCCAGTAA
ADX_5273_C01
(SEQ ID NO: 62)
MGVSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPVQEF
TVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISINYRTEIDK
PSQ*
(SEQ ID NO: 456)
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCCACCCC
CACCAGCCTGCTGATCAGCTGGTCTGACCCGTACGAAGAAGAACGATATT
ACCGCATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTC
ACTGTGCCTGCTTTCCATACTACAGCTACCATCAGCGGCCTTAAACCTGG
CGTTGATTATACCATCACTGTGTATGCTGTCACTTACAAACATAAATACG
CTTACTACTACCCGCCAATTTCCATTAATTACCGCACAGAAATTGACAAA
CCATCCCAGTAA
ADX_5273_D01
(SEQ ID NO: 75)
MGVSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPVQEF
TVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISINYRTEIDK
PSQ*
(SEQ ID NO: 457)
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCCACCCC
CACCAGCCTGCTGATCAGCTGGGAACCGTCTTACAAAGACGACCGATATT
ACCGCATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTC
ACTGTGCCTTCTTTCCATCAGACAGCTACCATCAGCGGCCTTAAACCTGG
CGTTGATTATACCATCACTGTGTATGCTGTCACTTACGAACCGGACGAAT
ACTACTTCTACTACCCAATTTCCATTAATTACCGCACAGAAATTGACAAA
CCATCCCAGTAA
ADX_5274_
(SEQ ID NO: 88)
MGVSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPVQEF
TVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISINYRTEIDK
PSQ*
(SEQ ID NO: 458)
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCCACCCC
CACCAGCCTGCTGATCAGCTGGTCTGGTGACTACCATCCGCATCGATATT
ACCGCATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTC
ACTGTGCCTGGTGAACATGAAACAGCTACCATCAGCGGCCTTAAACCTGG
CGTTGATTATACCATCACTGTGTATGCTGTCACTTACGACGGTGAAAAAG
CTGACAAATACCCGCCAATTTCCATTAATTACCGCACAGAAATTGACAAA
CCATCCCAGTAA
The binding characteristics of the 7 GPC3 binding Adnectins were determined via ELISA using recombinant GPC3 and flow cytometry, using the GPC3 positive CHO cell line and the HepG2 human tumor cell line. For the flow cytometry experiments, CHO-K1 or CHO-Glypican-3 cells or HepG2 tumor cell line were treated with Versene and resuspended in FACS Buffer (PBS 2.5% FBS). Adnectins diluted in FACS buffer were incubated with cells for 1 hour at 4° C. After 1 wash in FACS buffer the cells were incubated with an anti-His antibody at 2 ug/ml and incubated for 1 hour at 4° C. After 2 washes in FACS Buffer the cells were resuspended in FIX Buffer (2.5% formaldehyde in PBS). Analysis was done with the BB Biosciences FACS Canto.
The results of the ELISA experiments are shown in Table 3, and exemplary flow cytometry results are shown in
TABLE 2
ELISA and SEC scores of human GPC3 binding Adnectins
Clone
ELISA OD
SEC score
ADX_4578_F03
0.60
2
ADX_4578_H08
1.02
2
ADX_4578_B06
0.17
3
ADX_4606_F06
1.73
3
ADX_5273_C01
1.35
3
ADX_5273_D01
2.1
2
ADX_5274_E01
2.37
1
The C-terminus of ADX_5274_E01 was modified by inclusion of a C-terminal cysteine and a 6×His tail, to produce Adnectin ADX_6561_A01: MGVSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPVQEFTVPGEHETA TISGLKPGVDYTITVYAVTYDGEKADKYPPISINYRTPCHHHHHH (SEQ ID NO: 94)
The nucleic acid encoding ADX_6561_A01 was diversified by introducing a small fraction of substitutions at each nucleotide position that encoded an amino acid residue in loop BC, DE or FG. The resulting library of Adnectin sequences related to ADX_6561_A01 was then subjected to in vitro selection by PROfusion (mRNA display) for binding to human GPC3 under high stringency conditions. The clones enriched after selection was completed were sequenced, expressed in HTPP format, and further analyzed.
The selection identified Adnectin ADX_6077_F02 as binding to human GPC3 with high affinity. The amino acid sequence of ADX_6077_F02, and the nucleotide sequence encoding it are as follows:
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEF
TVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPCHH
HHHH (SEQ ID NO: 118; the BC, DE and FG loops are
shown in bold)
(SEQ ID NO: 459)
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCCACCCC
CACCAGCCTGCTGATCAGCTGGTCTGATGACTACCATGCGCATCGATATT
ACCGCATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAGGAGTTC
ACTGTGCCTGGTGAACATGTGACAGCTACCATCAGCGGCCTTAAACCTGG
CGTTGATTATACCATCACTGTGTATGCTGTCACTTACGACGGTGAAAAGG
CTGCCACAGATTGGTCAATTTCCATTAATTACCGCACACCGTGCCACCAT
CACCACCACCACTGA
Binding of the anti-GPC3 Adnectin to other glypican molecules was tested, and the results, indicate that ADX_6077_F02 binds specifically to human GPC3, and does not cross-react to the other human glypicans GPC 1, GPC2, GPC5 and GPC6.
For preparing Adnectins linked to a drug moiety, the Adnectins were modified at their C-terminus to comprise one of the following C-terminal amino acid sequences: NYRTPC (SEQ ID NO: 466; for forming DAR1 Adnectins, i.e., Adnectins with a single cysteine in the linker, for linking to a single drug moiety); NYRTPCC (SEQ ID NO: 467; for forming DAR2 Adnectins, i.e., Adnectins with two cysteines in the linker, for linking to two drug moieties, one per cysteine); NYRTPCHHHHHH (SEQ ID NO: 468; for forming DAR1 Adnectins with a 6×His tail) and NYRTPCPPPPPCHHHHHH (SEQ NO: 469; for forming DAR2 Adnectins with a 6×His tail).
To prevent disulfide-linked dimers of the unconjugated Adnectins containing one or more Cysteine residues, the cysteine residue(s) of the Adnectins were carboxymethylated as follows: An Adnectin solution was treated with a reducing agent (5 mM DTT or 5 mM TCEP) and incubated for 30 minutes at room temperature. Iodoacetamide (500 mM, Sigma P/N A3221-10VL) was added to a final concentration of 50 mM. Samples were incubated for 1 hour in the dark at room temperature. Samples were then dialyzed to PBS or Sodium Acetate buffer.
Production of Adnectins, e.g., GPC3 Adnectins:
A nucleic acid encoding an Adnectin, e.g., (SEQ ID NO: 459), which encodes a protein having the amino acid sequence MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGEHVTA TISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPCHHHHHH (SEQ ID NO: 118; ADX_6077_F02), was cloned into a pET9d (EMD Biosciences, San Diego, Calif.) vector and expressed in E. coli BL21 DE3 pLys-S cells. Twenty ml of an inoculum culture (generated from a single plated colony) was used to inoculate 1 liter of Magic Media E. coli expression medium (Invitrogen, Catalog K6803A/B) containing 50 ug/ml Kanamycin in a 2.5 Liter Ultra Yield flask (Thomson Instruments Co. P/N 931136-B). The culture was grown at 37° C. for 6 hours, followed by 20° C. for 18 hours with shaking at 225 RPM. After the incubation period, the culture was harvested by centrifugation for 30 minutes at >10,000 g at 4° C. Cell pellets were frozen at −80° C. The cell pellet was thawed and resuspended in 25 mL of lysis buffer (20 mM Sodium Phosphate, 500 mM Sodium Chloride, 5 mM Dithiothreitol, 1× Complete™ Protease Inhibitor Cocktail-EDTA free (Roche) using an Ultra-Turrax homogenizer (IKA—Works) on ice. Cell lysis was achieved by high pressure homogenization (>18,000 psi) using a Model M-110P Microfluidizer (Microfluidics). The insoluble fraction was separated by centrifugation for 30 minutes at 23,300 g at 4° C. and discarded. The soluble fraction was filtered with a 0.2 micron vacuum filter. The filtered supernatant was loaded onto a Histrap column (GE Healthcare P/N 17-5248-02) equilibrated with 20 mM Sodium Phosphate/500 mM Sodium chloride pH 7.4+5 mM DTT buffer. After loading, the column was washed with 10 CV equilibration buffer, followed by 10 CV of 40 mM Imidazole in equilibration buffer, followed by 10 CV 2.0M Sodium Chloride in PBS. Bound protein was eluted with 500 mM Imidazole in 20 mM Sodium Phosphate/500 mM Sodium Chloride pH 7.4+5 mM DTT. The eluate from the HisTrap column was buffer exchanged to 50 mM Sodium Acetate/10 mM Sodium Chloride pH 5.5 using G25 gel filtration chromatography. The sample was then applied to a cation exchange chromatography column (SP HP, GE Healthcare 17-1152-01). Bound protein was eluted in a gradient of increasing sodium chloride concentration in 50 mM Sodium Acetate pH 5.5 buffer. Fractions were pooled for conjugation with tubulysin.
Production of Tubulysin Analog-Linker:
A tubulysin analog-linker compound having the structure of formula (IV) was produced as described in U.S. Pat. No. 8,394,922 (hereby incorporated by reference).
##STR00023##
Adnectin-Drug Conjugation:
Conjugation of a tubulysin analog-linker to Adnectins comprising a C terminal cysteine was conducted as follows:
A sample of the adnectin to be conjugated to the tubulysin analog was treated with 5 mM TCEP and incubated at room temperature for approximately 1 h. TCEP was removed using a G25 gel filtration column (GE Healthcare) equilibrated with 50 mM NaOAc/10 mM NaCl pH 5.5. The tubulysin analog was dissolved in 100% DMSO and added to a final concentration of 5× molar and the reaction was incubated for 2 hours at RT followed by overnight at 4° C. To remove unreacted tubulysin analog, the reaction mixture was re-applied to the SP cation exchange column as described above.
Adnectins, e.g., GPC3 Adnectins, containing two cysteine residues near the C-terminus were conjugated to two molecules of tubulysin analog using the same methodology described above to generate DAR2 (Drug-Adnectin Ratio 2) Adnectins.
Protein concentration was determined using a Nanodrop 8000 spectrophotometer (Thermo Scientific). The molecular weight of conjugated and unconjugated Adnectin was determined by LC-mass spectrometry using an Agilent Technologies 6540 UHD Accurate Mass Q-ToF LC-MS equipped with a Zorbax C8 RRHD column.
Using these techniques of expressing, purifying, conjugating and alkylating Adnectins, the Adnectins and Adnectin-drug conjugates listed in Table 3 were prepared.
TABLE 3
Control and Anti-Glypican-3 Binding Adnectins
C-term
ADX ID
elements
Modifications
Protein sequence
ADX_6561_A01
Cys, His6
MGVSDVPRDLEVVAATPTSLLISWSGDYH
PHRYYRITYGETGGNSPVQEFTVPGEHETA
TISGLKPGVDYTITVYAVTYDGEKADKYPP
ISINYRTPCHHHHHH* (SEQ ID NO: 94)
ADX_6077_F02
Cys, His6
none
MGVSDVPRDLEVVAATPTSLLISWSDDYH
ADX_6077_F02
Cys, His6
alkylated
AHRYYRITYGETGGNSPVQEFTVPGEHVT
ADX_6077_F02
Cys, His6
Drug/linker
ATISGLKPGVDYTITVYAVTYDGEKAATD
DAR1
WSISINYRTPCHHHHHH* (SEQ ID NO: 11)
ADX_6077_F02
Cys
none
GVSDVPRDLEVVAATPTSLLISWSDDYHA
HRYYRITYGETGGNSPVQEFTVPGEHVTAT
ISGLKPGVDYTITVYAVTYDGEKAATDWSI
SINYRTP* (SEQ ID NO: 104)
ADX_6912_G02
2Cys,
none
MGVSDVPRDLEVVAATPTSLLISWSDDYH
His6
AHRYYRITYGETGGNSPVQEFTVPGEHVT
ADX_6912_G02
2Cys,
alkylated (2x)
ATISGLKPGVDYTITVYAVTYDGEKAATD
His6
WSISINYRTPCPPPPPCHHHHHH* (SEQ ID
ADX_6912_G02
2Cys,
Drug/linker (2x)
NO: 127)
His6
DAR2
ADX_6912_G02
2Cys
None
MGVSDVPRDLEVVAATPTSLLISWSDDYH
AHRYYRITYGETGGNSPVQEFTVPGEHVT
ATISGLKPGVDYTITVYAVTYDGEKAATD
WSISINYRTPCPPPPPC* (SEQ ID NO: 126)
ADX_6093_A01
Cys, His6
none
MGVSDVPRDLEVVAATPTSLLISWDAPAV
ADX_6093_A01
Cys, His6
alkylated
TVRYYRITYGETGGNSPVQEFTVPGSKSTA
ADX_6093_A01
C-term
Drug/linker
TISGLKPGVDYTITVYAVTGRGESPASSKPI
His6
DAR1
SINYRTPCHHHHHH* (SEQ ID NO: 348)
ADX_6093_A01
Cys
none
GVSDVPRDLEVVAATPTSLLISWDAPAVT
VRYYRITYGETGGNSPVQEFTVPGSKSTAT
ISGLKPGVDYTITVYAVTGRGESPASSKPISI
NYRTPC* (SEQ ID NO: 349)
2Cys,
none
MGVSDVPRDLEVVAATPTSLLISWDAPAV
His6
TVRYYRITYGETGGNSPVQEFTVPGSKSTA
2Cys,
alkylated (2x)
TISGLKPGVDYTITVYAVTGRGESPASSKPI
His6
SINYRTPCPPPPPCHHHHHH*
2Cys,
Drug/linker (2x)
(SEQ ID NO: 350)
His6
DAR2
Size Exclusion Chromatography:
Standard size exclusion chromatography (SEC) was performed on candidate Adnectins resulting from the midscale process. SEC of midscaled material was performed using a Superdex 200 10/30 or on a Superdex 75 10/30 column (GE Healthcare) on an Agilent 1100 or 1200 HPLC system with UV detection at A214 nm and A280 nm and with fluorescence detection (excitation 280 nm, emission 350 nm). A buffer of 100 mM sodium sulfate/100 mM sodium phosphate/150 mM sodium chloride, pH 6.8 was used at the appropriate flow rate for the SEC column employed. Gel filtration standards (Bio-Rad Laboratories, Hercules, Calif.) were used for molecular weight calibration.
Thermostability:
Thermal Scanning Fluorescence (TSF) analysis of HTPP Adnectins was performed to screen them by relative thermal stability. Samples were normalized to 0.2 mg/ml in PBS. 1 μl of Sypro orange dye diluted 1:40 with PBS was added to 25 μl of each sample and the plate was sealed with a clear 96 well microplate adhesive seal. Samples were scanned using a BioRad RT-PCR machine by ramping the temperature from 25° C.-95° C., at a rate of 2 degrees per minute. The data was analyzed using BioRad CFX manager 2.0 software. The values obtained by TSF have been shown to correlate well with Tm values obtained by DSC over a melting range of 40° C. to 70° C. This is considered the acceptable working range for this technique. A result of ND (“No data”) is obtained when the slope of the transition curve is too small to allow its derivative peak (the rate of change in fluorescence with time) to be distinguished from noise. An “ND” result cannot be interpreted as an indication of thermostability. Differential Scanning Calorimetry (DSC) analyses of dialyzed HTPP'd and midscaled Adnectins were performed to determine their respective Tm's. A 0.5 mg/ml solution was scanned in a VP-Capillary Differential Scanning calorimeter (GE Microcal) by ramping the temperature from 15° C. to 110° C., at a rate of 1 degree per minute under 70 p.s.i pressure. The data was analyzed vs. a control run of the appropriate buffer using a best fit using Origin Software (OriginLab Corp).
SPR Affinity Measurements:
Surface plasmon resonance (SPR) was performed to calculate off-rates (kd) and binding affinities of α-GPC3 adnectins and tubulysin-conjugated AdxDCs using a Biacore T100 instrument (GE Healthcare). Recombinant human (aa 1-559) and murine (aa 25-557) glypican-3 proteins (R&D Systems) were diluted to 10 g/ml in 10 mM sodium acetate pH 4.5 and individually immobilized onto active flow cells of a CM5 biosensor following the manufacturer's amine coupling protocol (GE Healthcare), targeting ˜1000RU immobilization density of each protein per flow cell. SPR experiments were conducted at 37° C. using HBS-P+(10 mM HEPES, 150 mM NaCl, 0.05% (v/v) Surfactant P20, pH 7.4) running buffer (GE Healthcare). For affinity measurements, a concentration series of 200-1.56 nM α-GPC3 adnectins and AdxDCs were prepared in running buffer and injected at 30 l/min across the human and murine GPC3 biosensor flow cells. For off-rate measurements, single 200 nM adnectin/AdxDC concentrations were injected using identical conditions. One 30s injection of 10 mM glycine pH 1.7 was used to remove bound adnectin and regenerate the GPC3 surfaces between assay cycles.
Rate constants ka (kon) and kd (koff) were derived from reference-subtracted sensorgrams fit to a 1:1 binding model in Biacore T100 Evaluation Software v2.0.4 (GE Healthcare). The affinity constant, KD was calculated from the ratio of rate constants kd/ka.
Cell Binding Assay:
The binding of GPC3 adnectins to huGPC3 positive cells Huh7 was evaluated by flow cytometry essentially as follows. Huh7 carcinoma cells grown in DMEM media with 10% FBS. Cells were harvested using Versene, an EDTA cell dissociation solution from Lonza, Cat. #17-711E. Tumor cells (1E5cells/reaction) were suspended in FACS buffer (PBS, 1% BSA, 0.05% Na Azide) and mixed with a serial dilution of AdxDC for one hour on ice. Cells were washed three times with FACS buffer, and bound AdxDC was detected with an in house anti-scaffold monoclonal Ab and PE-conjugated Antibody from (RnD Systems), cat #NL007, and read on a flow cytometer. Data analysis was done using FlowJo Software, and EC50 of 50% of maximum binding was determined using PRISM™ software, version 5.0 (GraphPad Software, La Jolla, Calif., USA).
Cell Growth Inhibition Assay:
A 3H thymidine assay, where the inhibition of incorporation of 3H thymidine indicates inhibition of proliferation of the tested cell line, was used to assess the dose-dependent inhibitory effect of the AdxDC on the proliferation of Hep3B, Huh7and HepG2 cells. The human tumor cell lines were obtained from the American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, Va. 20108, USA, and cultured according to instructions from ATCC. Cells were seeded at 1.25×104 cells/well in 96-well plates, and 1:3 serial dilutions of GPC3 AdxDC were added to the wells. Plates were allowed to incubate for 72 h. The plates were pulsed with 1.0 μCi of 3H-thymidine per well for the last 24 hours of the total incubation period, harvested, and read on a Top Count Scintillation Counter (Packard Instruments, Meriden, Conn.). The EC50 values—the Adnectin drug conjugate concentration at which 50% of maximum cell proliferation inhibition was achieved—were determined using PRISM™ software, version 4.0 (GraphPad Software, La Jolla, Calif., USA).
A summary of the in vitro properties of DAR1 and DAR2 forms of the AdxDC conjugate is summarized in Table 4.
TABLE 4
In vitro characterization of GPC3-Tubulysin AdxDC
Non-binding control
Glypican-3-binding
Adnectin ID
ADX_6093_A01
ADX_6077_F02
Conjugate
DAR1
DAR1
DAR2
DAR2
% monomer
100%
100%
DSC Tm (PBS)
86° C.
89° C., 93° C.
SPR KD (37° C.)
No binding
12 nM (hu)
11 nM (mu)
SPR koff (37° C.)
No binding
9.8 × 10−4 s−1 (hu)
7.7 × 10−4 s−1 (mu)
Adnectin
No binding
5 nM
(hu; Huh7)alk
cell-binding EC50
up to ~200 nMalk
AdxDC
No effect
0.2 nM
(hu; Huh7, HepG2)
cell-killing IC50
up to ~25 nM
alkmeasured for alkylated (capped Adnectin); all other measurements for DAR1 AdxDC (no PEG)
GPC3 AdxDC were evaluated by flow cytometry for binding to human Hep3B hepatocellular carcinoma cells grown in MEM with 10% FBS, and H446 small cell lung carcinoma cells grown in RPMI with 10% FBS. Cells were harvested using Cellstripper, a non-enzymatic cell dissociation solution from Mediatch (Corning: Manassas, Va. 20109), Cat. #25-056-CL. Tumor cells (25,000/reaction) were suspended in FACS buffer (PBS+5% FBS+0.01% NaN3) and mixed with a serial dilution of AdxDC for 1 hour on ice. Cells were washed three times with FACS buffer, and bound AdxDC was detected with His Tag PE-conjugated Antibody from R&D System, cat #IC050P, and read on a flow cytometer. Data analysis was done using FlowJo Software, and EC50 of 50% of maximum binding was determined using PRISM™ software, version 5.0 (GraphPad Software, La Jolla, Calif., USA).
The results, which are shown in
This Example shows that GPC3 AdxDC DAR1 and DAR2 inhibit cell proliferation of Hep3B (Glypican3 high) HCC cells, H446 (Glypican3 low) SCLC Cells and HepG2 tumor cells. Thymidine incorporation assays were conducted as described above. The results, which are shown in
To ensure maximum target engagement prior to internalization studies, binding of ADX_6077_F02 DAR1 (i.e., with a “PC” terminus, but not conjugated) to GPC-3 positive cells Hep3B was determined using the following binding assay: AF-488 fluorescently labeled adnectin ADX_6077_F02 and negative control (NBC) ADX_6093_A01 were used in Hep3B cell binding assay. For binding analysis, Hep3B cells were plated into a 384 well plate, incubated for 16h to allow cells to adhere and then the cells were fixed with 2% formaldehyde. ADX_6077_F02 and ADX_6093_A01 at 100 nM were added into the cell plate and incubated at room temperature for 7 time points: 0 minute, 10 minutes, 15 minutes, 20 minutes, 60 minutes, 120 minutes and 180 minutes. After binding, the cells were washed with phosphate-buffered saline (PBS) twice and total cell fluorescence intensity per cell was then measured using high content analysis.
The results, indicate that ADX_6077_F02 demonstrated fast association onto cell surfaces. Two hours was found to be sufficient to reach a greater than 95% binding plateau using 100 nM of the Adnectin.
To quantify anti-glypican 3 adnectin induced internalization, a high-content Alexa quenching assay was applied. Hep3B and H446 cells were seeded in 384 well plates and incubated for 16 hours at 37° C. AF-488 fluorescently labeled ADX_6077_F02 DAR1 at 100 nM were then added into the cell plates and incubated at 37° C. for the indicated time prior to fixation and quenching. Internalized Adnectin was measured as increased fluorescence above the unquenchable signal. Total fluorescence from “unquenched control” at each time point was monitored in parallel to be used as indicator of the amount of adnectin initially bound to the cells. The images of the cells were taken by Arrayscan to show the localization of the adnectin, and used for cell fluorescence intensity quantification.
Quantification studies confirmed high expression levels of the GPC3 receptor on Hep3B (approximately 1.1×106 active binding copies/cell) and lower levels on H446 cells (approximately 2.6×105 active binding copies/cell). Following fixation, total and intracellular FL were determined and used to measure internalization of the Adnectin molecules.
The results of these assays indicate that the anti-GPC3 adnectin is internalized by Hep3B and H446 cells (
The systemic exposure profile of anti-GPC3 AdxDC (DAR1) was determined in mice. Female NOD/SCID mice (13 weeks of age) were dosed intravenously with a single dose of high (240 nmol/kg) and low (24 nmol/kg) doses of GPC3-binding and non-binding-control AdxDCs (GPC3 DAR1 AdxDC and RGE AdxDC, respectively) as per the experimental design below. The indicated blood time points were serial tail vein collections using CPD anticoagulant (Citrate-phosphate-dextrose solution, Sigma C7165). Plasma obtained from these blood samples were aliquoted and stored at −80 C until ready for analysis.
TABLE 5
Dosing Schedule for Xenograft Model
Group
N
Test Article
Dose (nmol/kg)
1 Low dose
3
Glypican3 binding AdxDC
24
1 High Dose
3
240
Timepoints: 5 - 20-40 min, 1 - 1.5 - 2 - 3 - 4 - 6 - 8-24 h
AdxDC plasma levels where analyzed using Mesoscale (MSD) ligand binding assays with two different formats. MSD assays for total levels of conjugated and unconjugated Adnectin assays used for capture an in house generated anti-His monoclonal antibody (at 4 ug/ml), and for detection a pooled in-house generated rabbit anti-scaffold polyclonal at 1:10000 dilution followed by a goat anti-rabbit sulfotagged antibody (at 1 ug/ml). MSD assays for intact conjugated Adnectin used for capture an in-house generated anti-His monoclonal antibody (at 4 ug/ml), and for detection an in-house generated sulfotagged mouse anti-tubulysin antibody (at 1 ug/ml).
The results of this assay, which are summarized in Table 6 (Non compartmental Phoenix WinNonlin analysis, NCA model) and
TABLE 6
Pharmacokinetics Parameter Summary of GPC3 AdxDC
NCA
AUC_%
HL_Lambda_z
Cl_obs
Vss_obs
AUCall
AUCINF_obs
Extrap_obs
MRTINF_obs
Cmax
dose
species
(h)
(mL/h/kg)
(mL/kg)
(h*nmol/L)
(h*nmol/L)
(%)
(h)
(nmol/L)
high
total
0.74
288
136
835
836
0.11
0.47
2124
intact
0.80
353
249
740
740
0.06
0.71
1870
low
total
0.59
344
192
69
70
1.12
0.56
165
intact
0.63
445
233
58
59
0.48
0.52
145
The efficacy of unPEGylated GPC3-tubulysin drug conjugate was tested in CD1 mice and Fischer rats.
NOD-SCID and CD1 female mice (13 weeks old, from Charles River Laboratories, Wilmington, Mass.) and female Fischer rats (10 weeks of age, from Charles River laboratories, Wilmington, Mass.) were housed in a temperature-controlled room with a reversed 12 hour light/dark cycle. Water and standard chow food were available ad libitum. Animals for safety studies were randomized and distributed between treatment groups to receive either control or test AdxDC based on body weight (about 20-25 g).
Hep3B, a human hepatocellular carcinoma, was maintained in culture using EMEM Cat #ATCC 30-2003 supplemented with 10% FBS (Thermo Cat #ATK-33398). For efficacy studies, xenografts were generated by subcutaneous implantation of 100 ul of Hep3B 5×106 cells (50% cellular suspension with Standard Phenol Red Matrigel, Corning Cat #354234) in the right flank of NOD-SCID mice. In order to demonstrate in vivo efficacy, the AdxDCs were administered by intravenous injection in either 50 mM NaOAc/150 mM NaCl/pH 5.5, or Phosphate-Buffered Saline (PBS). Controls were treated with a non-binding control AdxDC. Test animals (n=8 animals/group) were dosed intravenously every three days with a total of six doses, with varying dosages of the AdxDC. Body weight measurements were recorded pre-randomization, on randomization day, and two times a week during the treatment periods and at the end of the study. Tumor growth was monitored using digital caliper measurements twice a week. The results were assessed using student's t-test 2 tailed paired analysis. Representative study design and results using every three days dosing administration are represented in Table 7 and
TABLE 7
Dosing Schedule
Dose
T/C (d 17)
AdxDC
DAR
μmol/kg
Schedule
(%)
ADX_6093_A01-961
1
0.3
Every 3 days
(non-binding control)
ADX_6077_F02-961
1
0.1
Every 3 days
96
ADX_6077_F02-961
1
0.3
Every 3 days
95
ADX_6912_G02-961
2
0.3
Every 3 days
96
ADX_6912_G02-961
2
0.3
Every 5 days
96
Weekly administration was evaluated in Hep3B xenografts. The results indicate that QW administration of ADX_6077_F02-961 DAR1 and DAR2 at 0.1 μmol/kg effectively inhibited HepG2 xenografts TV0=380-4803 (
In summary, weekly administration of GPC3 AdxDCs inhibits growth of HCC tumor xenografts, and DAR1 and DAR2 GPC3 AdxDCs demonstrated equivalent tumor growth inhibition, which was target-dependent. In addition, the prevention of tumor burden-induced weight loss was associated with the anti-tumor activity of the GPC3 AdxDCs.
In mice safety studies, CD1 mice treated intravenously every other day for a total of 9 doses at varying doses up to a highest dose of 0.5umol/kg, 5× the efficacious dose (0.1 umol/kg) with both GPC3 and non-binding control AdxDCs. No MTD was identified in the CD1 mice safety studies. No kidney toxicity was observed for any group, at any dose or frequency. In CD1 mice, the half-life of the AdxDC was approximately 20 minutes (MSD assays as described above). No body weight loss was observed and all mice survived treatment to scheduled necroscopy. Serum chemistry and hematology were evaluated at intervals through the dosing period using Abaxis Veterinary Diagnostics instruments, VETSCAN VS2 and HM5, respectively. There were no significant differences observed in serum chemistry or hematology compared to baseline. Histopathology was evaluated via H&E staining of heart, liver, spleen and kidney tissues collected at the end of the study. No dose-limiting toxicities were observed in any of the evaluated tissues, and minimal/mild tubular epithelium neuropathy was observed in all groups.
In Fischer rat safety studies, the half life of the AdxDC was approximately 30 minutes (MSD assays as described above). Some dose dependent tolerability and skeletal muscle degeneration were observed at the most frequent administration (every other day) of doses of 0.36umol/kg with no changes in bone marrow or liver histopathology or heart toxicity. These findings were not observed when the same rat studies were conducted using weekly administration of AdxDCs at the same dosage range.
Overall, excellent efficacy despite the short plasma half-life and low off-target toxicity, consistent with low systemic exposure, was observed in both rodent species.
The Adnectin binding site on human GPC3 (amino acid sequence shown in
Prior to mapping the Adnectin binding site on human GPC3 recognized by ADX_6077_F02 by HDX-MS, non-deuteriated experiments were performed to generate a list of common peptic peptides for GPC3 samples, achieving a sequence coverage of 87.4% for GPC3 (
For Adnectin binding site mapping experiments, 5 μL of each sample (GPC3 or GPC3 with ADX_6077_F02) was mixed with 55 μL HDX labeling buffer (10 mM phosphate buffer in D2O, pD 7.0) to start the labeling reactions. The reactions were carried out for different periods of time: 1 min, 10 min, and 240 min. By the end of each labeling reaction period, the reaction was quenched by adding quenching buffer (1:1, v/v) and the quenched sample was injected into Waters HDX-MS system for analysis. The observed common peptic peptides were monitored for their deuterium uptake levels in the absence/presence of ADX_6077_F02 (
Experimental data obtained from HDX-MS measurements indicate that AADX_6077_F02 recognizes a discontinuous Adnectin binding site comprised of two peptide regions in human GPC3:
-
- Region 1: HQVRSFF (amino acid residues 36-42 of GPC3); SEQ ID NO: 356
- Region 2: EQLLQSASM (amino acid residues 90-98 of GPC3); SEQ ID NO: 346
Analysis of the amino acid sequence of ADX_6077_F02 indicated that the DG in the FG loop of the molecule might be at low risk of aspartate isomerization.
(SEQ ID NO: 118)
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEF
TVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPCHH
HHHH
Eight variants of ADX_6077_F02 with mutations at the DG site were generated. The sequences of these mutants are summarized in Table 8.
TABLE 8
ADX_6077_F02 Variants
C-term
elements
Modification
Protein sequence
DG→EG
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYEGEKAATDWSISIN
YRTPC* (SEQ ID NO: 143)
DG→SG
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYSGEKAATDWSISIN
YRTPC* (SEQ ID NO: 169)
DG→AG
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYAGEKAATDWSISI
NYRTPC* (SEQ ID NO: 197)
DG→GG
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYGGEKAATDWSISI
NYRTPC* (SEQ ID NO: 224)
DG→DS
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYDSEKAATDWSISIN
YRTPC* (SEQ ID NO: 251)
DG→DA
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYDAEKAATDWSISIN
YRTPC* (SEQ ID NO: 278)
DG→DL
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYDLEKAATDWSISIN
YRTPC* (SEQ ID NO: 305)
DG→DV
Cys
alkylated
GVSDVPRDLEVVAATPTSLLISWSDDYHAH
mutant
RYYRITYGETGGNSPVQEFTVPGEHVTATIS
GLKPGVDYTITVYAVTYDVEKAATDWSISIN
YRTPC* (SEQ ID NO: 332)
One-hundred to one-hundred-fifty milligrams of each of the eight mutants was made, purified and alkylated as previously above. Three to five milligrams of each of eight alkylated variants at 1-3 mg/mL were subjected to SEC, DSC, GPC3 binding (SPR 1pt off-rates), MS and HIC. The results are summarized in Table 9.
TABLE 9
Biophysical properties of ADX_6077_F02_DG Variants
huGPC3
muGPC3
mono
koff
koff
%
Tm
Mutant
Clone ID
(mut/par)
(mut/par)
(SEC)
(DSC)
DG→EG
P1-055673
5.4
5.1
96%
88°
C.
DG→SG
P1-055668
5.2
4.8
96%
85, 91°
C.
DG→AG
P1-055669
5.9
5.5
96%
85, 91°
C.
DG→GG
P1-055670
14
12
96%
84, 90°
C.
DG→DS
P1-055667
3.5
3.3
96%
84°
C.
DG→DA
P1-055660
3.9
3.7
96%
86, 98°
C.
DG→DL
P1-055671
3.6
3.1
96%
84°
C.
DG→DV
P1-055672
7.9
7.0
96%
84°
C.
Six of the eight DG mutants demonstrated a 3-5 fold increase in koff compared to the parental adnectin, and were monomeric and thermostable. The binding affinities of the alkylated GPC3 DG mutant adnectins for human and murine GPC3 were further evaluated by Biacore T100 using HBS-P+ running buffer with direct immobilization of human and mouse GPC3 proteins [Hu (Fc 2,3) and Mu (Fc 4) GPC3-His (R&D Systems)] with a 200-1.56 nM series injected for 180s association, 600s dissociation. The data fit a 1:1 binding model in BiaEvaluation software and is summarized in Table 10.
TABLE 10
Binding Kinetics of DG Mutant Adnectins
huGPC3
muGPC3
Fold affinity
Fold affinity
(KD)
(KD)
difference vs
difference vs
alkylated
alkylated
Description
ka (1/Ms)
kd (1/s)
KD (M)
parent
ka (1/Ms)
kd (1/s)
KD (M)
parent
ADX_6077_F02
9.53E+04
5.34E−04
5.60E−09
1.0
1.3E+05
4.9E−04
3.8E−09
1.0
alkylated
6077_F02
7.22E+04
1.83E−03
2.54E−08
4.5
1.0E+05
1.7E−03
1.6E−08
4.3
DG−>DA
6077_F02
7.16E+04
1.66E−03
2.33E−08
4.2
1.0E+05
1.5E−03
1.5E−08
3.9
DG−>DS
6077_F02
9.40E+04
2.21E−03
2.35E−08
4.2
1.3E+05
2.0E−03
1.6E−08
4.1
DG−>SG
6077_F02
1.03E+05
2.43E−03
2.37E−08
4.2
1.4E+05
2.1E−03
1.5E−08
4.0
DG−>AG
6077_F02
7.26E+04
1.59E−03
2.19E−08
3.9
1.0E+05
1.5E−03
1.5E−08
3.8
DG−>DL
6077_F02
7.10E+04
3.09E−03
4.35E−08
7.8
8.5E+04
2.5E−03
3.0E−08
7.8
DG−>DV
6077_F02
7.63E+04
2.29E−03
3.00E−08
5.3
1.1E+05
2.1E−03
1.9E−08
5.1
DG−>EG
The data demonstrated that these GPC3 DG mutants have approximately 3-5 fold decreased affinity for human and murine GPC3 compared to parental ADX_6077_F02. The differences in affinities were driven by faster off-rates, whereas the on-rates were consistent with the parental adnectin (
The binding of DG variants to huGPC3 in DG GPC3 AdxDCs mutants were evaluated by flow cytometry for binding to Huh7 carcinoma cells grown in DMEM media with 10% FBS. Cells were harvested using Versene, an EDTA cell dissociation solution from Lonza, Cat. #17-711E. Tumor cells (1EScells/reaction) were suspended in FACS buffer (PBS, 1% BSA, 0.05% Na Azide) and mixed with a serial dilution of AdxDC for one hour on ice. Cells were washed three times with FACS buffer, and bound AdxDC was detected with an in house anti-scaffold monoclonal Ab and PE-conjugated Antibody from (RnD Systems), cat #NL007, and read on a flow cytometer. Data analysis was done using FlowJo Software, and EC50 of 50% of maximum binding was determined using PRISM™ software, version 5.0 (GraphPad Software, La Jolla, Calif., USA).
For anti-His detection of (non DG mutants), the same protocol was used, except in house generated APC-conjugated anti-His antibody was used.
The results, which are shown in Table 11, indicate that the mutants had similar EC50 values as that of the parent Adnectin.
The DG variants to huGPC3 were also assessed for their potential to elicit an immune response in humans using a human PBMC proliferation assay. PBMCs from 40 donor with HLA Class II haplotypes closely matching the world population frequencies were cultured in the presence of the DG variants or controls for 7 days. At the end of the assay, CFSE-labeled CD4+ T cells were analyzed by FACS for proliferation. The percentage of donors that showed proliferating CD4+T cells were analyzed as a read-out for human immunogenicity risk. Assay results indicate that the DG to DA mutant (PI-055660) has a significantly lower risk for immunogenicity (IMG) (18% of donors responded positive) compared to the other DG mutants (36-54% positive responses) as summarized in Table 11.
TABLE 11
Cell Binding Kinetics of DG Variants
huGPC3 on cells
Clone ID
EC50
IMG: % +ve
Mutant
P1-
(mutant/parent)
responders
DG→EG
055673
1.6
49%
DG→SG
055668
1.1
41%
DG→AG
055669
1.1
54%
DG→DS
055667
1.4
36%
DG→DA
055660
1.3
18%
DG→DL
055671
1.7
54%
A summary of the characteristics of the DA variant AdxDC DAR1 (“GPC3_AdxDC DA variant-DAR1” or “DA variant AdxDC DAR1”) are set forth in Table 12:
TABLE 12
Characteristics of the DA variant AdxDC DAR1
% monomer
100%
DSC Tm (PBS)
79, 87° C.
SPR Kd
25 nM (hu, 37° C.)
23 nM (mu, 37° C.)
SPR koff
2.1 × 10−3 s−1 (hu, 37° C.)
9.5 × 10−4 s−1 (mu, 37° C.)
Cell-binding EC50 (Huh7)
2.2 nM *
Cell-killing IC50 (Huh7)
0.2 nM
* Measured for unconjugated protein
FITC Labeling.: ADX_6077_F02 and non-binding control Adnectin were reduced with DTT or TCEP followed by G25 gel filtration chromatography or dialysis. Excess Fluorescein-5-maleimide reagent (Thermo Scientific) was then added and the mixture incubated at room temperature for approximately 2 hours followed by G25 gel filtration chromatography or extensive dialysis (3-4 buffer changes). The resulting degree of labeling was measured by absorbance following the manufacturer's instructions and/or by mass spectrometry. The binding affinities of FITC-labeled and PEGylated GPC3 for human and murine GPC3 was evaluated as described in the previous Examples, and the results are summarized in Table 13.
TABLE 13
Kinetics of Modified GPC3 Adnectins
huGPC3
muGPC3
Adnectin
ka (1/Ms)
kd (1/s)
KD (M)
ka (1/Ms)
kd (1/s)
KD (M)
ADX_6077_F02
8.90E+04
5.24E−04
5.88E−09
1.23E+05
4.53E−04
3.69E−09
alkylated
6077_F02-FITC
8.15E+04
4.98E−04
6.11E−09
1.12E+05
4.46E−04
3.97E−09
RGE-FITC
No binding
No binding
6077_F02.dPEG
7.35E+04
6.02E−04
8.19E−09
1.03E+05
5.59E−04
5.43E−09
6077_F02.dPEG
7.50E+04
6.07E−04
8.10E−09
1.06E+05
5.57E−04
5.26E−09
6077_F02-PEG3.4
7.18E+04
5.84E−04
8.14E−09
1.02E+05
5.23E−04
5.12E−09
The data demonstrated that both FITC-labeled and PEGylated anti-GPC3 adnectins retained binding affinity to both human and murine GPC3.
The GPC3_AdxDC DA variant-DAR1 was shown to be chemically and biophysically stable at pH 6.0, in accelerated-stability studies. In addition, its affinity for human GPC3 (by SPR) was unchanged after 4 weeks at 40° C.
Aspartate isomerization of the DA variant was about 4 fold lower than that of the parent DG molecule. The percent isomerization of D80 of the DG molecule, after incubation for 3 weeks at 40° C. at pH 6 or pH 7 was 3.6 and 2.4, respectively.
The GPC3_AdxDC (DG) shows a favorable toxicity profile under weekly dosing in CDF rats (Q7Dx4) (Table 14). No adverse responses were seen in hematology or serum chemistry profiles in CDF rats under weekly administration of GPC3 AdxDC (Q7Dx4).
TABLE 14
Toxicity profile of GPC3_AdxDC (DG)
Skeletal
Heart
Muscle
Treatment
(degener-
Liver
(regener-
Kidney
(umol/kg)
ation)
(↑ mitosis)
ation)
(↑ mitosis)
NBC*
0.28
minimal
none
none
minimal
AdxDC
GPC3
0.093
none
none
none
none
AdxDC
0.28
none
none
none
minimal
*“NBC” refers to non-binding AdxDC (Adnectin Drug Conjugate)
Human GPC3 high expression Hep3B xenograft tissue was incubated with FITC-conjugated GPC3-binding Adnectin DG molecule (“GPC3_AdxDC (DG)”) DAR1 at a concentration of 0.04 μg/ml or with a non GPC3 binding Adnectin at 0.2 μg/ml. The results indicate that the GPC3_AdxDC (DG) molecule binds Hep3B xenograft tissue, whereas the non-binding Adnectin did not significantly bind.
Other tissues were also tested for binding, and the results indicate that there is some non-specific binding of GPC3_AdxDC (DG) to placenta. However, the molecule does not bind significantly to stomach, heart, kidney, liver, skin or tonsil tissue.
GPC3_AdxDC (DA) DAR1 shows similar but weaker binding in Xenograft Hep3B. Saturated binding was achieved at 0.2 μg/ml.
Hep3B (hepatocellular carcinoma; 260,000 GPC3 molecules/cell) xenografts were used in NSG mice. GPC3_AdxDC (DA) DAR1 or a non-binding control Adnectin were administered i.v. weekly, 3 times, at the doses indicated in Table 15.
TABLE 15
Dosage and tumor growth inhibition
of Hep3B xenografts in NSG mice
Dose
TGID 26*
AdxDC
mpk
μmol/kg
(%)
GPC3_AdxDC (DA)
1.4
0.12
109
0.5
0.04
103
0.1
0.01
62
0.05
0.004
20
Non-binding Adnectin
1.4
0.12
—
(RGE; −ve control)
TGID26*: Tumor Growth Inhibition at Day 26
The results, which are shown in Table 15 and
A similar experiment was conducted with cell-line-derived xenografts with low expression of Glypican-3 (H446). H446 cells are small-cell lung carcinoma cells with about 40,000 human PC3 molecules/cell. The cells were injected into CB17 SCID mice.
TABLE 16
Dosage and tumor growth inhibition
of H446 cells in CB17 SCID mice
Dose (Q3Dx4)
TGID 21
AdxDC
mpk
μmol/kg
(%)
GPC3-binding
12
1.0
(BMT-279771)
8
0.67
53
4
0.33
2
0.17
16
RGE
1.4
0.12
—
(−ve control)
The results, which are shown in Table 16 and
Mice were dosed with 3H labeled GPC3_AdxDC at 0.015 or 0.22 μmol/kg, and radioactivity was measured by Whole-Body Autoradiography (QWBA) after 0.17 hours, 1 hour, 5 hours and 168 hours.
The results, which are shown in
-
- Rapid distribution to tumor and highly perfused tissues;
- High level radioactivity remained in the tumors 168 hours after dosing, with no, or low, radioactivity in other tissues;
- Significant radioactivity in kidney: about 30% of the radioactivity was excreted in the urine; and
- Similar patters of expression between high and low dose groups.
In a similar experiment, mice were dosed with 3H labeled GPC3_AdxDC or non-binding AdxDC control at 0.22 μmol/kg, and radioactivity was measured by QWBA after 0.17 hours, 1 hour, 5 hours and 168 hours.
The results, which are shown in
The total radioactivity concentration of GPC3_AdxDC in tumor and tissues is represented in
This Example describes positional scanning of 6077_F02 in which EIDKPSQ (SEQ ID NO: 369) was removed and PC was added, and wherein amino acid 79 (i.e., the “D” of “DG”) is either G (as in original clone) or A.
The two proteins, different only at amino acid 79, were mixed during the library construction. Binding to human glypican-3-biotin was determined at 100 nM, 10 nM and 1 nM. For each batch, the 10 nM selection elution was compared to the flag elution and the 1 nM selection elution was also compared to the flag elution. This generated 4 heat maps for each loop: 10 nM when 79 is G; 1 nM when 79 is G; 10 nM when 79 is A and 1 nM when 79 is A.
For the FG loop, the three segments were combined together to show the full heat map. For position 79, on heat map was generated where it was normalized to the G, and one heat map where it was normalized to the A.
The results, in the form of heat maps, are shown in
-
- In loop BC (i.e., sequence SDDYHAH (amino acids 15-21 of SEQ ID NO: 98)):
- S23 may be substituted with any amino acid;
- D24, is preferably not substituted with any other amino acid, although S and E may be acceptable.
- Other acceptable substitutions may be derived from the heat maps, wherein any substitution having a number >0.2 is acceptable and a number >1 is preferable.
- In loop BC (i.e., sequence SDDYHAH (amino acids 15-21 of SEQ ID NO: 98)):
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
TABLE 2
SUMMARY OF SEQUENCES
SEQ
ID
Description
SEQUENCE
1
Full length wild-type human 10Fn3
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPV
domain
QEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISI
NYRT
2
Core wild-type human 10Fn3
EVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGS
domain
KSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT
3
Human 10Fn3 domain six loop
VSDVPRDLEVVAA(X)uLLISW(X)vYYRITY(X)wFTV(X)xATI
sequences generically defined
SG(X)yYTITVYAV(XzISINYRT
4
Wild-type human 10Fn3 domain C-
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPV
terminal flexible linker
QEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISI
NYRTEIDKPSQ
5
ADX_4578_F03
EVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPVQEFTVEGS
Core
KSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYRT
6
ADX_4578_F03
HPPHPNIVS
BC loop
7
ADX_4578_F03
EGSKST
DE loop
8
ADX_4578_F03
VAPEIEKYYQ
DE loop
9
ADX_45708_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
T
10
ADX_4578_F03
MGVSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNS
full-length w/N-terminal leader
PVQEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWIN
and C-terminal tail
YRTEGSGS
11
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal PmXn
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
TPmXn
12
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
TPmCXn
13
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
PmCXn (m = 1; n = 0)
TPC
14
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
PmCXn (m = 1; n = 0) and His6 tag
TPCHHHHHH
15
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
PmCXn1CXn2
TPmCXn1CXn2
16
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
TPCPPPPPC
17
ADX_4578_F03
VSDVPRDLEVVAATPTSLLISWHPPHPNIVSYHIYYGETGGNSPV
full-length with C-terminal
QEFTVEGSKSTAKISGLKPGVDYTITVYAVAPEIEKYYQIWINYR
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
TPCPPPPPCHHHHHH
and His6 tag
18
ADX_4578_H08
EVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPVQEFTVPDG
core
SNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISINYRT
19
ADX_4578_H08
SGYDYGDSY
BC loop
20
ADX_4578_H08
PDGNST
DE loop
21
ADX_4578_H08
VEAYGKGYTRYTP
FG loop
22
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
NYRT
23
ADX_4578_H08
MGVSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNS
full-length w/N-terminal leader and
PVQEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPI
C-terminal tail
SINYRTEIDKPSQ
24
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
NYRTPmXn
25
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
NYRTPmCXn
26
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
PmCXn (m = 1; n = 0)
NYRTPC
27
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
28
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
PmCXn1CXn2
NYRTPmCXn1CXn2
29
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
NYRTPCPPPPPC
30
ADX_4578_H08
VSDVPRDLEVVAATPTSLLISWSGYDYGDSYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPDGSNTATISGLKPGVDYTITVYAVEAYGKGYTRYTPISI
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
NYRTPCPPPPPCHHHHHH
and His6 tag
31
ADX_4578_B06
EVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEFTVEGHKQT
core
AYISGLKPGVDYTITVYAAYISGLISINYRT
32
ADX_4578_B06
FPDRYV
BC loop
33
ADX_4578_B06
EGHKQT
DE loop
34
ADX_4578_B06
AYISGL
FG loop
35
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
RT
36
ADX_4578_B06
MGVSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQ
full-length w/N-terminal leader and
EFTVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISI
C-terminal tail
NYRTEGSGS
37
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal PmXn
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
RTPmXn
38
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal PmCXn
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
RTPmCXn
39
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
PmCXn (m = 1; n = 0)
RTPC
40
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
PmCXn (m = 1; n = 0) and His6 tag
RTPCHHHHHH
41
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
PmCXn1CXn2
RTPmCXn1CXn2
42
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
RTPCPPPPPC
43
ADX_4578_B06
VSDVPRDLEVVAATPTSLLISWFPDRYVYYITYGETGGNSPVQEF
full-length with C-terminal
TVEGHKQTAYISGLKPGVDYTITVYAIYYYPDDFQGYPQPISINY
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
RTPCPPPPPCHHHHHH
and His6 tag
44
ADX_4606_F06
EVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQEFTVPRYG
core
YTATISGLKPGVDYTITVYAVAHSEASAPISINYRT
45
ADX_4606_F06
NSGHSGQY
BC loop
46
ADX_4606_F06
PRYGYT
DE loop
47
ADX_4606_F06
VAHSEASAP
FG loop
48
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRT
49
ADX_4606_F06
MGVSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSP
full-length w/N-terminal leader and
VQEFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYR
C-terminal tail
TEIDKPSQ
50
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal PmXn
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
mXn
51
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal PmCXn
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
mCXn
52
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
PmCXn (m = 1; n = 0)
C
53
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
PmCXn (m = 1; n = 0)and His6 tag
CHHHHHH
54
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
PmCXn1CXn2
mCXn1CXn2
55
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
CPPPPPC
56
ADX_4606_F06
VSDVPRDLEVVAATPTSLLISWNSGHSGQYYRITYGETGGNSPVQ
full-length with C-terminal
EFTVPRYGYTATISGLKPGVDYTITVYAVAHSEASAPISINYRTP
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
CPPPPPCHHHHHH
and His6 tag
57
ADX_5273_C01
EVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPVQEFTVPAF
core
HTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISINYRT
58
ADX_5273_C01
SDPYEEERY
BC loop
59
ADX_5273_C01
PAFHTT
DE loop
60
ADX_5273_C01
VTYKHKYAYYYPP
FG loop
61
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
NYRT
62
ADX_5273_C01
MGVSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNS
full-length w/N-terminal leader and
PVQEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPI
C-terminal tail
SINYRTEIDKPSQ
63
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
NYRTPmXn
64
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
NYRTPmCXn
65
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
PmCXn (m = 1; n = 0)
NYRTPC
66
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
67
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
PmCXn1CXn2
NYRTPmCXn1CXn2
68
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
NYRTPCPPPPPC
69
ADX_5273_C01
VSDVPRDLEVVAATPTSLLISWSDPYEEERYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPAFHTTATISGLKPGVDYTITVYAVTYKHKYAYYYPPISI
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
NYRTPCPPPPPCHHHHHH
and His6 tag
70
ADX_5273_D01
EVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPVQEFTVPSF
core
HQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISINYRT
71
ADX_5273_D01
EPSYKDDRY
BC loop
72
ADX_5273_D01
PSFHQT
DE loop
73
ADX_5273_D01
VTYEPDEYYFYYP
FG loop
74
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
NYRT
75
ADX_5273_D01
MGVSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNS
full-length w/N-terminal leader and
PVQEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPI
C-terminal tail
SINYRTEIDKPSQ
76
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
NYRTPmXn
77
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
NYRTPmCXn
78
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
PmCXn (m = 1; n = 0)
NYRTPC
79
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
80
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
PmCXn1CXn2
NYRTPmCXn1CXn2
81
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
NYRTPCPPPPPC
82
ADX_5273_D01
VSDVPRDLEVVAATPTSLLISWEPSYKDDRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPSFHQTATISGLKPGVDYTITVYAVTYEPDEYYFYYPISI
PmCXn1CXn2 (m = 1, n1 = 5, n2 = 0)
NYRTPCPPPPPCHHHHHH
and His6 tag
83
ADX_5274_E01
EVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPVQEFTVPGE
core
HETAATISGLKPGVDYTITVYAVTYDGEKADKYPPISINYRT
84
ADX_5274_E01
SGDYHPHRY
BC loop
85
ADX_5274_E01
PGEHET
DE loop
86
ADX_5274_E01
VTYDGEKADKYPP
FG loop
87
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
NYRT
88
ADX_5274 E01
MGVSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNS
full-length w/N-terminal leader and
PVQEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPI
C-terminal tail
SINYRTEIDKPSQ
89
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length w/C-terminal PmXn
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
NYRTPmXn
90
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
NYRTPmCXn
91
ADC_5274_E01
EVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPVQEFTVPGE
core with PmCXn C-terminal
HETATISGLKPGVDYTITVYAVTYDGEKADKYPPISINYRTPC
modification (m = 1; n = 0); aka
ADX_6561_A01 core
92
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
(m = 1; n = 0)
NYRTPC
93
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
(m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
94
ADX_5274_A01
MGVSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNS
full-length w/N-terminal leader, C-
PVQEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPI
terminal PmCXn (m = 1; n = 0) and
SINYRTPCHHHHHH
His6 tag
95
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
PmCXn1CXn2
NYRTPmCXn1CXn2
96
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
97
ADX_5274_E01
VSDVPRDLEVVAATPTSLLISWSGDYHPHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHETATISGLKPGVDYTITVYAVTYDGEKADKYPPISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPCHHHHHH
and His6 tag
98
ADX_6077_A01
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRT
99
ADX_6077_F02
SDDYHAHRY
BC loop
100
ADX_6077_F02
PGEHVT
DE loop
101
ADX_6077_F02
VTYDGEKAATDWS
FG loop
102
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
NYRT
103
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal tail
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
NYRTEIEKPCQ
104
ADX_6077_F02
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSIS
(G)
INYRT
105
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
(MG)
SINYRT
106
ADX_6077_F02
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPmXn
107
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
NYRTPmXn
108
ADX_6077_F02
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
109
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
110
ADX_6077_F02
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPmCXn
111
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
NYRTPmCXn
112
ADX_6077_F02
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
113
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
114
ADX_6077_F02
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPC
n = 0)
115
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
(M = 1; n = 0)
NYRTPC
116
ADX_6007_F02
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader (G)
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSIS
and PmCXn C-terminal
INYRTPC
modification (m = 1; n = 0)
117
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
118
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/PmCXn C-terminal
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
modification
SINYRTPCHHHHHH
(m = 1; n = 0) and His6 tag
119
ADX_6077_F02
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPmCXn
1CXn2
120
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
PmCXn1CXn2
NYRTPmCXn1CXn2
121
ADX_6077_F02
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CXn2
122
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CXn2
PmCXn1CXn2
123
ADX_6077_F02
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
124
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSISI
PmCXn1Xn2 (m = 1; n1 = 5, n2 = 0)
NYRTPCPPPPPC
125
ADX_6077_F02
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
126
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
127
ADX_6077_F02
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/C-terminal
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDGEKAATDWSI
PmCXn1CXn2 (m = 1; n1 = 5,
SINYRTPCPPPPPCHHHHHH
n2 = 0) and His6 tag
128
ADX_6077_F02 DG→EG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISINYRT
129
ADX_6077_F02 DG→EG mutant
VTYEGEKAATDWS
FG loop
130
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
NYRT
131
ADX_6077_F02 DG→EG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSIS
(G)
INYRT
132
ADX_6077_F02 DG→EG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSI
(MG)
SINYRT
133
ADX_6077_F02 DG→EG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISINYRTPmXn
134
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
NYRTPmXn
135
ADX_6077_F02 DG→EG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
136
ADX_6077_F02 DG→EG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
137
ADX_6077_F02 DG→EG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISINYRTPmCXn
138
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
NYRTPmCXn
139
ADX_6077_F02 DG→EG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
140
ADX_6077_F02 DG→EG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
141
ADX_6077_F02 DG→EG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISINYRTPC
n = 0)
142
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
143
ADX_6077_F02 DG→EG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader (G)
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSIS
and PmCXn C-terminal
INYRTPC
modification (m = 1; n = 0)
144
ADX_6077_F02 DG→EG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
145
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
146
ADX_6077_F02 DG→EG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISINYRTPmCXn
1CX2
147
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
148
ADX_6077_F02 DG→EG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
149
ADX_6077_F02 DG→EG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
150
ADX_6077_F02 DG→EG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
151
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
152
ADX_6077_F02 DG→EG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPMGGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWS
(G), and C-terminal PmCXn1CXn2
ISINYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
153
ADX_6077_F02 DG→EG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
154
ADX_6077_F02 DG→EG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYEGEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
155
ADX_6077_F02 DG→SG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISINYRT
156
ADX_6077_F02 DG→SG mutant
VTYSGEKAATDWS
FG loop
157
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
NYRT
158
ADX_6077_F02 DG→SG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSIS
(G)
INYRT
159
ADX_6077_F02 DG→SG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSI
(MG)
SINYRT
160
ADX_6077_F02 DG→SG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISINYRTPmXn
161
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
NYRTPmXn
162
ADX_6077_F02 DG→SG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
163
ADX_6077_F02 DG→SG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
164
ADX_6077_F02 DG→SG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISINYRTPmCXn
165
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
NYRTPmCXn
166
ADX_6077_F02 DG→SG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
167
ADX_6077_F02 DG→SG
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
168
ADX_6077_F02 DG→SG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISINYRTPC
n = 0)
169
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
170
ADX_6077_F02 DG→SG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader and
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSIS
PmCXn (m = 1; n = 0)
INYRTPC
171
ADX_6077_F02 DG→SG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
172
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
173
ADX_6077_F02 DG→SG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISINYRTPmCXn
1CX2
174
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
PmCXn1CXn2
NYRTPmCXn1CX2
175
ADX_6077_F02 DG→SG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
176
ADX_6077_F02 DG→SG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
177
ADX_6077_F02 DG→SG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
178
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
179
ADX_6077_F02 DG→SG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
180
ADX_6077_F02 DG→SG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
181
ADX_6077_F02 DG→SG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYSGEKAATDWSISI
PmCXn1CXn2 (m = 1 ; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
182
ADX_6077_F02 DG→AG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISINYRT
183
ADX_6077_F02 DG→AG mutant
VTYAGEKAATDWS
FG loop
184
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
NYRT
185
ADX_6077_F02 DG→AG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSIS
(G)
INYRT
186
ADX_6077_F02 DG→AG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSI
(MG)
SINYRT
187
ADX_6077_F02 DG→AG mutant
LEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPG
core with C-terminal PmXn
EHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISINYRTPmXn
188
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
NYRTPmXn
189
ADX_6077_F02 DG→AG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
190
ADX_6077_F02 DG→AG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
191
ADX_6077_F02 DG→AG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISINYRTPmCXn
192
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
NYRTPmCXn
193
ADX_6077_F02 DG→AG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
194
ADX_6077_F02 DG→AG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
195
ADX_6077_F02 DG→AG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISINYRTPC
n = 0)
196
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
197
ADX_6077_F02 DG→AG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader (G)
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSIS
and PmCXn C-terminal
INYRTPC
modification (m = 1; n = 0)
198
ADX_6077_F02 DG→AG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
199
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
200
ADX_6077_F02 DG→AG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISINYRTPmCXn
1CX2
201
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
202
ADX_6077_F02 DG→AG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
203
ADX_6077_F02 DG→AG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
204
ADX_6077_F02 DG→AG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
205
ADX_6077_F02 DG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
206
ADX_6077_F02 DG→AG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
207
ADX_6077_F02 DG→AG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
208
ADX_6077_F02 AG→AG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYAGEKAATDWSISI
PmCXn1CXn2 (m = 1 ; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
209
ADX_6077 F02 DG→GG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISINYRT
210
ADX_6077_F02 DG→GG mutant
TYGGEKAATDWS
FG loop
211
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
NYRT
212
ADX_6077_F02 DG→GG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSIS
(G)
INYRT
213
ADX_6077_F02 DG→GG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSI
(MG)
SINYRT
214
ADX_6077_F02 DG→GG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISINYRTPmXn
215
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
NYRTPmXn
216
ADX_6077_F02 DG→GG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
217
ADX_6077_F02 DG→GG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
218
ADX_6077_F02 DG→GG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISINYRTPmCXn
219
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
NYRTPmCXn
220
ADX_6077_F02 DG→GG mutant
MVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
221
ADX_6077_F02 DG→GG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
222
ADX_6077_F02 DG→GG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISINYRTPC
n = 0)
223
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
224
ADX_6077_F02 DG→GG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPC
225
ADX_6077_F02 DG→GG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
Full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPC
226
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
227
ADX_6077_F02 DG→GG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISINYRTPmCXn
1CX2
228
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
229
ADX_6077_F02 DG→GG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
230
ADX_6077_F02 DG→GG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
231
ADX_6077_F02 DG→GG mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
232
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
233
ADX_6077_F02 DG→GG mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
234
ADX_6077_F02 DG→GG mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
235
ADX_6077_F02 DG→GG mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYGGEKAATDWSISI
PmCXn1CXn2 (m = 1 ; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
236
ADX_6077_F02 DG→DS mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISINYRT
237
ADX_6077_F02 DG→DS mutant
VTYDSEKAATDWS
FG loop
238
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
NYRT
239
ADX_6077_F02 DG→DS mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSIS
(G)
INYRT
240
ADX_6077_F02 DG→DS mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSI
(MG)
SINYRT
241
ADX_6077_F02 DG→DS mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISINYRTPmXn
242
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
NYRTPmXn
243
ADX_6077_F02 DG→DS mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
244
ADX_6077_F02 DG→DS mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
245
ADX_6077_F02 DG→DS mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISINYRTPmCXn
246
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
NYRTPmCXn
247
ADX_6077_F02 DG→DS mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
248
ADX_6077_F02 DG→DS mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
249
ADX_6077_F02 DG→DS mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISINYRTPC
n = 0)
250
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
251
ADX_6077_F02 DG→DS mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/ N-terminal leader (G)
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSIS
and PmCXn C-terminal
INYRTPC
modification (m = 1; n = 0)
252
ADX_6077_F02 DG→DS mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
253
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
254
ADX_6077_F02 DG→DS mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISINYRTPmCXn
1CX2
255
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
256
ADX_6077_F02 DG→DS mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
257
ADX_6077_F02 DG→DS mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
258
ADX_6077_F02 DG→DS mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
259
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
260
ADX_6077_F02 DG→DS mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
261
ADX_6077_F02 DG→DS mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
262
ADX_6077_F02 DG→DS mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDSEKAATDWSISI
PmCXn1CXn2 (m = 1 ; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
263
ADX_6077_F02 DG→DA mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISINYRT
264
ADX_6077 F02 DG→DA mutant
VTYDAEKAATDWS
FG loop
265
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
NYRT
266
ADX_6077_F02 DG→DA mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSIS
(G)
INYRT
267
ADX_6077_F02 DG→DA mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSI
(MG)
SINYRT
268
ADX_6077_F02 DG→DA mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISINYRTPmXn
269
ADX_6077_F02
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
DG→DA mutant
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
full-length with C-terminal PmXn
NYRTPmXn
270
ADX_6077_F02 DG→DA mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
271
ADX_6077_F02 DG→DA mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
272
ADX_6077_F02 DG→DA mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISINYRTPmCXn
273
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
NYRTPmCXn
274
ADX_6077_F02 DG→DA mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
275
ADX_6077_F02 DG→DA mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
276
ADX_6077_F02 DG→DA mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISINYRTPC
n = 0)
277
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
278
ADX_6077_F02 DG→DA mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader and
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSIS
PmCXn C-terminal modification
INYRTPC
(m = 1; n = 0)
279
ADX_6077_F02 DG→DA mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
280
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
281
ADX_6077_F02 DG→DA mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISINYRTPmCXn
1CX2
282
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
283
ADX_6077_F02 DG→DA mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
284
ADX_6077_F02 DG→DA mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
285
ADX_6077_F02 DG→DA mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
286
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
287
ADX_6077_F02 DG→DA mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
288
ADX_6077_F02 DG→DA mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
289
ADX_6077_F02 DG→DA mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDAEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
290
ADX_6077_F02 DG→DL mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISINYRT
291
ADX_6077_F02 DG→DL mutant
VTYDLEKAATDWS
FG loop
292
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
NYRT
293
ADX_6077_F02 DG→DL mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSIS
(G)
INYRT
294
ADX_6077_F02 DG→DL mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSI
(MG)
SINYRT
295
ADX_6077_F02 DG→DL mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISINYRTPmXn
296
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
NYRTPmXn
297
ADX_6077_F02 DG→DL mutant
MVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSIS
(G) and C-terminal PmXn
INYRTPmXn
298
ADX_6077_F02 DG→DL mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
299
ADX_6077_F02 DG→DL mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISINYRTPmCXn
300
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
NYRTPmCXn
301
ADX_6077_F02 DG→DL mutant
MVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
302
ADX_6077_F02 DG→DL mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
303
ADX_6077_F02 DG→DL mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISINYRTPC
n = 0)
304
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
305
ADX_6077_F02 DG→DL mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader and
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSIS
PmCXn C-terminal modification
INYRTPC
(m = 1; n = 0)
306
ADX_6077_F02 DG→DL mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
307
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
308
ADX_6077_F02 DG→DL mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISINYRTPmCXn
1CX2
309
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
310
ADX_6077_F02 DG→DL mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
311
ADX_6077_F02 DG→DL mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
312
ADX_6077_F02 DG→DL mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
313
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
314
ADX_6077_F02 DG→DL mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSIS
(G), and C-terminal PmCXn1CXh2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
315
ADX_6077_F02 DG→DL mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
316
ADX_6077_F02 DG→DL mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDLEKAATDWSISI
PmCXn1CXn2 (m = 1 ; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
317
ADX_6077_F02 DG→DV mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core
HVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISINYRT
318
ADX_6077_F02 DG→DV mutant
VTYDVEKAATDWS
FG loop
319
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
NYRT
320
ADX_6077_F02 DG→DV mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSIS
(G)
INYRT
321
ADX_6077_F02 DG→DV mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSI
(MG)
SINYRT
322
ADX_6077_F02 DG→DV mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmXn
HVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISINYRTPmXn
323
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
NYRTPmXn
324
ADX_6077_F02 DG→DV mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmXn
325
ADX_6077_F02 DG→DV mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSI
(MG) and C-terminal PmXn
SINYRTPmXn
326
ADX_6077_F02 DG→DV mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn
HVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISINYRTPmCXn
327
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal PmCXn
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
NYRTPmCXn
328
ADX_6077_F02 DG→DV mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSIS
(G) and C-terminal PmCXn
INYRTPmCXn
329
ADX_6077_F02 DG→DV mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSI
(MG) and C-terminal PmCXn
SINYRTPmCXn
330
ADX_6077_F02 DG→DV mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn (m = 1;
HVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISINYRTPC
n = 0)
331
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
PmCXn (m = 1; n = 0)
NYRTPC
332
ADX_6077_F02 DG→DV mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length w/N-terminal leader (G)
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSIS
and PmCXn C-terminal
INYRTPC
modification (m = 1; n = 0)
333
ADX_6077_F02 DG→DV mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length w/N-terminal eader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSI
(MG) and PmCXn C-terminal
SINYRTPC
modification (m = 1; n = 0)
334
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
PmCXn (m = 1; n = 0) and His6 tag
NYRTPCHHHHHH
335
ADX_6077_F02 DG→DV mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISINYRTPmCXn
1CX2
336
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
PmCXn1CX2
NYRTPmCXn1CX2
337
ADX_6077_F02 DG→DV mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPmCXn1CX2
338
ADX_6077_F02 DG→DV mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSI
(MG), and C-terminal
SINYRTPmCXn1CX2
PmCXn1CXn2
339
ADX_6077_F02 DG→DV mutant
EVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPVQEFTVPGE
core with C-terminal PmCXn1CXn2
HVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISINYRTPCPP
(m = 1; n1 = 5; n2 = 0)
PPPC
340
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0)
NYRTPCPPPPPC
341
ADX_6077_F02 DG→DV mutant
GVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSP
full-length with N-terminal leader
VQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSIS
(G), and C-terminal PmCXn1CXn2
INYRTPCPPPPPC
(m = 1; n1 = 5, n2 = 0)
342
ADX_6077_F02 DG→DV mutant
MGVSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNS
full-length with N-terminal leader
PVQEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSI
(MG), and C-terminal
SINYRTPCPPPPPC
PmCXn1CXn2 (m = 1; n1 = 5, n2 = 0)
343
ADX_6077_F02 DG→DV mutant
VSDVPRDLEVVAATPTSLLISWSDDYHAHRYYRITYGETGGNSPV
full-length with C-terminal
QEFTVPGEHVTATISGLKPGVDYTITVYAVTYDVEKAATDWSISI
PmCXn1CXn2 (m = 1; n1 = 5; n2 = 0),
NYRTPCPPPPPCHHHHHH
and His6 tag
344
Human GPC3
MAGTVRTACLVVAMLLSLDFPGQAQPPPPPPDATCHQVRSFFQRL
QPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNME
QLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYP
SLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYT
QLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQV
TRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMM
VKPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYD
MENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSA
YYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSAL
PGYICSHSPVAENDTLCWNGQELVERYSQKAARNGMKNQFNLHEL
KMKGPEPVVSQIIDKLKHINQLLRTMSMPKGRVLDKNLDEEGFES
GDCGDDEDECIGGSGDGMIKVKNQLRFLAELAYDLDVDDAPGNSQ
QATPKDNEISTFHNLGNVHSPLKLLTSMAISVVCFFFLVH
345
Human GPC3 Adnectin binding
HQVSFF
region 1
346
Human CPC3 Adnectin binding
EQLLQSASM
region 2
347
ADX_6093_A01 core
sEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPG
(non-binding control)
SKSTATISGLKPGVDYTITVYAVTGRGESPASSKPISINYRT
348
ADX_6093_A01 full-length w/N-
MGVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNS
leader, PmCXn C-terminal
PVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGESPASSKPI
modification
SINYRTPCHHHHHH
(m = 1; n = 0), and His6 tag
349
ADX_6093_A01 full-length w/N-
GVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSP
leader, PmCXn C-terminal
VQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGESPASSKPIS
modification
INYRTPC
(m = 1; n = 0)
350
ADX_6093_A01 full-length w/N-
MGVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNS
leader, PmCXn C-terminal
PVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGESPASSKPI
modification
SINYRTPCPPPPPCHHHHHH
(m = 1; n = 7), and His6 tag
351
N-terminal leader
MGVSDVPRD
352
N-terminal leader
GVSDVPRD
353
N-terminal leader
XnSDVPRD
354
N-terminal leader
XnDVPRD
355
N-terminal leader
XnVPRD
356
N-terminal leader
XnPRD
357
N-terminal leader
XnRD
358
N-terminal leader
XnD
359
N-terminal leader
MASTSG
360
C-terminal tail
EIEK
361
C-terminal tail
EGSGC
362
C-terminal tail
EIEKPCQ
363
C-terminal tail
EIEKPSQ
364
C-terminal tail
EIEKP
365
C-terminal tail
EIEKPS
366
C-terminal tail
EIEKPC
367
C-terminal tail
EIDK
368
C-terminal tail
EIDKPCQ
369
C-terminal tail
EIDKPSQ
370
6X His tail
HHHHHH
371
C-terminal tail
EIEPKSS
372
C-terminal tail
EIDKPC
373
C-terminal tail
EIDKP
374
C-terminal tail
EIDKPS
375
C-terminal tail
EIDKPSQLE
376
C-terminal tail
EIEDEDEDEDED
377
C-terminal tail
EGSGS
378
C-terminal tail
EIDKPCQLE
379
C-terminal tail
EIDKPSQHHHHHH
380
C-terminal tail
GSGCHHHHHH
381
C-terminal tail
EGSGCHHHHHH
382
C-terminal tail
PIDK
383
C-terminal tail
PIEK
384
C-terminal tail
PIDKP
385
C-terminal tail
PIEKP
386
C-terminal tail
PIDKPS
387
C-terminal tail
PIEKPS
388
C-terminal tail
PIDKPC
389
C-terminal tail
PIEKPC
390
C-terminal tail
PIDKPSQ
391
C-terminal tail
PIEKPSQ
392
C-terminal tail
PIDKPCQ
393
C-terminal tail
PIEKPCQ
394
C-terminal tail
PHHHHHH
395
C-terminal tail
PCHHHHHH
396
C-terminal tail
PPID
397
C-terminal tail
PPIE
398
C-terminal tail
PPIDK
399
C-terminal tail
PPIEK
400
C-terminal tail
PPIDKP
401
C-terminal tail
PPIEKP
402
C-terminal tail
PPIDKPS
403
C-terminal tail
PPIEKPS
404
C-terminal tail
PPIDKPC
405
C-terminal tail
PPIEKPC
406
C-terminal tail
PPIDKPSQ
407
C-terminal tail
PPIEKPSQ
408
C-terminal tail
PPIDKPCQ
409
C-terminal tail
PPIEKPCQ
410
C-terminal tail
PPHHHHHH
411
C-terminal tail
PPCHHHHHH
412
C-terminal tail
PCGC
413
C-terminal tail
PCPC
414
C-terminal tail
PCGSGC
415
C-terminal tail
PCPPPC
416
C-terminal tail
PCPPPPPC
417
C-terminal tail
PCGSGSGC
418
C-terminal tail
PCCHHHHHH
419
C-terminal tail
PCHHHHHHC
420
C-terminal tail
PCGCHHHHHH
421
C-terminal tail
PCPCHHHHHH
422
C-terminal tail
PCGSGCHHHHHH
423
C-terminal tail
PCPPPCHHHHHH
424
C-terminal tail
PCPPPPPCHHHHHH
425
C-terminal tail
PCGSGSGCHHHHHH
426
Exemplary linker
(PSPEPPTPEP)n n = 1-10
427
Exemplary linker
(EEEEDE)n n = 1-10
428
Linker
PSTPPTPSPSTPPTPSPS
429
Linker
GSGSGSGSGSGSGS
430
Linker
GGSGSGSGSGSGS
431
Linker
GGSGSGSGSGSGSGSG
432
Linker
GSEGSEGSEGSEGSE
433
Linker
GGSEGGSE
434
Linker
GSGSGSGS
435
Linker
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
436
Linker
GGGGSGGGGSGGGGSGGGGSGGGGS
437
Linker
GGGGSGGGGSGGGGSG
438
Linker
GPGPGPG
439
Linker
GPGPGPGPGPG
440
Linker
PAPAPA
441
Linker
PAPAPAPAPAPA
442
Linker
PAPAPAPAPAPAPAPAPA
443
Linker
PSPEPPTPEP
444
Linker
PSPEPPTPEPPSPEPPTPEP
445
Linker
PSPEPPTPEPPSPEPPTPEPPSPEPPTPEP
446
Linker
PSPEPPTPEPPSPEPPTPEPPSPEPPTPEPPSPEPPTPEP
447
Linker
EEEEDE
448
Linker
EEEEDEEEEDE
449
Linker
EEEEDEEEEDEEEEDEEEEDE
450
Linker
EEEEDEEEEDEEEEDEEEEDEEEEDEEEEDE
451
Linker
RGGEEKKKEKEKEEQEERETKTP
452
ADX_4578_F03 nucleotide
ATGGGAGTTTCTGATGTGCCGCGCGACTTGGAAGTGGTTGCCGCC
sequence encoding (SEQ ID NO:
ACCCCCACCAGCCTGCTGATCTCTTGGCATCCGCCGCATCCGAAC
10)
ATCGTTTCTTACCATATCTACTACGGCGAAACAGGAGGCAATAGC
CCTGTCCAGGAGTTCACTGTGGAAGGTTCTAAATCTACTGCTAAA
ATCAGCGGCCTTAAACCTGGCGTTGATTATACCATCACTGTGTAC
GCTGTTGCTCCGGAAATCGAAAAATACTACCAGATTTGGATTAAT
TACCGCACAGAAGGCAGCGGTTCCTAA
453
ADX_4578_H08
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCC
ACCCCCACCAGCCTGCTGATCAGCTGGTCTGGTTACGACTACGGT
GACTCTTATTACCGCATCACTTACGGCGAAACAGGAGGCAATAGC
CCTGTCCAGGAGTTCACTGTGCCTGACGGTTCTAACACAGCTACC
ATCAGCGGCCTTAAACCTGGCGTTGATTATACCATCACTGTGTAT
GCTGTCGAAGCTTACGGTAAAGGTTACACTCGTTACACTCCAATT
TCCATTAATTACCGCACAGAAATTGACAAACCATCCCAGTAA
454
ADX_4578
ATGGGAGTTTCTGATGTGCCGCGCGACTTGGAAGTGGTTGCCGCC
ACCCCCACCAGCCTGCTGATCTCTTGGTTCCCGGACCGTTACGTT
TACTACATCACTTACGGCGAAACAGGAGGCAATAGCCCTGTCCAG
GAGTTCACTGTGGAAGGTCATAAACAGACTGCTTACATCAGCGGC
CTTAAACCTGGCGTTGATTATACCATCACTGTGTACGCTATCTAC
TACTACCCGGACGACTTCCAGGGTTACCCGCAGCCGATTTCTATT
AATTACCGCACAGAAGGCAGCGGTTCCTAA
455
ADX_4606_F06
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCC
ACCCCCACCAGCCTGCTGATCAGCTGGAACTCTGGTCATTCTGGT
CAGTATTACCGCATCACTTACGGCGAAACAGGAGGCAATAGCCCT
GTCCAGGAGTTCACTGTGCCTCGTTACGGTTACACAGCTACCATC
AGCGGCCTTAAACCTGGCGTTGATTATACCATCACTGTGTATGCT
GTCGCTCATTCTGAAGCTTCTGCTCCAATTTCCATTAATTACCGC
ACAGAAATTGACAAACCATCCCAGTAA
456
ADX_5273_C01
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCC
ACCCCCACCAGCCTGCTGATCAGCTGGTCTGACCCGTACGAAGAA
GAACGATATTACCGCATCACTTACGGCGAAACAGGAGGCAATAGC
CCTGTCCAGGAGTTCACTGTGCCTGCTTTCCATACTACAGCTACC
ATCAGCGGCCTTAAACCTGGCGTTGATTATACCATCACTGTGTAT
GCTGTCACTTACAAACATAAATACGCTTACTACTACCCGCCAATT
TCCATTAATTACCGCACAGAAATTGACAAACCATCCCAGTAA
457
ADX_5273_D01
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCC
ACCCCCACCAGCCTGCTGATCAGCTGGGAACCGTCTTACAAAGAC
GACCGATATTACCGCATCACTTACGGCGAAACAGGAGGCAATAGC
CCTGTCCAGGAGTTCACTGTGCCTTCTTTCCATCAGACAGCTACC
ATCAGCGGCCTTAAACCTGGCGTTGATTATACCATCACTGTGTAT
GCTGTCACTTACGAACCGGACGAATACTACTTCTACTACCCAATT
TCCATTAATTACCGCACAGAAATTGACAAACCATCCCAGTAA
458
ADX_5274
ATGGGAGTTTCTGATGTGCCGCGCGACCTGGAAGTGGTTGCTGCC
ACCCCCACCAGCCTGCTGATCAGCTGGTCTGGTGACTACCATCCG
CATCGATATTACCGCATCACTTACGGCGAAACAGGAGGCAATAGC
CCTGTCCAGGAGTTCACTGTGCCTGGTGAACATGAAACAGCTACC
ATCAGCGGCCTTAAACCTGGCGTTGATTATACCATCACTGTGTAT
GCTGTCACTTACGACGGTGAAAAAGCTGACAAATACCCGCCAATT
TCCATTAATTACCGCACAGAAATTGACAAACCATCCCAGTAA
459
ADX_6077_F02
ATGGGAGTTT CTGATGTGCC GCGCGACCTG GAAGTGGTTG
CTGCCACCCC CACCAGCCTG CTGATCAGCT GGTCTGATGA
CTACCATGCG CATCGATATT ACCGCATCAC TTACGGCGAA
ACAGGAGGCA ATAGCCCTGT CCAGGAGTTC ACTGTGCCTG
GTGAACATGT GACAGCTACC ATCAGCGGCC TTAAACCTGG
CGTTGATTAT ACCATCACTG TGTATGCTGT CACTTACGAC
GGTGAAAAGG CTGCCACAGA TTGGTCAATT TCCATTAATT
ACCGCACACC GTGCCACCAT CACCACCACC ACTGA
460
ADX_6077_F02
GGTGTT AGTGATGTTC CGCGTGATCT GGAAGTTGTT
w/o His-tag and including leader
GCAGCAACCC CGACCAGCCT GCTGATTAGC TGGTCAGATG
sequence
ATTATCATGC CCATCGTTAT TATCGCATTA CCTATGGTGA
AACCGGTGGT AATAGTCCGG TTCAAGAATT CACCGTTCCG
GGTGAACATG TTACCGCAAC CATTAGCGGT CTGAAACCGG
GTGTTGATTA CACCATTACC GTTTATGCAG TTACCTACGA
TGGTGAAAAA GCAGCAACCG ATTGGAGCAT TAGCATTAAC
TATCGTACCC CGTGTTAA
461
ADX_6077_F02
ATGAAAAAAATC TGGCTGGCAC TGGCAGGTCT GGTTCTGGCA
w/leader sequence and PCPPPPPC
TTTAGCGCTA GCGCCGGTGT TAGTGATGTT CCGCGTGATC
TGGAAGTTGT TGCAGCAACC CCGACCAGCC TGCTGATTAG
CTGGTCAGAT GATTATCATG CCCATCGTTA TTATCGCATT
ACCTATGGTG AAACCGGTGG TAATAGTCCG GTTCAAGAAT
TCACCGTTCC GGGTGAACAT GTTACCGCAA CCATTAGCGG
TCTGAAACCG GGTGTTGATT ACACCATTAC CGTTTATGCA
GTTACCTACG ATGGTGAAAA AGCAGCAACC GATTGGAGCA
TTAGCATTAA CTATCGTACC CCGTGTCCGC CGCCACCGCC
GTGTTGATAA
462
ADX_6077_F02
ATGGGAGTTT CTGATGTGCC GCGCGACCTG GAAGTGGTTG
w/leader sequence and
CTGCCACCCC CACCAGCCTG CTGATCAGCT GGTCTGATGA
PCPPPPPCH6
CTACCATGCG CATCGATATT ACCGCATCAC TTACGGCGAA
ACAGGAGGCA ATAGCCCTGT CCAGGAGTTC ACTGTGCCTG
GTGAACATGT GACAGCTACC ATCAGCGGCC TTAAACCTGG
CGTTGATTAT ACCATCACTG TGTATGCTGT CACTTACGAC
GGTGAAAAGG CTGCCACAGA TTGGTCAATT TCCATTAATT
ACCGCACACC GTGCCCGCCG CCACCGCCGT GTCACCATCA
CCACCACCAC TGA
463
ADX_6093_A01 full length
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPV
QEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGESPASSKPISI
NYRT
464
linker
(GS)5-10
465
linker
(G4S)2-5
466
linker
(G4S)2G
467
linker
PVGVV
Carvajal, Irvith M., Chen, Guodong, Lipovsek, Dasa, Toth, Joseph, Barnhart, Bryan C., Krystek, Jr., Stanley Richard, Huang, Richard Y., Rakestraw, Ginger C., O'Neil, Steven R., Loffredo, John Thomas, Terragni, Christina
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 10584160, | Sep 23 2015 | Bristol-Myers Squibb Company | Glypican-3-binding fibronectin based scaffold molecules |
| 7115396, | Dec 10 1998 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| 9260492, | Nov 15 2010 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| 20120094909, | |||
| 20190077844, | |||
| WO232925, | |||
| WO2009133208, | |||
| WO2009142773, | |||
| WO2011103105, | |||
| WO2011130324, | |||
| WO2012016245, | |||
| WO2012065978, | |||
| WO2012073992, | |||
| WO2014159087, | |||
| WO2015023879, | |||
| WO2015143156, | |||
| WO9856915, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Mar 06 2018 | TERRAGNI, CHRISTINA | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0990 | |
| Jul 27 2018 | HUANG, RICHARD Y | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Aug 20 2018 | CHEN, GUODONG | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Aug 29 2018 | TOTH, JOSEPH | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Aug 29 2018 | CARVAJAL, IRVITH M | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Sep 04 2018 | O NEIL, STEVEN R | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Sep 12 2018 | KRYSTEK, STANLEY RICHARD, JR | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Sep 13 2018 | LOFFREDO, JOHN THOMAS | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Sep 14 2018 | RAKESTRAW, GINGER C | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Sep 14 2018 | LIPOVSEK, DASA | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Sep 24 2018 | BARNHART, BRYAN C | Bristol-Myers Squibb Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 052601 | /0942 | |
| Jan 24 2020 | Bristol-Myers Squibb Company | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Jan 24 2020 | BIG: Entity status set to Undiscounted (note the period is included in the code). |
| Date | Maintenance Schedule |
| Dec 13 2025 | 4 years fee payment window open |
| Jun 13 2026 | 6 months grace period start (w surcharge) |
| Dec 13 2026 | patent expiry (for year 4) |
| Dec 13 2028 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 13 2029 | 8 years fee payment window open |
| Jun 13 2030 | 6 months grace period start (w surcharge) |
| Dec 13 2030 | patent expiry (for year 8) |
| Dec 13 2032 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 13 2033 | 12 years fee payment window open |
| Jun 13 2034 | 6 months grace period start (w surcharge) |
| Dec 13 2034 | patent expiry (for year 12) |
| Dec 13 2036 | 2 years to revive unintentionally abandoned end. (for year 12) |